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Abstract
There are 90 different serotypes of Streptococcus pneumoniae and ciment pneumococcal 
vaccines are somewhat limited in their protection against invasive pneumococcal disease. 
The adult pneumococcal vaccine is composed of capsule polysaccharide from 23 of the 
most common disease causing serotypes. Infants are the major ‘at risk’ group from 
pneumococcal disease; however, polysaccharide-based vaccines are not protective in this 
age group. This has led to the development of a paediatric conjugate vaccine, which is 
composed of polysaccharide from seven of the most prevalent disease causing serotypes 
individually conjugated to a carrier protein. Although the conjugate vaccine is highly 
efficacious, it only elicits protection against disease caused by the seven homologous 
pneumococcal serotypes. Serotype specific immunisation is only a short-term solution to 
combating pneumococcal disease. Problems with serotype replacement have already 
arisen within five years since licensure of the paediatric vaccine, with non-vaccine 
serotypes replacing the eliminated vaccine serotypes. A solution to this is the development 
of pneumococcal vaccines containing a species wide pneumococcal protein to elicit non­
serotype specific protection.
Pneumolysin, the pore-forming toxin produced by S. pneumoniae, may have an application 
in future pneumococcal vaccines as it is produced by all invasive isolates, is a major 
virulence factor and has been demonstrated to confer non-serotype specific protection 
against pneumococcal disease. The toxicity of pneumolysin is problematic in terms of 
vaccine use and existing pneumolysin mutants possess residual cytotoxicity. By mutating 
a region involved in protein oligomerisation, pneumolysin pore formation was abolished. 
This resulted in a non-toxic form of pneumolysin that retained the immunogenicity of wild 
type pneumolysin without the associated effects such as hypothermia, inflammatory 
cytokine production and vascular leakage following intranasal administration to mice.
Vaccination of mice with this pneumolysin toxoid elicited high titres of neutralising 
antibody, which significantly protected animals from pneumococcal infection.
Conjugation of the pneumolysin toxoid to capsule polysaccharide from serotype 4 S. 
pneumoniae elicited full protection against infection from the homologous serotype. This 
indicated that the pneumolysin toxoid was as effective as the carrier protein used in the 
current pneumococcal conjugate vaccine. Active vaccination with free pneumolysin 
toxoid significantly increased suiwival times in mice following challenge with a non­
vaccine serotype. This research implies that combining conjugated and free pneumolysin 
toxoid may be more efficacious than current vaccines in protection against pneumococcal 
disease.
The importance of the pore-forming property of pneumolysin in pathogenesis of 
pneumococcal disease was investigated by construction of a pneumococcal strain carrying 
the same mutation used to construct the pneumolysin toxoid for vaccination. Pore 
formation was found not to be important for pathogenesis during murine pneumococcal 
pneumonia. This was further supported by the identification of serotype 1 strains from 
clinical disease that expressed non pore-forming pneumolysin yet were isolated from 
patients with invasive pneumococcal disease.
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Chapter 1 Introduction
1.1. Streptococcus pneumoniae
Streptococcus pneumoniae (the pneumococcus) is a Gram-positive facultative anaerobe 
that was discovered simultaneously by Pasteur in France and Sternberg in America in 
1880. It has since been found to be the predominant cause of fatal infections such as 
bacterial pneumonia and meningitis. Pneumococci can be divided into 90 serotypes 
depending upon the immunochemistry of their capsular polysaccharide (Henrichsen 1995). 
The classification of pneumococcal serotypes was originally by chronological order of 
discovery (Dochez et al. 1913), however, many of the capsule polysaccharides are cross­
reactive and this has led to the reclassification of serotypes using the Danish system of 
nomenclatui’e. Where serotypes 1 and 2 remain the same but serotypes that have similar 
capsules, for example serotypes 6 and 26 by American nomenclature, are now termed 
serotypes 6A and 6B (belonging to serogroup 6) (Smart 1987). The Quel lung (literally 
‘swelling’) reaction developed by Neufeld in 1902 allows the determination of serotypes 
by their reactivity with antibodies raised against homologous capsule polysaccharide. This 
technique is still employed in reference laboratories today. However, cross reactivity 
hinders the quelling reaction resulting in some isolates being mistyped or nonserotypcable 
(due to the lack of capsule expression). Molecular serotyping techniques are ciurently 
under investigation in attempt to develop serotyping techniques that are more accurate in 
determining serotype rather than serogroup and are less expensive and easier to perform 
(Batt et al. 2005; Pai et al. 2005a). Multiplex PCR has recently been shown to provide an 
accurate high through-put approach to the serotyping of pneumococci (Pai et al. 2006).
With the advent of Multi Locus Sequence Typing (MLST), pneumococci can now be 
genetically categorised (Enright et al. 1998). MLST involves the sequencing of seven 
housekeeping genes {aroE, gdh, gki, recP, spi, xpt and ddl) where each allele is assigned a 
number depending upon its sequence using the MLST website (http://www.mlst.net). This 
results in a seven digit ‘barcode’ for each isolate knovm as the sequence type (ST). MLST
17
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is a powerful tool in pneumococcal characterisation, providing an electronic form of
molecular typing that allows standardisation between laboratories. It has become evident
that different STs exist within one serotype and that polysaccharide capsules can switch
(Coffey et al. 1998; Coffey et al. 1999; Jefferies et al. 2004), making MLST a more
accurate tool for the genetic suiweillance of pneumococcal disease on a global scale. More
in depth analysis can be achieved using mlcroarray to compare whole genomes. This
allows assessment of gene content in individual isolates, however this technique provides
an overwhelming amount of data and remains too expensive and labour intensive for
routine clinical use. Microarray analysis of pneumococcal isolates has indicated that there
are genetic differences within an individual sequence type (Silva et al, manuscript
submitted), highlighting that variation occurs within a group considered identical by
MLST. Supplementary sequencing of essential virulence genes in addition to the seven
housekeeping genes may make MLST more powerful in reference laboratories (Hanage et
al. 2005) until microarray technology becomes more accessible.
1.2. Carriage of A. pneumoniae
s. pneumoniae colonises the upper respiratory tract of most of the human population at 
least one time in their lives. Nasopharyngeal colonisation is an evolving and transient 
process with different species and serotypes present at different times. This niche is a 
highly competitive enviromuent with Haemophilus influenzae, Moraxella cattarrhalis, 
Neisseria meningititis, Staphylococcus aureus and other Streptococcal spp. all colonisers 
of the nasopharynx (Bogaert et al. 2004). S. pneumoniae has been shown to produce H2 O2 
which inhibits or kills other microflora in the nasopharynx giving the pneumococcus a 
competitive advantage for colonising this environment (Pericone et al. 2000). The 
nasopharynx is the source of transmission from host to host and also where S. pneumoniae, 
which is highly transformable, is thought to pick up genes from other bacterial species. An 
example of this is the pneumococcal acquisition of genes that encode low affinity
18
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penicillin-binding proteins from other species such as Streptococcus mitis (Dowson et al.
1994) to confer penicillin resistance.
There are a number of factors that are associated with an increased frequency of 
pneumococcal carriage and therefore disease including overcrowding (as found in day care 
centres, large families in cramped housing, homeless shelters and prisons), smoking, 
antibiotic use and etlmicity (DeMaria et al. 1980; Kurtti et al. 1997; Obaro 2000; Bogaert 
et al. 2004). The most common serotypes isolated from nasopharyngeal swabbing of 
European children are 6A, 6B, 9V, 14, 18C, 19F and 23F; and the range of carried 
serotypes declines with age (Bogaert et al. 2004). These serotypes are also some of the 
most common disease causing serotypes in Europe, indicating that carriage preludes 
disease.
1.3. Diseases caused by S, pneumoniae
Although usually asymptomatically carried, S. pneumoniae can cause non-invasive 
diseases such as otitis media, sinusitis and bronchitis and the more severe and often fatal 
invasive diseases: pneumonia, meningitis and bacteraemia. In 2003, The World Health 
Organisation (WHO) estimated that at least one child dies from pneumococcal disease 
every minute (http://www.who.int/vaccines/en/pneumococcus.shtml). Host-pathogen 
interactions during pneumococcal pneumonia, bacteraemia, meningitis and otitis media are 
discussed in sections 1.7 to 1.9.
Although there is an overlap in pneumococcal strains that cause disease and those 
associated with caniage, some serotypes are more likely to be recovered from invasive 
disease (serotypes 1, 4, 14 and 18C) and others are more commonly isolated from 
nasopharyngeal swabbing of healthy individuals (serotype 3 ST180, 6B, 19F and 23F) 
(Brueggemann et al. 2003a). Invasive pneumococcal disease (IPD) has been shown to
19
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originate from a serotype with which the host was already colonised (Lloyd-Evans et al.
1996), though in some cases this colonisation period may be brief, e.g. with serotype 1
(Brueggemann et al. 2003b). The factors involved in a carried strain becoming invasive
are not fully understood. There is increasing evidence that viral infections are the
predisposing factor in converting pneumococcal carriage to invasive disease (McCullers et
al. 2002; Ishizuka et al. 2003; van der Sluijs et al. 2006). However, the host-pathogen
interaction is complex and mechanisms by which internalised pneumococci escape
endocytosis-mediated killing is not clear (Tuomanen et al. 1997). It is known that the
inflammatory cytokines IL-1 and TNF-a, produced during viral infections, up-regulate
expression of receptors on host cells, which facilitates pneumococcal binding. One
identified receptor is the platelet-activating-factor receptor (PAFr) on epithelial and
endothelial cells that pneumococcal cell surface phosphorylcholine binds to (Cundell et al.
1995; Tuomanen 1999). This interaction is thought to result in the internalisation of the
bacteria, permitting the translocation through the respiratory epithelium and vascular
endothelium (Cundell et al. 1995; McCullers et al. 2002).
1.4. Serotype 1 pneumococci
Serotype 1 S. pneumoniae, initially classified in 1913 (Dochez et al. 1913), remain one of 
the most prevalent invasive serotypes with reports of increases in serotype 1 IPD in 
Scotland (McChlery et al. 2005), Sweden (Henriques Normark et al. 2001) and Denmark 
(Komudsen et al. 2002) and a high prevalence of serotype 1 disease throughout Europe, 
South America, Africa and Asia (Scott et al. 1996; Hausdorff et al. 2000a; Hausdorff et al. 
2000b). Interestingly, serotype 1 disease has been reported to be decreasing in North 
America (Feikin et al. 2002) [ranked 17*‘’ (Brueggemann et ai. 2003b)] and Egypt (Wasfy 
et al. 2005). In developing countries, serotype 1 is associated with meningitis (Koek et al. 
2005; Leimkugel et al. 2005) whereas in westernised countries serotype 1 is associated 
with pneumonia, complicated pneumonia, pulmonaiy empyema, peritonitis and salpingitis
20
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(McFarlane et al. 1979; Westh et al. 1990; Sirotnak et al. 1996; Tan et al. 2002; Eltringham
et al. 2003; Sjostrom et al. 2006). Serotype 1 and 7F have recently been identified as
‘primary pathogens’ in that these serotypes aie most commonly isolated from IPD patients
with no underlying disease, whereas other serotypes, such as 11 A, were only found to
cause disease in immunocompromised patients and have been termed ‘opportunistic
pathogens’ (Sjostrom et al. 2006). The primary pathogens, although predominant in the
study group and rarely found in carriage, were less likely to cause death compared with the
opportunistic serotypes that are usually more carriage associated. Along with serotypes 5
and 7, serotype 1 is associated with higher ratio of hospitalisation versus ambulatory care
compared with pneumococcal infections from other serotypes (Alpern et al. 2001).
Serotype 1 is one of the few serotypes linked with non-hospital outbreaks of pneumococcal
disease, such outbreaks have occurred in over crowded institutions and/or where
alcoholism is a problem (DeMaria et al. 1980; Mercat et al. 1991; Gratten et ai. 1993;
Dagan et al. 2000).
Nasopharyngeal swabbing of healthy patients rarely results in the isolation of serotype 1 
pneumococci, because of this and a global association with IPD, serotype 1 is said to have 
a high attack rate (Brueggemann et al. 2003b). It may be that serotype 1 pneumococci 
have a different niche, i.e. adenoid tissue, which is not swabbed during collection of 
carriage isolates. Indeed, Escherichia coli 0157:H7 has recently been shown to have a 
highly specific niche in cattle (Naylor et al. 2003). It may be that carriage of serotype 1 is 
short lived as it remains sensitive to antibiotics (Brueggemann et al. 2003b) unlike strains 
associated with carriage that are thought to be under antibiotic pressure and in an 
environment which allows transfer of antibiotic resistance genes. During outbreaks of 
serotype 1 disease, the carriage rate increases, indicating that brief nasopharyngeal 
colonisation may occur with serotype 1 pneumococci.
21
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1.5. Virulence Factors of S. pneumoniae
Introduction
S. pneumoniae produces an array of virulence factors involved in pathogenesis including 
capsule polysaccharide, cell surface-associated proteins and toxins. Signature-tagged 
mutagenesis and full genomic sequencing studies have resulted in the identification of 
many putative virulence factors (Polissi et al. 1998; Lan et al. 2001; Tettelin et ai. 2001; 
Hava et al. 2002). The more characterised pneumococcal virulence factors and their roles 
in disease are listed in Table 1.1.
Table 1.1. Pneumococcal virulence factors
Virulence factor Location Function
Autolysin A (LytA)
Autolysin B (LytB) 
Autolysin C (LytC)
Cell wall Releases other vimlence factors, e.g. Ply, by 
breaking down cell wall 
LytA knockout strain is less virulent (Berry et 
al. 1989a)
Involved in transition of pneumococci from 
nasopharynx to lower respiratory tract 
(Orihuela et al. 2004)
Required for pnemnococcal suivival and 
replication in the lungs (Orihuela et al. 2004)
LytB and C are involved in nasopharyngeal 
colonisation (Gosink et al. 2000)
Capsule polysaccharide 
(CPS)
Outer
surface
Anti-phagocytotic
Masks cell surface antigens from host immune 
system
Expression levels are altered during disease 
(Hammersclimidt et al. 2005)
Cell Wall 
(including teichoic 
acids,
pho sphorylcholine, 
peptidoglycan and 
lipoteichoic acids)
Beneath
capsule
Inflammatory; activates complement cascade 
and cytokine production 
Provides a surface for anchoring surface- 
exposed proteins
Choline binding protein 
A (CbpA, PspC, SpsA)
Attached 
to cell 
wall
Involved in immune cell recruitment (Murdoch 
et al. 2002)
Has a major role in adhesion of pneumococci 
to nasopharyngeal cells (Rosenow et al. 1997) 
and translocation of pneumococci across 
human nasopharyngeal epithelial cells and for 
transition from nasopharynx to lower 
respiratory tract (Zhang et al. 2000; Orihuela et 
al. 2004)
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CbpD
Cbp E (or Pee) 
CbpG
Binds human complement factor H to avoid 
attack and opsonophagocytosis (Quin et al. 
2005)
Inhibits sIgA Ab binding to pneumococci
CbpD, E and G are involved in nasopharyngeal 
colonisation (Gosink et al. 2000)
CbpD is involved in triggering the release of 
Ply from non-competent pneumococci (Guiral 
et al. 2005)
CbpE and G are involved in adherence to 
human cells (Gosink et al. 2000)
CbpE removes phosphoryIcho 1 ine from the 
cell wall (de las Rivas et al. 2001)
CbpG has a role in sepsis (Gosink et al. 2000)
Caseinolytic protease C 
(ClpC)
ClpP
Cytoplasm Involved in autolysis in some strains and 
pneumococcal growth in the lungs and 
bloodstream (Ibrahim et al. 2005)
Involved in virulence, thermotolerance and 
resistance to oxidative stress (Ibrahim et al. 
2005)
Hyaluronidase (Hyl) Surface
(secreted)
Breaks down hyaluronic acid in mammalian 
comiective tissue possibly to promote 
pneumococcal dissemination (Paton et al. 
1993)
High temperature 
requirement A (HtrA)
Cytoplasm Essential for virulence in pneumonia and 
bacteraemia, involved in resisting oxidative 
stress and high temperatures (Ibrahim et al. 
2004)
Hydrogen peroxide 
(H2O2)
Produced
during
aerobic
growth
Inhibits/kills other bacterial species competing 
to colonise the nasopharynx (Pericone et al. 
2000)
IgAl protease Cytoplasm Cleaves human IgAl (Poulsen et al. 1996; 
Wani et al. 1996), possibly counteracts 
mucosal defences (Polissi et al. 1998) enabling 
pneumococci to persist on mucosal surfaces 
(Weiser et al. 2003)
Neuraminidase (Nan A) Surface 
exposed 
(Camara 
et ai. 
1994)
Cleaves N-acetyl neuraminic acid from 
lipoproteins, glycolipids and oligosaccharides 
on mammalian cells and breaks down mucin 
on mucosal surface thereby exposing receptors 
on cell surface allowing pneumococci to bind 
to host cells (Tong et al. 2000)
Thought to be involved in spread of 
pneumococci from the nasopharynx to the lung 
(Orihuela et al. 2003)
Important in colonisation and AOM (Tong et 
al. 2000) but not meningitis (Winter et al. 
1997).
Pili Surface
(extends
beyond
Initial adhesion to host cells and important for 
ability to invade host (Barocchi et al. 2006)
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CPS)
Pneumococcal surface 
adhesin A (PsaA)
Surface Manganese ABC transporter required for 
competence and virulence (Dintilhac et al. 
1997)
Binds to host cells, protects pneumococci from 
oxidative damage (Tseng et al. 2002)
Pneumococcal surface 
protein A (PspA)
Surface Binds pneumococci to host cells and inhibits 
complement activation on pneumococcal cell 
surface (Tu et al. 1999; Ren et al. 2004)
Binds to lactoferrin (protein involved in iron 
acquisition) at respiratory mucosal sites 
(Hammerschmidt et al. 1999)
May be involved in nasopharyngeal 
colonisation (LeMessurier et al. 2006)
Pneumolysin (Ply) Cytoplasm Potent toxin
Facilitates host tissue invasion and spread of 
disease (Orihuela et al. 2004)
Interferes with phagocyte function 
(Mouldsworth et al. 1994)
Slows ciliary beating (Feldman et al. 1990) 
Disrupts integrity of human respiratory 
epithelium (Feldman et al. 1990)
Required for pneumococcal suiwival and 
replication in the lungs (Orihuela et al. 2004) 
(see Table 1.2 for detailed list of roles of Ply)
Pyruvate oxidase 
(encoded by spxB)
Cytoplasm An enzyme responsible for hydrogen peroxide 
production. It decarboxylates pyruvate to give 
acetyl phosphate + H2O2 + CO2 
Involved in adhesion of pneumococci to host 
cells, spxB knockout strains are less able to 
colonise and are less virulent (Spellerberg et 
al. 1996; Orihuela et al. 2004)
Required for pneumococcal survival and 
replication in the lungs (Orihuela et al. 2004)
Streptococcal 
lipoprotein rotamase A 
(SlrA)
Surface Lipoprotein involved in colonisation of the 
nasopharynx and protects pneumococci from 
phagocytosis (Hermans et al. 2006)
Zinc metalloprotease 
(ZmpB)
Surface Induces inflammation in respiratory tract (Blue 
et al. 2003)
1.5.1. Capsule
The capsule polysaccharide of S. pneumoniae is a major virulence factor that enables the 
micro organism to resist phagocytosis (Jonsson et a l 1985). Unencapsulated strains are 
generally avirulent with rare cases of unencapsulated strains being recovered from
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immunocompromised hosts or from conjunctivitis patients (Muller-Graf et al. 1999;
Ishizuka et al. 2003; Martin et al. 2003). Changes in colony phenotype from transparent to
opaque are due to thickening of the capsule. The transparent phenotype is adapted to
colonisation of the nasopharynx with a thin capsule layer that allows cell wall
phosphorylcholine to bind to the platelet activating factor receptor (PAFr) on respiratory
epithelial cells. This permits colonisation o f the host. Opaque colonies are usually
recovered from the bloodstream and are unable to adhere to PAFr. These phenotypes are
reversible and thought to aid the progression from carriage to invasive disease (Tuomanen
1999; Hammerschmidt et al. 2005). Although 90 capsule polysaccharide types have been
identified (Hemichsen 1995), less than 20% of serotypes are the major cause of disease
(Hausdorff et al. 2000b).
The capsule has long been thought of as the first point of contact with host cells. However, 
pneumococci have recently been shown to possess pili that protrude the capsule 
polysaccharide and are responsible for the initial adhesion to host cells (Barocchi et al. 
2006). Using mutant strains (rlrA‘) that did not have pili, it was shown that pili also 
facilitate the ability of the pathogen to cause invasive disease in mice.
1.5.2. Cell wall and surface-exposed proteins
The pneumococcal cell wall is important in the attachment of the organism to host 
respiratory cells and is comprised of an array of surface-associated virulence factors. The 
pneumococcal cell wall is composed of peptidoglycan, teichoic and lipoteichoic acids. 
Phosphorylcholine, which is a component of the teichoic and lipoteichoic acids, acts as an 
adhesin for the platelet-activating factor receptor (PAFr) of host cells (Cundell et al. 1995).
There are three major groups of pneumococcal surface-exposed proteins: choline-binding 
proteins, lipoproteins and LPXTG-anchored proteins. Based on genome data, different
■&
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pneumococcal strains have been shown to vary in the proportion of these surface proteins
(Bergmami et al. 2006). Choline-binding proteins are non-covalently anchored to the
phosphorylcholine o f the cell wall by carboxy terminal repeats. Pneumococci produce 13
to 16 different choline-binding proteins including pneumococcal surface protein A (PspA),
choline binding protein A (CbpA, also termed pneumococcal surface protein C), and the
autolysins (LytA, A- acetyl -muramoyl -L- alanine amidase; LytB, p~N-
acetylglucosaminidase and LytC, p-N-acetylmuramidase [lysozyme]) (Bergmann et al.
2006).
Pneumococcal surface exposed lipoproteins are involved in substrate transport and include 
pneumococcal surface adhesin A (PsaA), the substrate-binding protein of a manganese 
transport system (Dintilhac et al. 1997), pneumococcal iron acquisition protein A (PiaA) 
and pneumococcal iron uptake protein A (PiuA) (Brown et al. 2001), Streptococcal 
lipoprotein rotamase A (SlrA) involved in colonisation of the host (Hermans et al. 2006) 
and putative proteinase maturation protein A (PpmA) involved in pneumococcal 
pneumonia (Ovei*weg et al. 2000).
LPXTG anchored proteins are covalently attached to peptidoglycan in the cell wall by 
sortases that recognise the LPXTG motif of such proteins. Different sortases are involved 
in processing the different surface-exposed proteins (Hava et al. 2002; Paterson et al. 
2006b). Hyaluronidase (Hyl) and neuraminidase A (NanA) are two well-characterised 
LPXTG-anchored proteins. Neuraminidases cleave the terminal sialic acid from 
glycolipids, glycoproteins and oligosaccharides on the cells of the host tissue and fluids 
providing a means of invasion for the pneumococci (Tong et al. 2000). Hyl hydrolyses 
hyalui’onic acid, which is found in mammalian connective tissue, permitting pneumococcal 
invasion of the host tissues (Paton et al. 1993).
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Protective immunity from pneumococcal infection has been demonstrated with a number
of these pneumococcal cell surface exposed proteins, this is discussed in section 1.14 and
potential vaccine candidates are given in Table 1.5.
1.5.3. Pneumolysin
Pneumolysin (Ply) is a pore-forming cytoplasmic toxin that belongs to the family of 
cholesterol-dependent cytolysins (see section 1.12). Ply is a multifunctional toxin 
produced by all disease causing isolates (Kalin et al. 1987) and is an important 
pneumococcal virulence factor with many roles in the pathogenesis of disease (Mitchell et 
al. 1997). There are two major functions associated with Ply: cytolysis by forming pores 
in membranes (Alouf 2000) and the ability to activate complement in the absence of 
specific antibody (Paton et al. 1984; Mitchell et al. 1991). Due to Ply’s ability to form 
pores in cholesterol containing membranes, it is cytotoxic to all eukaryotic cells tested to 
date including pulmonary epithelial and endothelial cells (Steinfort et al. 1989; Feldman et 
al. 1990; Rubins et al. 1992; Rubins et al. 1993; Rayner et al. 1995), cerebral epithelial 
cells (Zysk et al. 2001) and ciliated ependyma (Mohammed et al. 1999). Ply has been 
detected in the cerebrospinal fluid (CSF) of meningitis patients (Spreer et al. 2003b), 
middle ear fluid from otitis media cases (Virolainen et al. 1994), lung sputum from 
pneumonia patients (Wheeler et al. 1999) and lung tissue from mice with experimental 
pneumonia (Canvin et al. 1995). When Ply is administered intranasally to mice there is an 
immediate response with damage to lung integrity that results in vascular leakage (Maus et 
al. 2004). Ply is thought to have an essential role in pneumococcal pneumonia (See section 
1.7.1) and has been shown to induce inflammatory responses in the host lung similar to 
that caused by S. pneumoniae (Feldman et al. 1991). Interestingly, although Ply has 
distinct roles in the pathogenesis of pneumococcal disease, a study of virulence gene 
expression during pneumococcal infection of mice found ply  expression to be constantly 
up regulated in all niches from the nasopharynx to the blood. The authors suggest that it is
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the controlled timing of Ply release that is important for pneumococcal dissemination
rather than ply expression (LeMessurier et al. 2006). At sub-lytic concentrations, which
are more likely to be found during pneumococcal infection, Ply has a plethora of roles in
pathogenesis that are detailed in Table 1.2.
A recent micro array study compared cDNA from human monocytes following treatment 
with either WT S. pneumoniae or a Ply negative strain to assess Ply-dependent gene 
expression (Rogers et al. 2003). The authors found that of the 4133 genes assessed, 116 
were up regulated and 26 were down regulated in response to Ply. Up-regulated genes 
included those involved in synthesis of lysozyme, an antimicrobial enzyme that induces 
autolysis of pneumococci and enhances the phagocytic activity of neutrophils (Cottagnoud 
et al. 1993; Ibrahim et al. 2001). Mannose-binding lectin genes were also up regulated in 
monocytes incubated with the Ply positive strain, this molecule is involved in 
phagocytosis, cytokine production and complement activation and the authors imply that it 
could also be a core mediator in the inflammatory response to S. pneumoniae. Chemokines 
involved in inflammation, chemotaxis and cell adhesion were also up regulated in response 
to Ply, confirming existing data. Such experiments provide a valuable insight into genetic 
responses to Ply and offer the possibility of investigating whole host responses through the 
use of host based microarray chips, an area that will probably expand in the near future.
Table 1.2 details information derived from investigation of the effect of Ply in vitro and 
usually with only one cell type. Of course, this is not the case in vivo with cell to cell 
signalling and it may be that duiing infection some of the cells listed in Table 1.2 are never 
exposed to Ply. Studies on the in vivo effects of Ply, either by treatment of animals with 
purified toxin or by comparisons of animals treated with wild type (WT) S. pneumoniae 
and a Ply negative derivative, therefore reveal more about the role of Ply during infection 
and are discussed in the following sections.
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Table 1.2. Effects of sub-lytic levels of recombinant Ply on cells
Ply Target Effect Potential role in pathogenesis
Alveolar and 
bronchial epithelial 
cells
Disrupts cells (Rubins et al. 
1993) and inhibits cilial 
beat (Steinfort et al. 1989; 
Feldman et al. 1990; 
Adamouetal. 1998)
Facilitates pneumococcal growth 
and dissemination in the lungs
Pulmonary 
endothelial cells
Disrupts integrity (Rubins 
et al. 1992)
Activates phospholipase A 
(Rubins et al. 1994)
Breaches endothelial barrier 
possibly facilitating dissemination 
from lung to bloodstream (Rubins 
etal. 1992)
May contribute to tissue damage 
and inflammation
Microglial and 
neuronal cells
Induces apoptosis (Braun et 
al. 2 0 0 2 )
Possible role during meningitis
Neutrophils Inliibits respiratory burst 
and migration (Paton et al. 
1983a; Nandoskar et al. 
1986)
Induces necrosis (Zysk et 
al. 2 0 0 0 ) and calcium influx 
(Cockeran et al. 2001b)
Decreases ability of neutrophils to 
migrate towards and phagocytose 
pneumococci
Damages neutrophils
Fc fragment of 
antibody
Activates classical 
complement cascade in the 
absence of specific anti-Ply 
antibody by binding to Fc 
(Paton et al. 1984; Mitchell 
et al. 1991).
Reduces serum opsonic activity 
(Mitchell et al. 1997) 
Complement attack results in 
inflammation of host tissue 
(Mitchell et al, 1997), which 
facilitates dissemination of 
pathogen
Monocytes Stimulates TNF-a and IL- 
1(3 release (Houldsworth et 
al. 1994)
Inliibits respiratory burst 
and phagocytosis 
(Nandoskar et al. 1986)
Up regulation of ICAM-1 
(Thornton et al. 2005)
May facilitate pneumococcal 
adherence by up regulating binding 
receptors on host cells 
Prevents pneumococcal clearance
Facilitates transmediated 
endocytosis of neutrophils for 
pneumococcal clearance, the 
benefit to pneumococci is not clear
Dendritic cells (DC) Induces DC apoptosis 
(Colino et al. 2003)
DCs are critical for primary 
immune response to pathogens 
therefore this permits evasion of 
immune system
Spleen cells Stimulates IFN-y and Nitric 
Oxide release (Baba et al. 
2 0 0 2 ),
Alteration in adaptive immunity?
B cells Inhibits antibody production 
(Ferrante et al. 1984)
But can be used as a vaccine? Is 
adjuvant important?
Lymphocytes Blocks proliferation of cells 
in response to mitogens 
(Ferrante et al. 1984)
Prevents T-cell proliferation, 
thereby altering adaptive immunity
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1.6. Role of Ply in pneumococcal carriage
Ply has been to shown to facilitate adherence of S. pneumoniae to human epithelial cells 
but it was not essential for successful colonisation of the host (Rubins et al. 1998). Another 
study suggested that Ply was essential for colonisation of the nasopharynx in serotype 2 but 
not serotype 3 S. pneumoniae (Kadioglu et al. 2002). A recent study has suggested that Ply 
elicits inflammation during carriage, which actually promotes clearance of pneumococci 
(van Rossum et al. 2005). The authors suggest that the reason a virulence factor would aid 
clearance is that the induced inflammation facilitates the spread of pneumococci, therefore 
sacrifice of some of the population may be required to allow the rest to disseminate and 
cause infection in susceptible hosts.
Ply has recently been shown to interact with Toll-Like Receptor (TLR) 4 and is thought to 
be essential in preventing pneumococcal colonisation from progressing to invasive disease 
(Malley et al. 2003). This interaction is suggested to result in tolerated carnage of the 
pneumococcus, however, what is not clear is what happens when hosts get ÏPD. Mice with 
defective TLR-4 (C3/HeJ) were shown to be more susceptible to fatal pneumococcal 
infection than WT mice (C3/HeOuJ), highlighting an essential role for TLR-4 in host 
innate immunity against pneumococcal infection.
To assess whether the cytolytic property of Ply was essential for TLR-4 activation, 
peritoneal macrophages from C3/HeJ (TLR4 -/- mice) and C3/HeOuJ mice were treated 
with either WT Ply or PdT (a mutant form of Ply that carries 3 amino acid substitutions 
D385NC428GW433F that abrogates the haemolytic activity and complement-activating 
properties of the toxin, discussed in section 1.15.1). PdT was still found to interact with 
TLR-4 to produce the inflammatory cytokine TNF-a, as C3/HeOuJ mice elicited a TNF- 
respouse to PdT (and Ply) whereas the C3/HeJ strain did not. Therefore the presence of 
Ply, but not its haemolytic or complement activating activities is important for activation of
30
Chapter 1 Introduction
TLR-4 dependent inflammatory responses. This is in contrast to another study that
claimed strains expressing Ply promoted clearance of the pneumococci and this was in a
TLR-4 independent mamier (van Rossum et al. 2005). These studies differ in that
recombinantly purified Ply was used in one and a Ply knockout strain was used in the
other. Further investigation into the interaction between Ply and TLR-4 suggests that
apoptosis is involved (Srivastava et al. 2005). Ply induced apoptosis of macrophages was
shown to be mediated by TLR-4 and that administration of an inhibitor of apoptosis into
the nasopharynx of mice significantly increased their susceptibility to IPD (Srivastava et
al. 2005). From this work the authors suggest that Ply induced apoptosis and interaction
with TLR-4 in the nasopharynx is an innate immune response against pneumococcal
disease.
1.7. Pneumococcal pneumonia and bacteraemia
Pneumonia is characterised by fluid in the lungs, which hinders oxygen from reaching the 
bloodstream through the alveoli. According to WHO
(www.who.iLit/vaccines/en/pneumococcus.shtml). more children die each year from pneumonia 
than any other infectious disease including AIDS and Malaria. S. pneumoniae is the 
leading cause of pneumonia and is thought to be responsible for the deaths of 1 million 
children every year, mostly in developing countries. In industrialised countries, S. 
pneumoniae is also the most common cause of community acquired pneumonia with 
1 0 0 , 0 0 0  cases/population and a 1 0 -2 0 % mortality rate, though this is greater in high-risk 
groups such as infants, the elderly and HIV patients (Johnston 1991; Amdahl et al. 1995). 
Recently differences in serotype distribution have been identified, with IPD from serotype 
llA  exclusively associated with adult patients with underlying diseases such as cancer and 
HIV whereas serotype 1 was more likely to cause disease in otherwise healthy adults 
(Sjostrom et al. 2006).
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Bacteraemia is characterised by the presence of bacteria in the bloodstream and is a 
condition that progresses rapidly. There is a high mortality rate associated with 
pneumococcal bacteraemia and it is often associated with pneumonia, after the 
pneumococci enter the bloodstream. Antibiotics (in particular penicillin and 
clarithromycin) are usually effective in the treatment of pneumonia and bacteraemia 
though with the rise of antibiotic resistant strains, this may not be the case for much longer. 
Vaccines offer the most effective protection against pneumococcal disease (see section 
1.13).
1,7,1. Role of Ply in pneumococcal pneumonia and bacteraemia
Ply knockout strains of S. pneumoniae are less virulent than WT strains during 
pneumococcal pneumonia (Berry et al. 1989b) and bacteraemia (Berry et al. 1989b; Berry 
et al. 1992), indicating an important role of Ply in the pathogenesis of these diseases. It is 
thought that Ply significantly contributes to stimulation of the host inflammatory response 
during pneumonia, as mice infected with Ply negative S. pneumoniae have a delayed and 
less intense cell influx into the lungs (Kadioglu et al. 2000). Ply has been shown to be 
particularly important during the early stages of pneumococcal pneumonia and bacteraemia 
(Benton et al. 1995; Canvin et al. 1995). The inflammation caused by the release of Ply is 
thought to facilitate pneumococcal dissemination throughout the host (van Rossum et al. 
2005). It is thought that Ply prevents the initiation of host immunity for the first few hours, 
possibly diverting the immune system, to allow the pneumococci to establish within the 
host.
One of the major host responses to pneumococcal pneumonia is the recruitment of 
neutrophils from the vascular space to the alveolar airways by cytokines such as TNF-a,
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IL-1 and IL- 8  (or KC in mice). Neutrophils are the major immune cells responsible for
clearance of the pneumococci from the lung (Jones et al. 2005) and neutrophil recruitment
during pneumococcal pneumonia has been shown to be Ply dependent (Jouiiblat et al.
2003; Moreland et al. 2005), demonstrated in Figure 1.1. Neutrophil recruitment from the
circulation has also been identified in the nasopharynx in response to pneumococcal
colonisation (van Rossum et al. 2005).
Recruitment of leukocytes (neutrophils, monocytes, eosinophils, lymphocytes and 
basophils) to sites of infection involves cell adhesion molecules, in particular ICAM-1 
(intracellular cell adhesion molecule-1). Expression of ICAM-1 on the leukocyte cell 
surface adheres the leukocytes to the vascular endothelium enabling the leukocytes to 
migrate to sites of inflammation (Figure 1.1). Ply has been shown to up regulate the 
expression of ICAM-1 in human monocytes using both recombinant Ply and comparing 
serotype 3 (WU2) and serotype 2 (D39) S. pneumoniae with isogenic ply  knockout mutants 
(Thornton et al. 2005). However, another research group found that both WT and a Ply 
negative mutant of D39 S. pneumoniae up regulated ICAM-1 in endothelial cells, 
indicating that at least for endothelial cells ICAM-1 expression is not Ply dependent 
(Moreland et al. 2005).
The regulation of cell adhesion molecules is controlled by inflammatory cytokines such as 
TNF-a and IL- 8  (See section 1.10 for cytokines involved in pneumococcal infection). It is 
possible that the induction of cytokine release (e.g. IL- 8  and the murine homolog KC) from 
monocytes and neutrophils by Ply (Cockeran et al. 2002; Rijneveld et al. 2002b; Thornton 
et al. 2005; Kirkham et al. 2006a), results in the up regulation of ICAM-1 to recruit 
leukocytes to the site of infection. In contrast to other studies, IL- 8  production by 
endothelial cells was not found to be Ply dependent (Moreland et al. 2005). The variation 
in results may be due to the different cell types investigated.
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Alveolar macrophages are the predominant cell type in bronchoalveolar space of healthy 
animals and there is a rapid recruitment of macrophages during inflammation (Reynolds 
1987). These cells are involved in the immune response to pneumococcal pneumonia by 
phagocytosing invading bacteria and also inducing pulmonary inflammatory responses by 
secreting inflammatory mediators such as TNF-a and IL- 6  that recruit other cells types, 
induce phagocytosis and antigen presentation (Reynolds 1987; Cavaillon 1994).
Previously, amino acid substitutions have been introduced into Ply in order to investigate 
whether it is the cytolytic (haemolytic) activity or complement activating ability of the 
toxin that contributes to pneumococcal virulence (Berry et al. 1995). These mutants are 
detailed in section 1.15.1. The cytolytic activity of Ply was demonstrated to be more 
important for virulence during bacteraemia rather than complement activating activity.
The complement system is essential to innate immunity by protecting hosts from bacterial 
infections (Walport 2001). Humans with complement deficiencies are more susceptible to 
pneumococcal infection (Alper et al. 1970; Alper et al. 2003). During pneumococcal 
pneumonia, the complement protein C3 has been shown to be important for host survival 
during the initial stages of infection (Kerr et al. 2005b). By constructing a single amino 
acid substitution (D385N), the complement activating ability o f Ply is abrogated (Mitchell 
et al. 1991). Cytolytic activity was shown to be important during early bacterial growth at 
3h and 6 h and for acute lung injury, whereas, the complement activating function was
?!
important for bacteraemia at 24h post infection (Rubins et al. 1996). The complement- i ;  
activating factor of Ply has been shown to affect T cell accumulation and the cytolytic 
activity influences neutrophil recruitment into lung tissue during pneumonia (Jounblat et 
ai. 2003).
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Figure 1. 1. Interaction of Ply and the host immune system during pneumococcal 
pneumonia
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1 : Pneumococci enter the lung airways via the upper respiratory tract. Phosphorylcholine of the 
pneumococeal cell wall binds to PAF receptors on the respiratory traet epithelial cells to facilitate 
pneumococcal invasion into the lungs (Cundell et al. 1995). 2: Upon entering the bronchoalveolar 
airspace, pneumococci invade the lung epithelium, releasing the major virulence factor Ply. 3: 
Mast cells are in abundance at the lung/airway interface (Abraham et al. 1997) and may form part 
of the first defence against pneumococcal infection. They release prestored cytokines such as 
TNF-a to recruit immune cells to the site of infection inducing production of more 
proinflammatory cytokines. 4: Alveolar macrophages residing in the bronchoalveolar space are 
also some of the first immune cells to attack pneumococci. They phagoeytose pneumococci and 
release inflammatory cytokines, which recruit more immune cells. 5: Pneumococci that 
successfully evade such immune responses then disseminate throughout the host. Ply destroys lung 
epithelial cells allowing pneumococcal invasion into the lung tissue. 6: Leukocytes in the blood 
release IL-8 in response to Ply (Cockeran et al. 2002). Monocytes do not need to interact directly 
with the baeteria, instead soluble inflammatory mediators such as those released by mast cells and 
macrophages can up regulate cytokine release from monocytes. IL-8 is a neutrophil
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chemoattractaiit that directs the recruitment of neutrophils to the site of infection. 7: Ply up
regulates ICAM-1 expression on the cell surface of leukocytes (Thornton et al. 2005), probably
indirectly by Ply inducing IL-8 production. 8: Up regulation of ICAM-1 facilitates transmediated
endocytosis of neutrophils from the blood to the site of infection, e.g. the lung tissue in the case of
pneumococcal pneumonia. The complement system is important in the innate immune defence
against pneumococcal invasion (Paterson et al. 2006a), including pneumonia (Kerr et al. 2005b).
Ply has been shown to activate the complement cascade (Paton et al. 1984) and the inflammation
induced by complement activation is thought to aid the spread of pneumococci. Complement
products C3a and later C5a, in addition to IL-8, are neutrophil chemoattractants. Neutrophils
phagoeytose the pneumococci via C3b complement based opsonophagocytosis, resulting in the
release of more cytokines, which induces fiirther neuti'ophil (and macrophage) recruitment to the
site of infection and therefore further phagocytosis of pneumococci (9). Ply release from
pneumococci has been shown to induce nitric oxide (NO) production in vitro from host cells
(Braun et al. 1999), this makes macrophages that have undergone phagocytosis more susceptible to
apoptosis, resulting in clearance of engulfed pneumococci (Marriott et al. 2004). High levels of Ply
release may increase the survival of invading pneumococci by inhibiting neutrophil and monocyte
respiratory burst (Paton et al. 1983a). The mass influx of neutrophils into the lung and high levels
of NO are, at least in part, responsible for acute inflammation in the lung during pneumococeal
pneumonia (10). Acute inflammation results in oedema and release of serum proteins, which can
act as a nutrient source and mode of transport for the pneumococci, thereby facilitating their spread
throughout the host. If pneumococci are successful in evading the immune responses in the lung
they can enter the bloodstream and cause bacteraemia (11). (Schematic of lungs from the oxford
illustrated science encyclopaedia, www.oup.co.ukL This figure has been composed from in vivo
experiments and in vitro analysis permitting hypothesis of the roles of cells during pneumococcal
disease.
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1.8. Pneumococcal meningitis
1.8.1. Role of Fly in pneumococcal meningitis
Although Ply is a potent neurotoxin, a decade ago Ply was not considered to be essential 
for the pneumococcus to cause meningitis (Friedland et al. 1995). It was shown that 
although recombinant Ply caused inflammation in rabbits when injected intracisternally a
Meningitis is characterised by inflammation of the meninges (fluid filled membranes that J
surround the brain and spinal chord) and can be caused by viral or bacterial pathogens. S. a
pneumoniae causes the most severe form of meningitis with 40-75% of cases of y
pneumococcal meningitis in developing countries resulting in death or disability 
(www.who.int/vaccines/en/pneumococcus.shtml). There are often devastating sequelae associated 
with meningitis with high possibility of mental retardation, learning disabilities, focal 
neurological difficulties and hearing loss in patients that survive the infection (Bohr et al.
1984; Bohr et al. 1985).
The mechanism by which colonising pneumococci then cause meningitis remains unclear. 
It was originally thought that pathogens must gain access to the blood prior to invading the 
central nervous system (CNS), however, a recent report indicates that S. pneumoniae can 
enter the CNS directly via the olfactory neurones (van Ginkel et al. 2003). Providing there 
is no intervention by the immune system, circulating pneumococci can breach the Blood 
Brain Barrier (BBB) and colonise the CSF. Once in the CSF there is a massive 
inflammatory response by the host with intense leukocyte recmitment that often results in 
brain injury (Hirst et al. 2004a).
Ply negative strain of S. pneumoniae caused similar levels of inflammation to the wild type 
strain. However, further research has changed this view. Wellmer et al showed that 
intracerebral infection of mice with a ply  negative strain of S', pneumoniae was less virulent
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than the parent strain with reduced bacterial loads in the blood (Wellmer et al. 2002).
However the cerebellar bacterial titres and meningeal damage were similar following
infection whether Ply was present or not. Zysk et al have indicated that Ply is important
during meningitis and that it may aid in penetration of the BBB to allow the pneumococci
access to the CSF (Zysk et al. 2001). This was demonstrated in vitro with brain
microvascular endothelial cells using both purified Ply and Ply expressing pneumococci.
Ply knockout strains have been used in a guinea pig model of pneumococcal meningitis to 
demonstrate that hearing loss, as a result of cochlear damage, is Ply dependent (Winter et 
al. 1997). Purified Ply has also been demonstrated to be toxic to ependymal cells (the cells 
that separate CSF from neuronal tissue) (Mohammed et al. 1999; Hirst et al. 2000) and to 
mediate apoptosis of human microglial cells (Braun et al. 2002). Braun et al have also 
shown that S. pneumoniae deficient in Ply and H2O2 production was unable to cause 
apoptosis of brain cells in comparison with the wild type parent strain (Braun et al. 2002). 
There are concerns with p-lactam treatment of pneumococcal meningitis patients in that it 
results in the release of Ply from the lysed pneumococci into the CSF and this may add to 
neurological damage (Spreer et al. 2003a).
1.9. Acute Otitis Media
Acute otitis media (AOM) is a middle ear infection that is highly prevalent in children, 
with an estimated 7 million cases of AOM in America each year 
twww.who.int/vaccines/en/pneumococcus.shtmO and even higher incidence rates in Australian 
aboriginals with 25-50% of children suffering from AOM at least once in their lives 
(Morris et al. 2005). Up to 50% of all AOM is caused by S. pneumoniae (Prellner et al. 
1999), which is thought to migrate along the Eustachian tube from the nasopharynx. Such 
high levels of infection impose a significant burden on healthcare systems and there can be 
problems with integration of children into school that have suffered hearing loss as a result
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of pneumococcal AOM. Serogroups 3, 19 and 23 may be more associated with an ability
to cause otitis media than other types (Hausdorff et al. 2000a), however, other studies have
failed to identify AOM associated serotypes or clonal groups (Hanage et al. 2004).
1.9.1. Role of Ply in AOM
The role of Ply in AOM is not known and it is thought that teichoic acids on the cell wall 
are more involved in inducing inflammation than the toxin. The ability of a Ply negative 
serotype 3 pneumococci to cause AOM in chinchillas was not significantly attenuated 
compared with WT serotype 3 (Sato et al. 1996). Anti-Ply antibodies have however been
■ir
I
identified in the middle ear fluid of patients with AOM (Virolainen et al. 1995) and direct 
instillation of Ply into the cochlea of guinea pigs damages the inner and outer hair cells, 
suggesting that Ply is responsible for clinical outcomes such as deafness following AOM 
and meningitis (Comis et al. 1993). Purified streptolysin O (SLO), the cholesterol- 
dependent toxin produced by Streptococcus pyogenes (see section 1.12) that is related to 
Ply, has been shown to cause permeabilisation of the round window membrane of guinea 
pigs (Engel et al. 1998). The authors suggest that SLO is the cause of hearing loss in 
patients with otitis media caused by S. pyogenes.
1.10. Cytokines involved in pneumococcal infection
The host response to pneumococcal infection involves the mediation of phagocytes as the 
first line of the imiate immune defence. During pneumococcal pneumonia, resident 
alveolar macrophages and, a few hours later, recruited neutrophils are the two major cell 
types involved in fighting infection (Figure 1.1). Recruitment of inflammatory cells to the 
site of infection is orchestrated by soluble proteins known as cytokines and chemokines 
(chemotactic cytokines) produced by the host immune system. Cytokines often function 
synergistically to control immune responses and they have different functions depending
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on the cells involved, the stage at which they are produced and the combination of
mediators involved (Borish et al. 2003). Cytokine production is a feature of both adaptive
and innate immunity. During adaptive immunity, antigen-presenting cells stimulate
cytokine production during the processing and presentation of antigen to T cells. The
innate immune system uses pattern recognition receptors, such as Toll-like receptors
(TLR), on cell surfaces that stimulate cytokine production upon recognition of an antigen
(Borish et al. 2003).
Tumour Necrosis Factor (TNF)-a, Interleulcin (IL)-l, IL-6 , IL-8 , IL-10, IL-12, Interferon 
(IFN)-y (though this does not play a protective role in pneumococcal pneumonia as it does 
in pneumonia caused by other bacterial species), Macrophage Inflammatory Protein (MIP)- 
2 and murine cytokine-induced neutrophil chemoattractant KC (Ziegler-LIeitbrock et al. 
1992; Bergeron et al. 1998; Ebong et al. 1999; Madsen et al. 2000; Rijneveld et al. 2002a; 
Ling et al. 2003; Zwijnenburg et al. 2003; Albiger et al. 2005; Jones et al. 2005) have been 
identified as being involved in the complex host response to pneumococcal infection, 
though their exact roles remain undetennined. The balance of the host cytokine response 
to infection is crucial to the outcome of pneumococcal disease, as discussed below for 
TNF-a.
1.10.1. TNF-a
Mononuclear phagocytes, neutrophils, mast cells, activated lymphocytes, natural killer 
(NK) cells and endothelial cells produce TNF-a. This cytokine activates neutrophils, 
controlling their adherence, chemotaxis, degranulation and respiratory burst. A TNF-a 
response to pneumococcal infection has been shown to be essential for sui-vival as CBA 
mice, that do not produce as much TNF-a in response to pneumococcal pneumonia as 
BALB/c mice, succumb to disease in contrast with BALB/c mice that survive infection
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(Kerr et al. 2002). Although TNF-a is essential in a successful immune response to
antigens, it also has detrimental effects on the host including vascular leakage and it is the
main mediator involved in toxic shock and sepsis (Borish et al. 2003).
I
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1.10.2. IL-6
The greatest source of IL- 6  is from mononuclear phagocytic cells but T and B cells, 
endothelial cells, fibroblasts and hepatocytes also produce IL-6 . IL- 6  has pro and anti­
inflammatory properties however during pneumococcal infection it is thought to play an 
anti-inflammatory role (Wang et al. 2000) by inhibiting TNF-a and IL-1 (3 production.
Serum IL- 6  and TNF-a levels are elevated in mice with pneumococcal sepsis (Albiger et
al. 2005). IL- 6  has also recently been shown to induce the production of hepcidin from the 
.liver (Nemeth et al. 2004), which sequesters free iron in the blood making it unavailable to 
pathogens thereby inliibiting their growth in the host. IL- 6  production and hepcidin 
production have recently been linked dming pneumococcal sepsis (Albiger et al. 2005).
1.10.3. KC
Produced by many cell types, KC (and the human homolog, IL-8 ) is involved in inducing 
neutrophil recruitment to sites of infection and degranulation (Cockeran et al. 2002; Borish 
et al. 2003). KC is a potent murine chemoattractant for neutrophils and is found in high 
levels in the lungs of mice with experimental pneumococcal pneumonia (Albiger et al.
2005). KC has also been shown to induce leukocyte recruitment into the CSF during 
pneumococcal meningitis (Zwijnenburg et al. 2003). The complexity of leukocyte 
recruitment during pneumococcal infection is an area currently under investigation, 
however, it does involve Ply (Kadioglu et al. 2000; Thornton et al. 2005), see section 1.7.1 
and Figure 1.1.
41
Chapter 1 Introduction
1.10.4. Role of Ply in cytokine induction
The stimulation of cytokine production during pneumococcal infection has been indicated 
to be at least partly due to the release of Ply (Benton et al. 1998; Kerr et al. 2005a). IL-6 , 
KC and MIP-2 levels are high in mice following treatment with purified Ply and cytokine 
production tends to be localised to the site of instillation of the toxin (Rijneveld et al, 
2002b). The stimulation of cytokines may be a result of Ply’s pore forming activity as 
mice treated with Ply carrying a point mutation that reduces haemolytic activity had lower 
cytokine responses than WT treated mice (Rijneveld et al. 2002b). In tissue culture 
experiments, IL-ip, TNF-a (Houldsworth et al. 1994) and IFN-y (Baba et al. 2002) release 
has been obsei-ved in response to treatment with Ply. However, when Ply was 
administered intranasally to mice these cytokines were not detected in the BALF, lung 
tissue homogenate or serum within 24h post treatment (Rijneveld et al. 2002b; Kirkham et 
al. 2006a).
1.11. Cytokines involved in thermoregulation
Inducers of febrile responses in humans such as bacterial or viral infections often induce a 
hypothermic response in rodents (Roberts 1979), for example pneumococcal infection 
elicits a hypothermic response in mice (Kerr et al. 2002) but humans usually develop a 
febrile response. This may be due to the inability of rodents to maintain their core body 
temperature as they have a large surface area in comparison to body weight. Ambient 
temperature, host genetic background and age have been shown to be important in 
determining whether rodents develop a hypothermic or febrile response to LPS treatment 
(Derijk et al. 1994; Romanovsky et al. 1998). Hypothermia or fever during infection is a 
survival mechanism that can decease mortality (Romanovsky et al. 1998). This has been 
demonstrated with pneumococcal pneumonia in two strains of mice where the strain that 
exhibited a hypothermic response survived the infection whereas the strain that did not
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elicit such a response succumbed to infection (Kerr et al. 2002). Hypothermia has been
shown to attenuate lung injury by reducing the number and function of circulating 
neutrophils (Lim et al. 2003) and this was the case during pneumococcal pneumonia where 
animals that exhibited a hypothermic response had heightened TNF-a responses and 
different recruitment patterns of immune cells into the lungs (KeiT et al. 2002).
4The main cytokines involved in the regulation and induction of hypothermia or fever are e
4TNF-a, IFN-y, IL-1 p, IL- 6  and IL-10 (Leon 2004). TNF-a is involved in the initiation of 4
Ihypothermia whereas IL- 6  is involved in thermoregulation and anorexia during sepsis 
(Leon et al. 1998; Remick et al. 2005). Whether IL- 6  is involved in hyperthermic or
4 'fc,;hypothermic responses during infection is unclear as there are many factors that can 4
■4
tS'influence thermogenesis. One major influence is the ambient room temperature as was I
shown in an experimental sepsis model where mice maintained in a 30°C room developed 
fever but mice maintained at 22°C became hypothermic (Remick et al. 2005). In both ;;
cases the mice had elevated IL- 6  levels during sepsis. In a model of experimental sepsis in 
ambient conditions, IL- 6  -/- mice did not develop hypothermia but mortality was not 
altered compared with WT mice that did exhibit a hypothermic response. IL- 6  is therefore 1
involved in thermoregulation during infection, however other factors determine whether 
there is a hypothermic or hyperthermic response and also the outcome of disease. There 
are indications that IL- 6  is the main inducer of hypothermia during bacterial infection 
(Leon 2004). IL-10 is an anti-inflammatory cytokine that is responsible for switching off 
inflammatory responses. IL-10 has been shown to modulate TNF-a production and 
therefore control hypothermia (Leon 2004).
Mild hypothermia modifies cytokine production from immune cells, favouring the 
production of pro-inflammatory cytokines. This has been shown with isolated human 
monocytes that are treated with LPS and incubated under hypothermic or normothermic
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conditions for 48h. Mild hypothermia was found to result in an increase in IL-lp, IL-6 ,
IL-12 and TNF-a production from monocytes treated with LPS (Matsui et ai. 2006). The
clinical relevance of this remains unclear, as does the actual function of these inflammatory
cytokines during hypothermia. It is not known whether during infection, changes in body
temperature result in the induction of pro-inflammatory cytokines or whether the
production of pro-inflammatory cytokines induces the change in body temperature. In
Dantzer’s review ‘How do cytokines say hello to the brain?’ (Dantzer 1994), he points out
that it is inadequate to think of the symptoms of infection and inflammation to merely be
mediated by cytokines acting on the brain. Instead the interaction of cytokine activated
immune cells should be taken into consideration and the neural pathways involved that
then activate peripheral sensory neiwes. It is generally thought that cytokines do not cross
the blood brain barrier but that they interact with target cells at the circumventricular
organs, which release signalling molecules such as prostaglandins that can diffuse
tliroughout the brain. Indeed, Ply has been shown to stimulate prostaglandin Ei (PGE2)
production from human neutrophils (Cockeran et al. 2001a) and during pneumococcal
pneumonia there is an abundance of PGE2 produced in the lungs (N'Guessan P et al. 2006).
How such molecules control thermoregulation and behaviour is not yet clear.
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1.12. The Cholesterol-Dependent Cytolysins
The cholesterol dependent cytolysin (CDC) family comprises of toxins from at least seven 
genera of Gram-positive bacteria. The toxins form large pores in cholesterol containing 
membranes making these toxins cytotoxic to all mammalian cells (Palmer 2001; Gilbert
2002). Identified CDCs and the species that produce them are listed in Table 1.3. Ply is 
different from all other CDCs as it has no secretion signal sequence and relies upon 
autolysin A to degrade the cell wall to allow its release into the surrounding environment. 
However, it has been indicated that LytA may not always be required for Ply release 
(Balachandran et al. 2001).
The molecular basis of pore formation has been the focus of several studies. Following 
membrane binding via cholesterol in a perpendicular mamier (Ramachandran et al. 2005), 
the CDC monomers oligomerise into ring-shaped structures of 30-50 monomers and insert 
into the host cell membrane to create pores (Jedrzejas 2001; Palmer 2001; Gilbert 2002; 
Giddings et al. 2003). The molecular structures of Perfringoiysin O (PFO) (Rossjohn et al. 
1997) and Intermedilysin (ILY) (Polekhina et al. 2005) have been resolved. Most Ply 
structure/function studies use a homology model based on the PFO structure (Figure 1.2) 
(Gilbert et al. 1999b). CDCs are composed of 4 domains and it is domain 4 that is 
involved in host cell recognition and binding (see section 1 .1 2 .1 ).
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Figure 1.2. PFO model with domains and transmembrane helices highlighted
Structural model of PFO with transmembrane helices (TMH) highlighted in red (TMHl) and green 
(TMH2) (Ramachandran et al. 2002). Domains are labelled D1 to 4 and the host cell-binding 
domain is highlighted in blue.
1.12.1. Cholesterol as the binding receptor of CDCs
CDCs bind to eukaryotic cell membranes as well as synthesised cholesterol-containing 
liposomes. A generally conserved undecapeptide region o f domain 4 
(ECTGLAWEWWR) has been shown to be involved in host cell binding (Jacobs et al.
1999) and is widely thought to form the receptor for cholesterol recognition on eukaryotic 
cells (Alouf 2000; Tweten et al. 2001). There is some variation at this region within the 
CDCs (Billington et al. 2000), with ILY, the human specific CDC possessing the most 
diverse sequence (GATGLAWEPW R). This variation has been shown to be responsible 
for the human specificity o f ILY (Nagamune et al. 2004). The undecapeptide region forms 
a loop that is thought to act as a dagger for insertion into lipid bilayers. It has been 
suggested that cholesterol is involved in insertion of oligomers into the membrane rather
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than ceil binding (Giddings et al. 2003). Recombinant forms of domain 4 of Ply or
Streptolysin O (SLO) can block binding and subsequent pore formation of the native toxin
to the host cell membrane (Baba et al. 2001; Weis et al. 2001). This demonstrates that
domain 4 controls host cell binding, however, domain 4 does not self-associate to create
pores, it is domain 3 that is instrumental in oligomerisation and pore formation.
Intermedilysin is an exception in the CDC family in that it is human specific and the
cytolytic action of this toxin is not blocked with pre-incubation with cholesterol
(Nagamune et al. 2004). In 2004, the complement control protein CD59 was identified as
the binding receptor for intermedilysin (Giddings et al. 2004).
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Table 1.3. Bacteria that produce cholesterol dependent cytolysins (CDCs)
Species CPC produced
Arcanobacterium pyogenes Pyolysin
Bacillus anthracis Antlirolysin 0
B. cereus Cereolysin
B. thuringiensis Thuringiolysin O
Brevibacillus laterosporous Laterosporolysin
Clostridium perfringens Perfringolysin O
C. bifermentas Bifermentolysin
C. botulinum Botulinolysin
C. chauvoei Chauveolysin
C. histolyticum Histolyticolysin
C. septicum Septicolysin
C. tetani Tetanolysin
C. novyi Novyilisin
Listeria ivanovii Ivanolysin 0
L. monocytogenes Listeriolysin 0
L. seeligeri Seeligeriolysin O
Paenibacillus alvei Alveolysin
Streptococcus canis Streptolysin 0
S. equisimilis Streptolysin O
S. intermedins Intermedilysin
S. pneumoniae Pneumolysin
S. pyogenes Streptolysin 0
S. suis Suilysin
Data from a CDC review (Billington et al. 2000), with the exception of Anthrolysin O produced by 
Bacillus anthracis which was identified and characterised in 2003 (Shannon et al. 2003).
1.12.2. CDC oligomerisation and pore formation
Cysteine labelling of amino acids tliroughout PFO was used to reveal which parts of the
molecule are in hydrophilic or hydrophobic environments during pore formation (Shepard
et al. 1998). The cysteine in each mutant was derivatised with NBD, (N'dimethyl N
[iodeacyl]"N’" [7 nitrobenz-2-oxa-l, 3-diazolyl] ethylenediamine). When the derivatised
cysteine is in a hydrophilic environment, the fluorescence is quenched but upon moving
into the hydrophobic lipid bilayer, the fluorescence intensity increases. From this work,
three a-helices in domain 3 were shown to move from the hydrophilic enviromiient into
the hydrophobic membrane during pore formation; suggesting that the a-helices form an
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anti-parallel amphipathic (3-hairpin during oligomerisation. A year later another region in |
domain 3 was identified to behave in a similar manner (Shatursky et al. 1999). This led to j
the theory that 2 hairpin loops (Figure 1.2) from each domain 3 monomer combine within
the oligomers to form a p-barrel pore within host cell membranes. In 2000, Tweten and
colleagues strengthened this data by showing that domain 3 of PFO inserts into the host
cell membrane following binding to initiate pore formation (Heuck et al. 2000).
Cryo-Electron Microscopy has been used with Ply to reveal that domain 2 of the CDCs is 
situated on the outside of the oligomers and domain 3 and 4 face inwards (Gilbert et al.
1999b), this is also the case in PFO (Dang et al. 2005a). Domain 4 also appears to rotate 
during oligomerisation (Gilbert et al. 1999b). The mechanism by which CDC monomers 
oligomerise and insert into the membrane to form pores is a subject of intense research 
with two main theories as to how pores are formed.
1.12.2,1. Simultaneous binding and insertion theory
Weis and Palmer suggested that CDC monomers independently insert into the lipid bilayer, 
‘skating’ around the membrane surface and colliding with other monomers to associate and 
form multimers in a imidirectional or bi-directional manner (Weis et al. 2001). A 
schematic is shown in Figure 1.3. Pores are then thought to form when oligomerisation is 
stopped by a limiting factor, possibly toxin concentration or oligomer size. This stage may 
be controlled by a conserved tryptophan in domain 4 of CDCs as Korchev and co-workers 
showed that a W433F substitution made in Ply increased the functional size of pores but 
reduced their frequency (Korchev et al. 1998). This theory allows for an explanation of 
arcs that are observed by EM on membranes treated with CDC toxins. Arcs may be 
incomplete pores, however, it is difficult to imagine that a free edge of lipid is viable.
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Figure 1.3. Simultaneous binding, insertion and pore formation theory
\
Monomers of CDC toxin (in blue) bind to and insert into lipid membranes either independently or 
as dimmers and trimers. As the oligomer grows so does the hole in the membrane. This process 
may stop to form arcs or continue to form pores. The dashed line indicates the ‘free edge’ of lipid.
1.12.2.2. The ‘prepore’ theory
It has recently been proposed that CDCs oligomerise on the surface o f membranes to form 
‘a prepore complex’ prior to insertion o f the pore into the lipid bilayer (Shepard et al.
2000), see Figure 1.4. This group have continued to strengthen this theory with intricate 
investigation o f the interaction o f the domains o f PFO and the host cell membrane (Hotze 
et al. 2001b; Hotze et al. 2002; Heuck et al. 2003; Czajkowsky et al. 2004; Dang et al. 
2005a; Ramachandran et al. 2005). Atomic force microscopy has been used to 
demonstrate that the prepore collapses upon membrane insertion (Czajkowsky et al. 2004) 
with a reduction in height between a mutant form of PFO that remains in the prepore form 
(Hotze et al. 2002) and the inserted PFO pore. This theory has been further strengthened 
by the use o f Cryo-EM with Ply to directly observe the transition from prepore to pore 
(Tilley et al. 2005). The prepore to pore theory can also explain data such as the ability o f 
Ply to independently form oligomers in solution (Gilbert et al, 1998). However, insertion 
o f such a large entity (the prepore) into the cell membrane would require a large amount o f
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energy. Ramachandran proposed that the energy for this insertion comes from the
unfolding o f two transmembrane helices in domain 3 upon oligomerisation which act as
coiled springs (Ramachandran et al. 2005). Arcs are not accounted for in this theory and
although they are evident in the figures o f these papers (Czajkowsky et al. 2004; Dang et
al. 2005a), their existence is not addressed. Also, the fate o f the lipid membrane following
pore insertion has not been investigated (Waltz 2005).
Figure 1.4. Prepore theory of CDC pore formation
CDC monomers (blue) bind to the lipid membrane surface but do not insert. The oligomer builds 
up to form a complete prepore which then inserts into the membrane as one entity. Note the 
change in height of the prepore as it ‘collapses’ upon insertion into the membrane (Czajkowsky et 
al. 2004). What happens to the eliminated piece of membrane, represented with the dashed line, is 
not known (Waltz 2005).
The prepore to pore theory seems to be more accepted with further research (Gilbert et al. 
1999a; Tilley et al. 2005). Using FRET (Fluorescence Resonance Energy Transfer), Hotze 
and colleagues suggested that insertion o f the prepore into the membrane is an all or 
nothing process and that monomers can not insert their transmembrane loops 
independently (Hotze et al. 2001a; Hotze et al. 2002). This has been developed further
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with evidence that the TMHs are poised high above the membrane in the prepore and then
insert to form the pore (Ramachandran et al. 2005).
It is possible that what actually occurs is a combination of the two theories, as eluded to by 
Gilbert (Gilbert 2005) or it may be that different CDCs have different mechanisms of pore 
formation. Indeed, the two theories are based on studies with different CDCs with 
Tweten’s group using PFO and Palmer focusing on SLO as representative CDCs. 
Although related, there may be differences in their interaction. Indeed PFO was shown to 
exist in solution as an anti-parallel dimer whereas Ply exists as a monomer (Solovyova et 
al. 2004) and IL Y has a unique human-specific binding receptor though it shares 
considerable structural homology with PFO (Giddings et al. 2004; Polekhina et al. 2005). 
Studies, such as those reviewed here for the CDCs, which allow an understanding of the 
mechanisms of action of virulence factors permits the rational design of vaccine candidates 
such as genetically modified toxoids.
1.13. Pneumococcal vaccines
Protection against invasive disease was generally accepted to be antibody mediated, with 
high circulating anti-pneumococcal antibodies (in particular anti-capsule antibodies) in 
patients that survive pneumococcal infection. However, recent work has disputed this and 
shown that protection against pneumococcal disease can be independent of antibodies but 
requires functional CD4+ T cells (Lipsitch et al. 2005; Malley et al. 2005). This research 
was instigated from the observation that the sharp decline in pnemnococcal disease in 
infants occui's before the natural acquisition of anti-capsular antibodies (Lipsitch et al. 
2005). This finding may have major implications for future pneumococcal vaccine design, 
although the research focuses on CD4+ T cells providing protection from carriage rather 
than protection against invasive disease (Malley et al. 2005). Currently, the basis of all
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licensed pnemnococcal vaccines is aimed at raising protective antibodies to capsule
polysaccharide.
Advances in the development of pneumococcal vaccines are shown in Table 1.4. The first 
pneumococcal vaccines were composed of killed pneumococci, but with the advent of 
antibiotics in the 1940s, such vaccines were thought to no longer be required. With the 
development of antibiotic resistant pneumococci, which was first observed in Australia and 
Papua New Guinea in the 1960s and by the 1970s multi-drug resistant strains were 
responsible for hospital-acquired pneumococcal outbreaks in South Africa (Tomasz 1997),
•i
new pneumococcal vaccines were introduced using purified capsule polysaccharide from
disease causing serotypes (section 1.13.1). The newest generation of pneumococcal
vaccines involve conjugation of capsule polysaccharides to a carrier protein to improve
their immunogenicity, especially in infants (section 1.13.2), Although the new 
.polysaccharide protein conjugate vaccine is highly efficacious against disease caused by 
the vaccine serotypes, protection is not afforded against non-vaccine serotypes. New 
approaches to pneumococcal vaccine design are currently being investigated with the 
possible inclusion of conserved pneumococcal proteins to confer species wide protection 
(section 1.14). Investigation into the use of killed unencapsulated pneumococci as a 1
vaccine has also re-emerged, which has been reported to prevent pneumococcal 1
colonisation and IPD in mice and rats (Hvalbye et al. 1999; Malley et al. 2001).
1.13.1. Pneumococcal polysaccharide vaccines
In 1977, the first pneumococcal vaccine based on purified capsule polysaccharide (CPS) 
was introduced and was composed of CPS from the top 14 disease causing serotypes. In 
the 1980s the valency of the pneumococcal polysaccharide vaccine (PPV) was increased to 
23 with the amount of polysaccharide for each serotype being reduced from 50pg to 25pg 
(French 2003). The 23-valent PPV is still administered to adults >65 years of age and to
53
Chapter 1 Introduction
patients with immune conditions such as asplenia, sickle cell disease and HIV infection
where there is an increased risk of IPD (Gebo et al. 1996; Fiore et al. 1999; Pebody et al.
2005). However, the efficacy of PPV in these patients requires further investigation as
immunisation trails of 23-valent PPV in Uganda of HIV infected patients proved that the
vaccine was ineffective at preventing IPD and in terms of efficacy against pneumonia in
HIV patients, 23-PPV was considered detrimental (French et al. 2000). Although PPV
protects healthy immunocompetent adults (<65yr) from IPD, protection of the elderly is
disputable (Oitqvist et al. 1998) and nonexistent for children <2yr. CPS from serotype 1 is
included in the 23-valent PPV vaccine yet it is poorly immunogenic in all age groups
(Scott et al. 1996).
Vaccination with free polysaccharide induces production of anti-CPS antibodies in a T-cell 
independent mamier (Weintraub 2003). The injected CPS stimulates the clonal expansion 
of B-cells by binding and cross-linking sig on the B-cell. This results in the maturation of 
B-cells into antibody producing plasma cells. However, these cells have a short life span 
(a few days) and no immune memory is created. The B-cell response is improved by 
opsonins e.g. C3 cleavage products which bind to the CPS and act as ligands for CD21 (a 
complement receptor). Children have poor CD21 expression levels and this may be a 
reason why PPV is poorly immunogenic in children (Weintraub 2003). As memory B- 
cells are not produced with PPV, boosting does not increase immunity. The antibody 
levels produced to free CPS are not long lasting and revaccination is recommended 
depending on the age/condition of patients. As PPV does not confer protection to infants, 
the major age group at greatest risk to pneumococcal disease, an alternative to 
polysaccharide vaccination has been developed (section 1.13.2).
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Table 1.4. Development of pneumococcal vaccines
Introduction
Year Advances in pneumococcal vaccines
1914 Whole killed piieumococci prevented pneumonia in South African 
miners*
1930s Antibodies developed in response to injection of CPS
1940s Prevention of pneumonia by immunisation with particular serotypes’^
1970s Protection from CPS proven, leading to the introduction of 14-valent 
PPV in 1977*
1980s PPV was modified to include CPS from 23 serotypes*
2 0 0 0 Licensure of Prevnar in the USA (7-valent PCV)
2 0 0 1 Licensure of Prevenar in Europe
2 0 0 1 Re-emergence of investigation into a whole-cell based vaccine 
(Malley et al. 2001)
2006 Proposed introduction of Prevenar into the UK immunisation schedule
2007 Proposed introduction of a 10-valent PCV (Streptorix, 
GlaxoSmitliKline)
Future Plans to develop a 13-valent PCV (Wyeth)
Future Predicted incorporation of pneumococcal proteins into the next 
generation pneumococcal vaccines (see section 1.14)
from review in 2003 (French 2003)
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1,13.2. Pneumococcal conjugate vaccines
Conjugation of CPS to various proteins has been shown to improve the immunogenicity of 
CPS and also elicits a T-cell dependent immune response in infants. The first conjugate 
vaccine to be used in routine childhood vaccination was for protection against 
Haemophilus influenzae type b (Hib b), the major cause of invasive H  influenzae disease 
out of 6  serotypes (Kelly et al. 2004). The protein conjugated to CPS from H. influenzae 
type b varies depending upon the company that produces the vaccine, however, vaccination 
with these conjugates has successfully resulted in a 90-100% reduction in invasive disease 
from serotype b H. influenzae (Peltola 2000; Kelly et al. 2004). The problem with S. 
pneumoniae is the large number of serotypes and due to the complexity, and therefore 
expense of the conjugation process, only a small number of polysaccharides can be 
included in each PCV vaccine. In 2000, Wyeth Vaccines launched Prevnar, a heptavaient 
PCV using the diphtheria toxoid CRM 197 as the protein component to confer an increased 
immune response to the capsule polysaccharides in infants (Black et al. 2000; Pelton et al.
2003). Serotype coverage by Prevnar is limited and varies globally with pneumococcal 
serotype prevalence (Hausdorff et al. 2000b; Spratt et al. 2000) as only seven out of a 
possible ninety (Henrichsen 1995) pneumococcal serotypes are included (serotypes 4, 6 B, 
9V, 14, 18C, 19F and 23F). In 2000, when Prevnar was first introduced the included 
serotypes covered almost 90% of IPD causing serotypes in North America and Canada but 
<60% of the predominant serotypes in Asia where serotypes 1 and 5 are the predominant 
cause of IPD (Hausdorff et al. 2000b).
Prevnar is currently the most effective paediatric vaccine available for protection against 
pneumococcal disease. However, the extent of protection against pneumococcal 
pneumonia (in comparison with protection obseived against pneumococcal meningitis, 
bacteraemia and otitis media) is difficult to determine due to the difficulties in diagnosing 
pneumonia with radiographs (Black et al. 2000; Black et al. 2002; Obaro 2002). In the
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Kaiser trial Black and co-workers found that overall, Prevnar was effective in reducing f
pneumococcal pneumonia in children <5 years of age and that globally this vaccine could
offer considerable protection to this age group (Black et al. 2002). Prevnar has also been
found to be immunogenic in HIV infected adults, regardless of previous exposure to 23-
PPV (Miiro et al. 2005) but this vaccine is not as efficacious in elderly populations (Briles
2004). M
Vaccination within a population not only protects those that are given the vaccine but can 
protect non-vaccinated individuals by reducing carriage rates and transmission of disease. 
This is known as herd immunity and is becoming apparent for pneumococcal disease in the 
United States sinee the implementation of childhood vaccination with Prevnar. Since 
2000, there has been a dramatic decrease in IPD in non-vaccinated adults from the seven 
vaccine serotypes. By 2004, a 53% decrease in the 18-39 year group and a 26% decrease 
in the 40-64 year group of vaccine type IPD has been observed (Whitney 2005). In >65yr 
olds in America, there has been a decrease in IPD from vaccine types by 75% since the 
introduction of Prevnar (thought to be due to herd immunity from vaccinated 
grandchildren), however this coincides with a significant increase of 14% for IPD from 
non vaccine types (Lexau et al. 2005). There was also a 50% reduction in vaccine type 
IPD in children out with the vaccination range (<2months and >5-17years) (Whitney
2005).
In order to improve global protection with polysaccharide conjugate vaccines, separate 
vaccines composed of the most invasive serotypes in each region would be required. The 
problem with vaccinating against a subset of serotypes is that the serotypes that are Icirculating in the population change. This has been observed in America since the 
introduction of Prevnar, which has been so successful in terms of herd immunity, that now 
coverage of IPD from the seven vaccine serotypes in the United States is currently only
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20% (Whitney 2005). This leads to the largest problem with vaccinating against a
subpopulation of serotypes, which is vaccine evasion by the pathogen. Termed
‘replacement disease’ or ‘serotype replacement’, many studies have monitored serotype f
distribution and have observed the replacement of vaccine serotypes with non-vaccine
serotypes either in carriage or IPD in vaccinated children and in adults as a result of
contact with immunised children (Whitney 2005). Carriage studies in children in the , ■4
United States over four years since Prevnar was introduced have revealed a 98% decrease 
in vaccine serotypes and a 79% decrease in vaccine-related serotypes but this has 
coincided with a 148% increase in carriage of serotype 19A (and an increase in 19A 
disease) and a 45% increase in carriage of other non vaccine types (Pai et al. 2005b; 
Whitney 2005). Serotype 19A is also becoming increasingly antibiotic resistant and more 
frequently switching capsule with vaccine type strains (Pai et al. 2005b). In a study of pre 
and post childhood immunisation with Prevnar, there was found to be an overall reduction 
in IPD by 19% in adult HIV patients since introduction of the vaccine and a 62% decrease 
in IPD from the seven vaccine types. However, a 44% increase in IPD from non vaccine 
serotypes in HIV patients was also observed over this time period (Flannery et al. 2006).
Earlier vaccine trials of children vaccinated with Prevnar in Finland revealed a 57% 
decrease of AOM caused by the seven vaccine serotypes, however, this coincided with a 
34% increase in AOM caused by non-vaccine serotypes (Kipli et al. 2000). Such promoted 
selection for non-vaccine serotypes is a major shortcoming of current pneumococcal ' 
vaccines, with an increase in serotype replacement reported by most countries where PC Vs 
have been evaluated or introduced (Obaro et al. 1996; Kipli et al. 2000; McEllistrem M. C.
2003; Frazao et al. 2005); reviewed by Bernatoniene and Finn (Bernatoniene et al. 2005).
Capsule polysaccharide from serotype 1 pneumococci is not included in Prevnar and with 
the rise in non-vaccine serotypes this situation needs to be closely monitored. Trials with a 
9-valent and 11-valent vaccine containing serotype 1 CPS have shown increased protection
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against IPD causing serotypes (Klugman et al. 2003; Nurkka et al. 2004), and serotype 1
CPS will be included in the 10-valent PCV soon to be licensed by GlaxoSmithKline
(PneumoADIP, www.pneumoadip.org). Although this will significantly increase
protection against pneumococcal disease, it will also increase the cost of what is already a
vaccine that is too expensive for use in developing countries. CPS from all 90
pneumococcal serotypes camiot be included in one vaccine (Klein 1995), and even within
the PCV some CPSs are less immunogenic than others (Kamboj et al. 2003). Therefore
research is focusing on alternatives to serotype specific vaccination such as the use of
species-common immunogenic pneumococcal proteins in ftitui'e vaccines (Alexander et al.
1994; Michon et al. 1998; Briles et al. 2001; Ogunniyi et al. 2001).
1.14. Potential candidates for the next generation of pneumococcal 
vaccines
The use of conserved pneumococcal proteins for vaccine production should confer broad 
serotype-independent protection against pneumococcal disease in all age groups. 
Recombinant protein vaccines are cheaper than the prohibitively expensive conjugate 
vaccines ($50/dose), making protein-based vaccines globally accessible. The main vaccine 
candidates are pneumococcal virulence factors, in particular surface proteins, as antibodies 
raised against them are likely to protect against pneumococcal infection. Pneumococcal 
surface proteins are of particular interest, as antibodies against them should promote 
opsonophagocytosis of the pneumococci. However, surface-exposed proteins are 
subjected to more selective pressure and tend to be variable between serotypes. 
Cytoplasmic proteins are more conserved as they are protected from such environmental 
pressure. Advances in genomics have opened up research of potential vaccine candidates 
with lists of putative virulence factors being produced (Tettelin et al. 2001; Wizemann et 
al. 2001). Potential vaccine candidates are shown in Table 1.5 with their homogeneity 
throughout the 90 pneumococcal serotypes given where known and also the protection
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elicited by each protein. Some proteins protect against colonisation such as PsaA (Briles et
al. 2000a; Briles et al. 2000b) and others protect against bacteraemia and/or pneumonia
e.g. CbpA and Ply (Paton et al. 1983b; Oguimiyi et al. 2001). Protection is also dependent
upon the route of administration for example Nan A protects animals against carnage when
administered intranasally (Tong et al. 2005) but it is not as protective when administered
intraperitonealy (Lock et al. 1988). Whether these proteins eliminate carriage or invasive
disease needs to be thoroughly investigated prior to inclusion in vaccines and also the
outcome of eliminating carriage needs to be assessed.
The proteins that seem to have the most potential are PsaA and Ply due to their sequence 
conservation throughout the serotypes and that they are highly immunogenic in animal 
models (Paton et al. 1983b; Talkington et al. 1996; Briles et al. 2000a; Ogumiiyi et al. 
2001). PspA was a promising vaccine candidate as it is highly immunogenic and can 
confer protection against carriage and IPD (Briles et al. 2003), however, when PspA 
entered Phase I of clinical trials it was found to share 27% sequence similarity with human 
cardiac myosin (Maleckar 2004); further investigation has ceased.
%
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Table 1.5. Pneumococcal proteins that are potential vaccine candidates
Protein Sequence conseivation Protection studies (reference)
CbpA
(PspC, SpsA)
Only present in 75% of 
serotypes, highly 
variable N-terminus 
(Berry et al. 2000)
Protects mice against bacteraemia and 
carriage (Brooks-Walter et al. 1999; 
Ogunniyi et al. 2001)
ClpP - Protects against sepsis (Kwon et al. 2004)
LytA Present in all strains 
(Neeleman et al. 2004) 
but sequence 
conservation not 
determined
Partially protects mice against infection 
when used alone (Berry et al. 1989a) or as 
a carrier protein to 9V CPS (Lee et al. 
2001b)
Nan A Highly diverse (King et 
al. 2005)
Protects against pneumonia and sepsis 
though not as well as Ply (Lock et al. 1988) 
and protects chinchillas against 
nasopharyngeal colonisation (Tong et al. 
2005)
Pht proteins
(Histidine
triad)
Conserved Protect mice against lethal sepsis (Adamou 
et al. 2001)
PhpA protects mice against pneumonia 
(Zhang et al. 2001)
PiaA & PiuA Highly conserved 
(Whalan et al. 2006)
Protects against bacteraemia (Brown et al. 
2001)
Ply Originally thought to be 
highly conserved 
(Mitchell et al. 1990), 
but further analysis has 
revealed variation 
between and also within 
serotypes (Kirkham et 
al. 2006b) (Jefferies et 
al, manuscript in 
preparation)
Humans with a-Ply IgG have reduced risk 
of bacteraemia
Human a-Ply IgG passively protects mice 
from challenge with type 1 and 4 
pneiunococci (Musher et al. 2001)
Protects against pneumonia (Paton et al. 
1983b) and bacteraemia (Ogunniyi et al. 
2001)
An effective carrier protein when 
conjugated to CPS (Alexander et al. 1994; 
Lee et al. 2001b)
PpmA Limited variation 
(Overweg et al. 2000)
Hyper-immune anti-PpmA sermn is 
effective in phagocytosis of pneumococci 
(Overweg et al. 2000)
Immunogenic in humans (Vainio et al. 
2006)
PppA Conserved Reduces colonisation (Green et al. 2005)
PsaA Variable (Berry et al. 
1996)
PsaA protects mice against pnemnococcal 
colonisation (Briles et al. 2000a) and sepsis 
(Talkington et al. 1996)
PspA Serologically variable 
(2 families, 6 clades)
Anti-PspA antibodies protect against 
carriage and invasive disease in humans 
(Palaniappan et al. 2005)
Mucosal immunisation protects mice 
against carriage (Wu et al. 1997)
Confers protection against AOM (White et 
al. 1999) and pneumonia (Briles et al. 
2003)
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CbpA, choline binding protein A; ClpP, caseinolytic protease P; Lyt A, Autolysin A; Nan A, 
neuraminidase A; Pht, pneumococcal histidine triad protein; PiaA, pneumococcal iron acquisition 
protein A; Pin A, pneumococcal iron uptake protein A; Ply, pneumolysin; PpmA, putative 
proteinase maturation protein A; PppA, pneumococcal protective protein A; PsaA, pneumococcal
1.14.1. Combinations of pneumococcal proteins may be more 
efficacious
It may be that a combination of pneumococcal proteins would provide the best protection 
against pneumococcal disease. This area requires further investigation though some 
groups are begimiing to focus on this (in particular the research groups of David Briles in 
Alabama and James Paton in Adelaide), see Table 1.6 for a list of vaccination studies with 
combinations of pneumococcal proteins. There is also developing interest on mucosal 
presentation of pneumococcal proteins to the host to elicit protection against carriage or 
pneumonia. Mucosal immunity against pneumococcal pneumonia has been demonstrated 
by vaccination with Lactococcus lactis ghosts displaying combinations of pneumococcal 
proteins (van Seim et al. 2005). Another area of research is the use of DNA based 
vaccines where DNA encoding the protein antigen is directly injected into the host to raise 
a protective immune response. There have been a few studies using DNA encoding 
pnemnococcal antigens such as Ply, type 4 polysaccharide, PspA and PsaA (Lee et al. 
2001a; Lesinski et al. 2001; Miyaji et al. 2001; Miyaji et al. 2002; Miyaji et al. 2003). 
Generally the major problems with DNA vaccination is that a large amount of DNA is 
required to elicit a good immune response and although promising cell-mediated protection 
was observed in animal vaccination models, this was not the case in human trials of DNA
I
surface adhesin A; PspA, pneumococcal surface protein A; -, sequence conservation between 
pneumococcal serotypes has not been determined.
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vaccination where antibody mediated immune responses were poor if raised at all (Dr. Gill
R. Douce, personal communication, 2006).
Table 1.6. Combinations of pneumococcal proteins that increase 
protection
Protein combination Reports of additive protection against pneumococci
Ply (PdB) + PspA Improves protection against bacteraemia (Ogunniyi et al. 
2000) and pneumonia (Briles et al. 2003)
Ply (PdB) + PsaA Protects against bacteraemia better than PdB alone 
(Ogunniyi et al. 2000)
Significantly improves protection against pneumonia 
(Briles et al. 2003)
PspA 4- PsaA Elicits additive protection against bacteraemia (Ogunniyi 
et al. 2000), pneumonia (Briles et al. 2003) and carriage* 
(Briles et al. 2000a; Briles et al. 2001)
Ply (PdB) + CbpA Protects against bacteraemia better than PdB alone 
(Ogunniyi et al. 2001)
Suggested Ply + Hyl Double knockout of these genes attenuates pneumococci 
(Berry et al. 2000)
Ply, pneumolysin; PdB, Ply with reduced cytolytic activity; PspA, pneumococcal surface protein 
A; PsaA, pneumococcal surface adhesin A; CbpA, choline binding protein A, * when administered 
mucosally; Hyl, hyaluronidase.
1.15. Potential use of Ply as a vaccine candidate
Pneumolysin, is of particular interest as a vaccine candidate as it is produced by all strains 
of S. pneumoniae (Kalin et al. 1987) and is protective in animal models of vaccination 
(Paton et al. 1983b; Alexander et al. 1994; Kuo et al. 1995; Michon et al. 1998). Ply could 
be used alone (Paton et al. 1983b; Alexander et al. 1994) or as a carrier protein to the 
polysaccharides in current vaccine preparations (Paton et al. 1991; Kuo et al. 1995; 
Michon et al. 1998), conferring increased protection against pneumococcal disease, 
including pneumonia that is not well protected by the current conjugate vaccine.
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Generally, the amino acid sequence of pneumolysin was thought to be highly conserved
tliroughout all pneumococcal serotypes with little variance over time and geographic
distance (Mitchell et al. 1990). However, in 1996 Ply from serotypes 7 and 8 was reported
to possess a threonine to isoleucine substitution at amino acid position 172 that reduces the
specific activity of the toxin (Lock et al. 1996). Ten years later, Ply from serotype 1
clinical isolates has also been found to be variable (Kirkham et al. 2006b), see chapter 7.
1.15.1. The PdB pneumolysin toxoid and other existing Ply mutants
Immunogenic Ply mutants (Paton et al. 1991; Alexander et al. 1994) with reduced 
cytotoxicity have previously been constructed (Boulnois et al. 1990; Baba et al. 2001), 
however, these mutants retain the ability to form pores in host cell membranes. One Ply 
mutant extensively researched and commonly referred to as the PdB toxoid has a 
tryptophan to phenylalanine substitution at amino acid position 433 in domain 4 (W433F). 
This mutant retains 0.1 to 1% haemolytic activity compared with WT Ply (Paton 1996; 
Korchev et al. 1998). Another Ply mutant with negligible activity was reported (Michon et 
al. 1998), yet the location of the mutation was not identified and protection against 
pneumococcal disease was not proven. It is important to note that residual haemolytic 
activity of Ply is adequate for full virulence of the pneumococcus as demonstrated by the 
clii'omosomal replacement of WT Ply with Ply carrying a mutation that reduces the 
specific activity of the toxin to 0.1% of WT Ply (Berry et al. 1995). PdT is a triple point 
mutation D385N, C428G, W433F derived from PdB that is devoid of lytic and 
complement activating activities (Berry et al. 1995). However, this mutant is highly 
unstable with degradation observed in Western blots with a monoclonal antibody (PLY5) 
that recognises the C-terminal end of the protein (Prof. Tim J. Mitchell, personal 
communication, 2005). It may be that the complement activating properties of Ply are of 
an actual benefit in terms of use as a vaccine candidate as complement activation may 
promote a protective immune response.
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In 1994, a series of Ply mutations were constructed by random mutagenesis and resulted in |  
the first N-terminal mutations that affected haemolytic activity of the toxin (Hill et al.
1994). Substitution of histidine at amino acid position 156 with tyrosine (H156Y) resulted 
in a 98% reduction in haemolytic activity. In 1996, monoclonal antibodies (mAbs) were 
raised against various regions of Ply and used to probe the whole toxin and a ‘proteinase K 
nicked’ form (de los Toyos et ai. 1996). Proteinase K. cuts Ply into a 37kDa and 15kDa /
fragment and sequencing of the 37kDa fragment revealed that the N ’ terminus began 
NVPAR (amino acids 143-147, Figure 1.5). This N143 region in Ply has been shown to be 
highly antigenic by epitope scamiing and is recognised by both human sera and rabbit 
hyper-immune sera (Salo et al, 1993). Some of the mAbs were found to neutralise the 
haemolytic activity of Ply (de los Toyos et al. 1996). All mAbs probed against Ply 
recognised both whole Ply and the 37kDa fragment, except mAh Ply 4, which recognised 
whole Ply but not the fragments, indicating that the epitope for this antibody was within 
the nicked region. Pre-incubation of Ply with mAh Ply 5 and Ply 8 was found to block 
binding of the toxin to the host cell membrane whereas pre-incubation with mAh Ply 4
prevented pore formation on liposome membranes.
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Figure 1.5. Proteinase K cleaves pneumolysin into two fragments
Introduction
(a) Proteolytic
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(a) When pneumolysin is treated with proteinase K it is cleaved into two fragments (15kDa and 37 
kDa) and the 37kDa fragment begins with amino acid N143 (de los Toyos et al. 1996). (b) the site 
of proteolytic cleavage (N142/N143) is Inghlighted in red and is in domain 1 at the linker sequence 
to domain 3.
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This implied that the site blocked by mAb Ply 4 (thought to include the N143 region) is
responsible for interaction of Ply with other Ply monomers to form pores. Indeed, this
region has recently been confirmed to be involved in CDC oligomerisation (Ramachandran
et al. 2004), discussed in section 1.12. Fine epitope mapping revealed that the epitope for
mAh Ply 4 was actually located further downstream of Ply than previously suggested
(Suarez-Alvarez et al. 2003). The Ply 4 epitope was found to be conformation dependent
and only recognised fragments of Ply where domain 1 and 3 were together (as occurs in the
structural model). From this work, the epitope for mAh Ply 4 was shown to encompass a
core structure between amino acids E l51 and Y247 (Suarez-Alvarez et al. 2003). This
region is highlighted in red in Figure 1.6 and demonstrates that this epitope spans domains
1 and 3. The epitope on Ply for mAh Ply 8 was determined to include amino acids 450 to
458 at the C’ terminus, which are known to be involved in host cell binding (see section
1.12). More recent work has shown that these monoclonal antibodies can significantly
increase suivival times of mice from pneumococcal pneumonia (Garcia-Suarez et al.
2004). Intravenous treatment with combinations of these monoclonal antibodies resulted
in an even greater increase in survival times following pneumococcal challenge, suggesting
a synergistic effect from the antibodies blocking different actions of Ply such as
oligomerisation and host cell binding.
Prior to the epitope mapping in 2003 (Suarez-Alvarez et al. 2003), modifications around 
the N143 region in Ply were hypothesised to result in a non-oligomerising form of the 
toxin by altering the Ply-Ply interaction site. A N142N143 deletion and N143D 
substitution within Ply were previously constructed in oui' laboratory as initial steps to 
understanding this region and its role in oligomerisation, however both mutants behaved 
identically to native Ply in terms of haemolysis and pore formation (Search, 2002).
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Figure 1.6. Proposed epitope for mAb Ply 4 that blocks oligomerisation
The epitope in Ply for monoclonal antibody Ply 4 was conformation dependent and fine epitope 
mapping identified the epitope to encompass amino acids E l51 to Y247, highlighted in red 
(Suarez-Alvarez et al. 2003), that spans domains 1 and 3.
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1.16. Aims of this project
The aim of this project was to construct mutations at the site of Ply thought to be involved 
in monomer-monomer recognition, thereby preventing oligomerisation and pore formation 
of the toxin. As the project progressed there was more information available as to the 
regions of Ply that may be involved in oligomerisation (Suarez-Alvarez et al. 2003; 
Ramachandran et al. 2004). Construction of a non-oligomerising Ply mutant was in view 
of creating a non-toxic form of Ply for use in the next generation of pneumococcal 
vaccines. Purification of the mutants would be investigated to determine the most efficient 
tecliniques in LPS removal, protein yield and purity. Upon production of a non­
oligomerising form of Ply, toxicity of the mutants would be determined using existing 
assays and with the development of a more sensitive in vitro assay. Non-toxic mutants 
would then be assessed in vivo and their immunological properties compared with WT Ply.
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&2.1. Bacterial strains, storage and growth conditions
s. pneumoniae strains were grown from a single colony in BHI (Brain Heart Infusion 
broth: Oxoid) at 37°C without shaking to mid-log phase (ODeoonm 0 6) and stored in 1ml 
aliquots at -80°C with Protect beads (Technical Service Consultants, Lancashire, UK) or in
10% glycerol (Sigma-Aldrich, Dorset, UK). Strain purity and optochin sensitivity was ;
I
checked by streaking the culture on BAB plates (Blood Agar Base; Oxoid) supplemented 
with 5% horse blood (E & O Laboratories, Bonnybridge, UK) prior to freezing. E. coli
%strains were grown overnight from a single colony with the appropriate antibiotic in LB 
(Luria broth; Sigma-Aldrich) at 37°C with shaking at 200rpm. 1ml aliquots were then 
stored at -80°C in 10% glycerol.
2.2. Preparation of pneumococcal genomic DNA and E, coli 
plasmid DNA
lOml of mid-log phase grown pneumococci were centrifuged at 3000g for 20 min at 4°C to 
pellet cells. The culture media was discarded and the cell pellet lysed with lysis buffer 
(lOmM Tris, lOOmM EDTA, 0.5% SDS in dHiO) to extract the genomic (g) DNA using 
Qiagen midi columns (Qiagen, West Sussex, UK) and following the manufacturers 
instructions. Plasmids carrying mutations made by site-directed mutagenesis were purified 
from 5ml overnight cultures o f E. coli using a plasmid miniprep kit (Qiagen) and following 
the manufacturers instructions. DNA quantity and quality was monitored by agarose gel 
electrophoresis.
2.3. Pneumolysin PCR and DNA sequencing
Pneumococcal ply  genes (1.4Kb) were amplified by PCR from gDNA preparations using 
Taq polymerase (Promega, Southampton, UK) and primers 27R and 278 (Table 2.1) to
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give an amplicon size of 2406bp. PCR products were cleaned using PCR purification
columns (Qiagen) and then sent for DNA sequencing (DBS Genomics, Durham, UK) using
primers 27R, 4T, 4V, 4W, 9Y and 27T (Table 2.1). Sequence data for each ply gene was
assembled, aligned and translated using Vector NTF"^ software (Invitrogen, Paisley, UK).
Plasmid DNA, containing the ply  gene, was sent for sequencing with the same primers.
The ply gene was amplified by PCR from gDNA of the 00-3645 strain using primers 9Y
and 9Z that encode restriction enzyme sites (Table 2.1, enzyme sites underlined) for
subsequent digests to give an amplicon size of 1418bp. The 00-3645 Ply PCR product was
cut with Bamliil and S a d  (Promega) and ligated into Bam RllSad  digested pET33b (Merck
Biosciences) to give pETplyOO-3645. This plasmid was transformed into E. coli XL-1
cells (Stratagene, Amsterdam, Zuidoost, Netherlands) and the sequence of the insert
confirmed. Work with 00-3645 was in collaboration with Dr. Johamia Jefferies and Ms Yu
Jing.
Table 2.1. Primers used for ply  PCR and DNA sequencing
LAB reference Sequence 5'-3'
4V CAATACAGAAGTGAAGGCGG
4T GTTGATCGTGCTCCGATGAC
4W GATCATCAAGGTAAGGAAGTC
27R CTTGGCTACGATATTGGC
27S TACTTAGTCCAACCACGG
27T ATAAGTCATCGGAGCACG
9Y CGGGATCCGGCAAATAAAGCAGTAAATGACTTT
9Z GACGGAGCTCGACTAGTCATTTTCTACCTTATC
15C GGAGGTAGAAGATGGCAAATAAAGC
15D CTAGTCATTTTCTACCTTATCCTCTACC
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2.4. Multi-locus Sequence Typing (MLST)
MLST was carried out at the Scottish Meningococcal and Pneumococcal Reference 
Laboratory using previously described primers (Enright et al. 1998) and a semi-automated 
method (Jefferies et al. 2004). MLST involves DNA sequencing of seven housekeeping 
genes {aroE, gdh, gki, recP, spi, xpt and ddl) from the gDNA of pneumococcal isolates 
(Enright et al. 1998). Using the MLST website (http://www.mlst.net), each allele is 
assigned a number depending upon its sequence and this results in a seven digit ‘barcode’ 
for each isolate. This barcode is then used to determine the sequence type (ST) of the 
isolate, allowing isolates with new allelic numbers to become a new ST and isolates with 
barcodes already in the database are assigned the same ST number. This allows the global 
comparison and surveillance of pneumococcal strains at a genetic level rather than by 
serotype.
2.5. Preparation of pneumococcal cell extract for analysis of Ply
Single colonies of each isolate were selected from blood agar base plates (Oxoid) 
supplemented with 5% horse blood (E & O laboratories) and grown to mid log phase in 
15ml or 50ml BHI. 10ml of each 15ml culture and 40ml of each 50ml culture were 
centrifuged at 3000g for 20min at 4°C and the cell pellet stored overnight at -20°C. The 
cell pellets were resuspended in 1.5ml 1 x PBS (Phosphate Buffered Saline: Oxoid, 
Basingstoke, UK) and sonicated on ice using a high intensity ultrasonic processor (Jencons 
Scientific Ltd, Bedfordshire, UK) with 3 x 1 0  sec and 10 sec in between at an amplitude of 
10%. Cell lysates were centrifuged in eppendorfs at 20,000g for 30min at 4°C. The 
soluble fraction (cell extract) was transferred to a separate tube and the insoluble fraction 
(pellet) washed in 1 x PBS and resuspended in 1.5ml PBS. The total protein content of the 
cell extract and pellet was determined using Bradford’s assay (Bradford 1976), detailed in
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section 2.7,1. Cell extracts were diluted to 300|ag/ml total protein (or 2.35mg/ml total
protein for the concentrated samples) to give a baseline from which Ply expression levels
and haemolytic activity were measured.
2.6. Expression and purification of recombinant Ply
2.6.1. Protein expression
The template plasmid was the high expression vector pKK233-2 (Clontech Laboratories 
Inc, Palo Alto, CA) in which p/y from D39 51 pneumoniae was previously inserted (Paton 
et al. 1991). All Ply mutants were made in pKK233-2, unless otherwise stated. Wild type 
(WT) Ply and all Ply mutants were expressed in E. coli XL~1 cells (Stratagene) in either IL 
HySoy J media (Sigma-Aldrich, manufacture discontinued in 2004) or Terrific Broth (TB, 
see appendix for recipe). Each litre was inoculated with 5ml of overnight culture plus 
lOOpg/ml of ampicillin and filter sterilised glucose to give 1% glucose/L in the case of 
Hysoy J media or phosphate buffer to TB. Flasks were shaken at 37”C, 200rpm until 
cultures reached an OD^oo^m 1.5 then induced with ImM IPTG (Sigma-Aldrich). Flasks
:were shaken for a further 3 hours at 37°C. Cells were haiwested by centrifugation for
'
15min at 4000g at 4°C using a 4K15 centriffige. Pelleted cells were frozen overnight at -
20°C then resuspended in 20ml 1 x PBS per litre of harvested cell culture. To disrupt cells 
and release Ply, cells were passed tlirough the One-shot Cell Disrupter (Constant systems 
Ltd, Warwick, UK) at pressure of 12,000 psi. Cell lysates were centrifuged at 20,000g for 
30 mill at 4°C to remove cell debris.
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2.6.2. Purification of Ply and derivatives
2.6.2.1. Hydrophobic interaction chromatography
Different columns were used to purify WT Ply and the mutants to avoid cross 
contamination. Cell lysate containing Ply was diluted in chilled 3M NaCl to give a final 
salinity of 1.5M NaCl. This was performed in 10ml aliquots and prepared immediately 
before purification. The sample was then filtered using 0.2pM syringe filters (Sartorious, 
Harmover, Germany). The matrix used for Hydrophobic Interaction Chromatography 
(HIC) was POROS 20 PE packed into a 100mm column with 4.66mm diameter (Applied 
Biosystems Ltd, Warrington, UK). The BioCAD 700E workstation (Applied Biosystems 
Ltd) was used for both HIC and anion exchange chromatography (AEC) purification. All 
buffers were made in Millipore distilled water and filtered and degassed prior to use (see 
Appendix for buffer recipes). The column was flushed with dialysis buffer (PB-S, 
appendix I) to prepare the system, removing ethanol from column storage and then 
equilibrated with 1.5M NaCl. 5ml of sample was loaded onto the column that was then 
washed with a NaCl gradient ranging from 1.5M NaCl to OM over 7 column volumes, 
collecting wash off from the column in 2ml aliquots. Protein is eluted from the column in 
0.2M -  O.IM NaCl. For WT Ply this was in fractions 6-9. Eluted fractions were run on 
10% SDS-PAGE and stained with coomassle blue using standard protocols (Laemmli 
1970).
2.6.2.2. Dialysis of HIC purified protein for further purification
Fractions containing >98% pure Ply were pooled and dialysed overnight to remove any 
traces of salt. Dialysis tubing with a molecular weight cut off point of 14,000Da (Medicell 
International Ltd, London, UK) was previously boiled in 2% sodium bicarbonate solution 
with ImM EDTA for lOmin, thoroughly washed in distilled water and stored in 20%
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contaminants, DNA and LPS, remained bound to the column until higher salt 
concentrations were passed tln*ough the column. Ply eluted in fraction 14 (in the 24^ 
column volmne for both WT and mutant Ply) and this fraction from each run was pooled to 
give purified protein, which was stored in small aliquots at -20°C. Samples were not 
repeatedly freeze/thawed.
2.6.2.4. Construction, expression and purification of eGFP 
tagged proteins
Mr. Graeme Cowan constructed, expressed and purified eGFP tagged versions of WT Ply 
and A6 Ply in the following manner: the coding sequence of Ply was amplified by PCR 
using primers 9Y and 9Z (Table 2.1). The PCR product was ligated into BamHHSacl 
(Promega) digested pET33b (Merck Biosciences, Nottingham, UK) to produce pET33bPly 
and transformed into TOP 10 E, coli (Invitrogen). The GFP coding sequence was amplified
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ethanol at 4°C. Prior to use, a section of dialysis tubing was cut and washed in distilled
water to remove ethanol traces, one end was sealed with two dialysis clips and the HIC
purified protein transferred into the tubing and sealed with two clips. The pooled protein
fractions were dialysed overnight in IL phosphate buffer (without NaCl), this was then ■ ) schanged a further two times prior to 2-3 fold concentration of the sample using Amicon  ^
ultra-15 centrifugal filter tubes (Millipore, Watford, UK). Samples were centrifuged in the 
filter tubes at lOOOg at 4°C and the concentrated samples were pooled together.
's
2.6.2.3. Anion Exchange Chromatography
The concentrated sample from overnight dialysis was further purified by AEC using 
Poros® HQ20 Micron media and the BioCAD® 700E workstation (Applied Biosystems 
Ltd, Warrington, UK). A NaCl gradient from OM to IM NaCl was introduced once the
Lprotein was bound to the column and washed. The protein eluted in O.IM NaCl whilst
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from pNF320 (Freitag et al. 1999) by PCR using primers GFPpet33bfwd and
GFPpet33brev (Table 2.3). The PCR product was cut with Nhel and BglW (Promega),
ligated into NheVBamHl digested pET33bPly and transformed into TOP 10 E. coli.
Mutations F64L and S65T (Cormack et al. 1996) were introduced into GFP by site-
directed mutagenesis as described in section 2.8 using primers EGFP-fwd and EGFP-rev
(Table 2.3) to give enhanced(e)GFP. A6eGFP-Ply was created by site directed
mutagenesis of pET33bEGFPPly using the A6 fwd and A6 rev primers (Table 2.3).
Sequences were confirmed and the plasmids were transformed into BL21 (DE3) E. coli
(Stratagene).
Cell extracts of recombinant eGFP WT Ply and eGFP A6 Ply were expressed and disrupted 
as described for WT Ply in section 2.6. The pET33b vector was used to clone a six- 
histidine tag to the N' terminus of eGFP-Ply. The histidine tag allows purification of 
proteins using immobilised metal affinity cluomatography (IMAC). The principle of 
IMAC is based on the interaction between histidine and nickel. Cell extract is passed 
through a Ni-NTA (Nickel-Nitrilotriacetic acid resin) column (charged with immobilised 
nickel cations) and the histidine tagged protein is retained on the column and non-specific 
proteins are eluted. An imidazole gradient, from 0 - 300mM (Search 2002), is then 
introduced to compete with histidine in binding to the nickel charged column resulting in 
the elution of the histidine-tagged protein (pneumolysin elutes between 150-200mM 
imidazole). Fractions containing purified toxins were dialysed thiee times at 4°C against a 
greater than 50-fold volume of 1 x PBS. The disadvantages of IMAC are that the sample 
is eluted in imidazole, which must be removed by dialysis prior to in vivo studies, and that 
the incoiporation of a histidine tag may affect the structure or function of the protein.
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2.7. Analysis of purified proteins (and pneumococcal lysates)
2.7.1. Determination of protein concentration by Bradford’s 
reaction
Total protein content of samples was determined using a standard Bradford’s assay 
(Bradford 1976). This assay is based on the principle of an absorbance shift from A465 to 
A595 when protein binds to acidic Brilliant Blue G-250. The amount of absorbance shift 
is directly proportional to the amount of protein present. A standard curve was prepared 
from serial dilutions of 2mg/ml BSA (Bovine Serum Albumin; Sigma) from 1.5mg/ml to 
Omg/ml, diluted in PBS. lOpl of standards and samples were transferred in duplicate to a 
flat bottom 96-well plate and 200pl Bradford’s reagent was added (Bio-rad, Hertfordshire, 
UK). Absorbance was read at 570nm and the protein concentration of the sample was 
determined using the standard curve. For pneumococcal cell lysates, all samples were 
diluted to the same total protein level prior to ftirther analysis.
2.7.2. Haemolytic Assay
The haemolytic activity of purified protein (or pneumococcal cell extract with standardised 
protein content) was assessed by a haemolysis assay (Walker et al. 1987) using a 2% 
(vol/vol) sheep erythrocyte suspension (E & O laboratories) or human erythrocyte 
suspension (Blood Transfusion Sei-vices, Scotland) in 1 x PBS. Two fold dilutions of 
samples were prepared in duplicate in U-bottom 96-well plates with IxPBS. For purified 
protein 50pi of sample and 50pi PBS were placed in the first well, whereas for 
pneumococcal lysates lOOpl of lysate was used neat in the first well. Following dilution, 
50pl of 2% erythi'ocyte suspension was added to each well and the plates were incubated at 
37°C for 30min. Plates were then left for 30min at RT to allow red blood cells to settle. 
The endpoint is the well where there is 50% lysis of erythi'ocytes, leaving 50% pelleted
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erythrocytes. The reciprocal of the dilution at which the endpoint is reached is used to give
Haemolytic Units (HU) per ml o f sample, e.g. the first well has 50pl o f sample and 50pl
PBS, which is a two-fold dilution, then 50pl is removed for subsequent dilutions and 50pl
o f erythrocyte suspension is added resulting in a four-fold dilution but this is only in a total
volume o f lOOpl and is therefore multiplied by 10 to give the dilution per ml, which is 1/40
for the first well. This means that well 2 represents a 1/80 dilution and well 3 a 1/160
dilution, therefore, if  the endpoint was well 3, there would be 160 HU per ml o f sample, as
shown in Table 2.2.
Table 2.2. Haemolytic titre endpoints to give HU/ml
1 40 7 2560 13 . 1 % U 0 ^ ^ ^
2 80 8 i1 , 5120 14 3.3 X lO’
3 160 9 1.0 X lO"* 15 6.6 X 10*
■4 320 2.0 X 10^
- 1 7 ' 4 : ^ '
1.3 X 10*
:s 640 11 4.1 X 10“* 2.6 X 10*
6 1280 12 ' 8.2 X 10“* 5.2 X 10*
In order to measure the percentage o f haemolysis for a quantitative haemolytic assay, 
1 OOpl o f supernatant was carefully transferred from each well into a flat bottom plate and 
the amount o f haemoglobin released into the supernatant measured with an absorbance o f  
540nm. The percentage haemolytic activity was calculated using 0.04% ammonia to give 
100% lysis and plotted against toxin concentration.
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2.7.3. SDS-PAGE and Western Blotting
SDS-PAGE was used to assess the purity of fractions at each stage of purification. Unless 
otherwise stated 10% gels were used throughout. Samples were diluted two fold in sample 
buffer and boiled for 5min prior to loading on gels. Kaleidoscope marker (Bio-Rad) was 
used for all SDS-PAGE intended for Western blotting. Gels were run for 80min at 100 
Volts and either stained or transferred to Hybond-C nitrocellulose membrane (Amersham 
Biosciences, Buckinghamshire, UK) and blotted for 90 minutes at 80 Volts. For detection 
of Ply expression, Western blots were blocked overnight at RT in 3% skimmed milk in 
Tris-NaCl pH 7.4 with shaking and then incubated at 37°C with shaking for 2h in 3% 
skimmed milk with 1:2000 polyclonal rabbit anti-Ply serum (Mitchell et al. 1989). 
Membranes were then washed x 4 in Tris-NaCl pH 7.4 and incubated for Ih with 1:1000 
HRP-linked anti-rabbit IgG (Amersham Biosciences) in 3% skimmed milk, washed x 4 
and developed in developing solution. The reaction was stopped with distilled water. For 
all recipes see Appendix I.
2.7.4. Analysis of Lipopolysaccharlde (LPS) contamination in 
purified proteins
2.7.4.1. Silver staining for LPS
The presence of LPS in the samples post purification was assessed using a slightly 
modified method from Tsai and Frasch (Tsai et al. 1982) which is explained below, recipes 
for all solutions are given in Appendix I. Prior to running protein samples on SDS-PAGE, 
samples were incubated with lOOpg of Proteinase K (Sigma)/ml of sample for Ih at 37°C 
in order to digest the protein and leave only LPS in the sample. An equal volume of 5 x 
SDS sample buffer (e.g. 10pi sample + lOpl buffer) was added to each sample and boiled 
for 5mill. The samples were then loaded on to a 15% SDS-PAGE gel and run until the
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smallest marker reached 2/3 down the gel (LPS runs at 6kDa). The LPS in the gel was
then fixed by shaking overnight in Fixing solution. The gel was then placed into 0.7%
periodic acid in Fixing solution for 5 min to oxidise the LPS. The gel was then washed by
shaking for 15 min x 3 in 500ml distilled water. Following washing, the gel was immersed
in staining solution and shaken vigorously for lOmin while covered, as the stain is light
sensitive. The gel was then washed again x 3 and then placed in the formaldehyde
developer for 2-5min until a band was visible on the gel for the positive LPS sample
(kindly provided by Mr. Gordon Cheung). The reaction was stopped before there was any
background staining by placing the gel in 10% acetic acid for 30 sec. The gels were
washed and stored in water.
2.7.4.2. Quantification of LPS using the Limulus Amebocyte 
Lysate assay
Lipopolysaccharlde (LPS) content of purified protein was determined using the Limulus 
Amebocyte Lysate (LAL) Kinetic-QCL® Kit (Cambrex, Nottingham, UK), which was run 
according to manufacturer's instructions and with the help of Dr. Rosie Smith. The LAL 
assay is a standardised protocol approved by the Food and Drug Administration for the 
measurement of endotoxin levels in pharmaceuticals and biological products. In 1964, 
endotoxin was discovered to react with a protein in the circulating amebocytes of 
horseshoe crabs (Limulus polyphemus). This protein was identified as coagulase and 
purified for exploitation of its enzymatic reaction with Gram negative endotoxin (Young et 
al. 1972). Samples are mixed with a LAL substrate reagent (Ac-Ile-Glu-Ala-Arg-pNA) 
and the time taken for the conversion of this colourless substrate to p-nitroaniline, which is 
yellow in colour, is measured photometrically. The reaction time is inversely proportional 
to the amount of endotoxin present in the samples and a standard curve using known 
amounts of endotoxin fi'om E. coli 055:B5 is used to determine endotoxin levels in 
samples.
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All test tubes, plates, pipette tips and water were endotoxin free (Cambrex). LPS from E. 
coli 055 :B5 (Cambrex) was reconstituted in endotoxin free water and vortexed for lOmin 
to give 50EU (Endotoxin Units)/ml. Four 10-fold dilutions of this were prepared to give a 
standard curve ranging from 50EU/nil to 0.005EU/ml, with thorough vortexing in between 
dilutions. Samples were diluted by 1/100 and 1/10,000. Samples and standards were 
added in quadruplicate to a flat bottom 96-well plate. Two wells for each sample were 
then spiked with a known amount of endotoxin. Incorporation of a known amount of 
endotoxin into samples allows for investigation of whether or not the sample inhibits or 
enhances the enzymatic reaction, which is automatically calculated by the Kinetic-QCL 
software. The blank was endotoxin free water, which was the last sample to be added. 
The plate was then incubated in the plate reader at 37°C for lOmin. The supplied lysate 
was reconstituted with the appropriate volume of water and lOOpl added to each well. The 
plate was then read at an absorbance of 405nm over 90min. The time taken for the 
reaction to reach saturation was recorded and samples within the range were selected for 
reading from the standard curve to give the amount of EU/ml of sample.
2.8. Construction of Ply mutants by site-directed mutagenesis
Eight double amino acid deletions and a single A 146 deletion were created in the ply gene
using a Quikchange® site directed mutagenesis kit (Stratagene). The template plasmid for
all ply manipulation unless otherwise stated was the high expression vector pKK233-2
(Clontech Laboratories Inc) in which ply was previously inserted (Paton et al. 1991). Mr.
Graeme J. M. Cowan cloned Perfringolysin O into the pKK233-2 vector (Solovyova et al.
2004). Primers (Sigma-Genosys Ltd, Haverhill, UK) designed to delete or substitute the
relevant amino acids are shown in Table 2.3. The principles of site-directed mutagenesis
are shown in Figure 2.1. Complementary forward and reverse primers (25-40 bases) were
designed against the region of toxin to be mutated with the desired mutation made in the
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middle of each primer (Primer sequences in Table 2.3). PCR reactions were set up in 50pl
dH20 with 5pi lOxreaction buffer, 125ng of each primer, l-3pl purified plasmid DNA
(~10ng) carrying the ply gene, 2mM dNTPs, and Ipl PfuTurbo® polymerase (2.5U),
which is a high fidelity enzyme that reads the whole plasmid on each cycle, resulting in the
creation of plasmids carrying the desired mutation. PCR conditions varied depending upon
the mutation required (12 cycles for point mutations and 18 cycles for deletions or
insertions) and the size of the template plasmid.
PCR conditions: 95°C for 30sec
12 or 18 cycles of 95°C for 30sec
55°C for Imin
68°C for 2min/Kb of plasmid 
Final extension of 68°C for lOmin
An enzyme digest with lOU Dp>i?I/50pl sample is used after PCR in order to digest the 
methylated parental DNA (the parental plasmid DNA must be isolated from a dam-^ E. coli 
strain to enable the isolation of the daughter DNA through digestion of methylated parental 
DNA. According to the manufacturers guidelines, DNA from almost all strains of E. coli 
is methylated with the exception of the JMl 10 and SCSI 10 series. In this work, plasmids 
were isolated from XL-1 and XL-10 E. coli). The unmethylated PCR product, which is not 
digested, can then be transformed into E. coli cells such as XL-1 blue supercompetent cells 
for protein expression and purification (see Figure 2.1. for schematic of s.d.m. process).
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Figure 2.1. Principal of site-directed mutagenesis
+
(a) (b) (c) (d)
Site-directed mutagenesis, (a) Shows parental plasmid DNA with insert of the gene that will be 
mutated e.g. ply in white. The primers are the bars above, which are complementary to each other 
and have the desired mutation in the middle of the primer (shown in blue); this can be base pair 
substitutions, deletions or insertions, (b) The parental plasmid and the primers are mixed and used 
in a PCR reaction with PFU Turbo polymerase, dNTP’s and reaction buffer, supplied in kit from 
Stratagene. The DNA polymerase replicates the whole of the plasmid with the new primers 
annealed to this. This results in the production daughter plasmid DNA containing the desired 
mutation. However, the parental plasmid DNA remains (c). A Dpnl digest is introduced to digest 
the methylated parental DNA, leaving the daughter plasmid DNA (d) that can then be transformed 
into E. coli for protein expression and purification.
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Table 2.3. Primers used for site-directed mutagenesis
Primer Lab.
Ref.
Sequence 5'-3' Amino acid 
change
A1 fwd 22P CGATTTGTTGGCTAAGCAAGATTATGGTCAGG AW134H135
A1 rev 22Q CCTGACCATAATCTTGCTTAGCCAACAAATCG
A2 fwd 22R GTTGGCTAAGTGGCATTATGGTCAGGTCAATAATGTC
CC
AQ136D137
A2 rev 22S GGGACATTATTGACCTGACCATAATGCCACTTAGCCA
AC
A3 fwd 22T GGCTAAGTGGCATCAAGATCAGGTCAATAATGTCCC AY138G139
A3 rev 22U GGGACATTATTGACCTGATCTTGATGCCACTTAGCC
A4 fwd 22V GGCATCAAGATTATGGTAATAATGTCCCAGCTAG AQ140V141
A4 rev 22W CTAGCTGGGACATTATTACCATAATCTTGATGCC
A5 fwd 22Z GGTCAGGTCAATAATGCTAGAATGCAGTATG AV144P145
A5 rev 23A CATACTGCATTCTAGCATTATTGACCTGACC
A6 fwd 23B GGTCAATAATGTCCCAATGCAGTATGAAAAAATAAC
GGCTC
AA146R147
A6 rev 23C GAGCCGTTATTTTTTCATACTGCATTGGGACATTATT
GACC
A7fwd 23D GGTCAATAATGTCCCAGCTAGATATGAAAAAATAAC
GGCTC
AM148Q149
A7 rev 23E GAGCCGTTATTTTTTCATATCTAGCTGGGACATTATT
GACC
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A8 fwd 23F GTCCCAGCTAGAATGCAGAAAATAACGGCTCACAGC AY150E151
A8 rev 23G GCTGTGAGCCGTTATTTTCTGCATTCTAGCTGGGAC
A9 fwd 27V GCTAGAATGCAGTATGAAACGGCTCACAGCATGG AK152I153
A9 rev 27W CCATGCTGTGAGCCGTTTCATACTGCATTCTAGC
AlO fwd 27X GCAGTATGAAAAAATACACAGCATGGAACAACTCAA AT154A155 
GGTC
AlO rev 27Y GACCTTGAGTTGTTCCATGCTGTGTATTTTTTCATACT 
GC
A11 fwd 27Z GCAGTATGAAAAAATAACGGCTATGGAACAACTCAA AH156S157 
GGTC ,1
A11 rev 28 A GACCTTGAGTTGTTCCATAGCCGTTATTTTTTCATACT
GC
A12fwd 28B CGGCTCACAGCCAACTCAAGGTCAAGTTTGG AM158E159
A12 rev 28C CCAAACTTGACCTTGAGTTGGCTGTGAGCCG
A16 fwd 28D GGAACAACTCAAGGTCAAGTTTGACTTTGAAAAGAC AG166S167 
AGGG
A16 rev 28E CCCTGTCTTTTCAAAGTCAAACTTGACCTTGAGTTGT
TCC
AA146 331 GGTCAGGTCAATAATGTCCCAAGAATGCAGTATGAA AA146
fwd AAAATAAC
AA146 33J GAGCCGTTATCATACTGCATTCTTGGGACATTATTGA
rev CCTGACC
A6 PFO 31Y CTACACATACTTTACCAACTCAATATTCAGAATCTAT AA191R192
fwd GG
A6 PFO 31Z CCATAGATTCTGAATATTGAGTTGGTAAAGTATGTGT
rev AG
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GFPpET 
33b fwd
20G GTCAGGCTAGCATGAGTAAAGGAGAAGAAC
GFPpET 
33b rev
20H CCACGCAGATCTTTGTATAGTTCATCC
EGFPpl 
y fwd
24W CACTTGTCACTACTCTGACTTATGGTGTTCAATGC Introduces 
F64L and 
S65T in GFP
EGFPpl 
y rev
24X GCATTGAACACCATAAGTCAGAGTAGTGACAAGTG
2.9. Janus mutagenesis
In order to assess the effect of the double deletion of A146 and R147 in Ply within a 
pneumococcal genetic background, the mutation was constructed in the chiomosomal 
DNA of serotype 2 D39 S. pneumoniae using Janus mutagenesis (Sung et al. 2001), see 
schematic in Figure 2.2. The advantage of Janus mutagenesis is that it allows the 
introduction of mutations with non-selectable phenotypes into the pneumococcal genome.
The Janus cassette carries a kanamycin resistance marker and an rpsL-^ marker that confers 
streptomycin susceptibility, which is dominant over the rpsh- resistant allele of the wild 
type strain. This cassette is inserted into a desired site in the pneumococcal genome using 
homologous recombination (Figure 2.2.a). The resulting strain is kanamycin resistant and 
streptomycin susceptible compared with the parent strain that is kanamycin sensitive and 
streptomycin resistant. This allows the selection of strains carrying the Janus cassette. 
Homologous recombination is used again to insert a DNA sequence of choice (e.g. the ply 
gene caiTying desired mutations, Figure 2.2.b) in place of the Janus cassette. This results in 
the loss of kanamycin resistance and streptomycin susceptibility and is used to select for 
transformants canying the desired mutation (Figure 2.2.c).
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2.9.1. Construction of Janus intermediates
The streptomycin resistance gene was amplified from R6 CP 1200 S. pneumoniae (Sung et 
al. 2001) and transformed into D39 S. pneumoniae (Paterson 2003) to give a streptomycin 
resistant D39 S. pneumoniae (SmRi) for Janus mutagenesis. The Janus cassette was 
amplified from strain R1036 (Sung et al. 2001) and inserted into the genome of the 
streptomycin resistant D39 at the ply  gene by Dr. Gavin Paterson using homologous 
recombination. This resulted in an intermediate strain of D39 S. pneumoniae, JP PCR B, 
which is kanamycin resistant and streptomycin sensitive (and pneumolysin negative). Dr. 
Gavin K. Paterson also amplified the ply  gene from D39 X. pneumoniae with flanking D39 
DNA (2.345 kb) and cloned it into the 3.5 kb TOPO-XL vector (Invitrogen). This 
provided the donor DNA for homologous recombination into the JP PCR B strain.
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Figure 2.2. Janus mutagenesis
Materials and methods
0  D39 gDNA (Kan®, Sm\ ply  +ve)
Janus cassette I (Kan\ Sm^ )
b
Janus cassette
P ly  w ith  D 3 9  
f la n k in g  D N A
T O P O  -X L
D39 gDNA (Kan'', Sm®, ply  -ve)
D39 gDNA (Kan®, Sm*", ply  +ve)
The principle of Janus mutagenesis is demonstrated with the replacement of the wild type 
pneumolysin gene {ply) shown in red (a) with a mutant form of ply  (e). The Janus cassette, 
carrying kanamycin resistance and streptomycin susceptibility is inserted into the desired site on 
the chromosome of a streptomycin resistant strain of D39 S. pneumoniae by homologous 
recombination (a). A plasmid carrying the DNA that is to take place of the original gene is used for 
a further homologous recombination step to insert the desired DNA (yellow) in place of the Janus 
cassette (b). This results in a strain of D39 that carries the new chromosomal DNA without 
selection markers (c).
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2.9.2. Construction of A6 Ply in D39 Ply
The TOPO-XL vector containing D39 WT ply  and flanking DNA was purified from TOP­
IC coli cells (Invitrogen) with a miniprep kit (Qiagen) to provide the parental DNA in 
which to construct the A6 mutation (AA146AR147) by site-directed mutagenesis using the 
original A6 Ply primers (23B and 23C, Table 2.3) and as described in section 2.8. This 
mutation was checked by DNA sequencing and provided the donor DNA for -i'.
transformation into D39 S. pneumoniae gDNA. The parental plasmid with WT ply  was 
also used to donate DNA to give a positive control that had been thi'ough the same 
transformation process as the A6 Ply mutant.
2.9.3. Transformation of mutants into the D39 chromosome by 
Janus mutagenesis
lOml BHI, supplemented with ImM CaClz, was inoculated with 3OOpl of JP PCR B from a 
glycerol stock and grown statically at 37°C to an ODeoo 0.1. 1ml aliquots of the cell 
culture were taken, one aliquot per sample, e.g. 1: negative control (no DNA), 2: positive 
control with streptomycin resistant WT gDNA, 3: 30pl miniprep plasmid DNA of A6 Ply 
in TOPO-XL, 4: 30pl miniprep plasmid DNA of WT ply in TOPO-XL vector. CSP-1 
(Complement Stimulating Peptide; synthesised by Sigma-Aldrich) was added to each 
aliquot at lOOng/ml to promote uptake of external DNA. The cultures were incubated in a 
37°C water bath for 15 min and DNA was added to the appropriate tubes and the samples 
were further incubated for 75 min. The transformations were plated out onto BAB plates 
supplemented with 5% horse blood and 300pg/ml streptomycin. Plates were incubated for 
9h at 37°C under anaerobic conditions using GasPak™ Pouches (Becton Dickenson, 
Oxford, UK). This short anaerobic incubation time minimises the chance of streptomycin 
resistant revertants occurring that have lost the Janus cassette.
a
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2.9.4. Selection of Janus mutants
100 single colonies for each transformation were picked and stabbed onto two blood agar 
plates, one with streptomycin (300pg/ml) and another with kanamycin (150pg/ml). Plates 
were incubated overnight at 37°C in a candle jar. Stabbed colonies that were streptomycin 
resistant and kanamycin sensitive were selected from the BAB plates and grown up at 
37°C overnight in 20ml BHI with 300pg/ml streptomycin. Overnight cultures of these 
transformants were streaked onto BAB plates to check for purity and optochin sensitivity 
with optochin discs (Mast Group Ltd., Merseyside, UK). The overnight cultures were used 
to seed 20ml BHI containing 300pg/ml streptomycin, which was grown to mid-log phase 
then 10ml was frozen as 1ml aliquots in 20% glycerol. 10ml of mid-log phase culture was 
used to prepare gDNA (see section 2.2) for PCR analysis to check for presence of the ply  
gene using primers 15C and 15D (Table 2.1), which anneal to the 5’ and 3’ ends of the ply  
gene. Positive ply  tranformants were further characterised for Ply expression, Ply activity 
and virulence using techniques already described in this chapter.
2.10. In vitro assays with Ply and derivatives
2.10.1. L929 fibroblast cytotoxicity assay
L929 murine fibroblasts (ECACC no.85011425, Wiltshire, UK) were cultured in RPMI 
1640 media supplemented with 10% Foetal Bovine Serum, 1% of 5U/ml penicillin G 
sodium/5fxg/ml Streptomycin sulphate and 2mM L-glutamine (Invitrogen, Paisley, UK). 
Cells were quantified using a haemocytometer, diluted in media to give 3x10^ cells/ml and 
transferred as 200pl aliquots to a 96-well plate and incubated for 24h at 37°C, 5% CO2 . 
Serial dilutions of purified WT Ply and derivatives were prepared in RPMI 1640 media
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from a stock concentration of 0.03mg/ml and added to the L929 fibroblasts in triplicate.
Cell viability upon 24h incubation with Ply was assessed using 50pl/well of Ipg/ml of
MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5“diphenyltetrzolium bromide) (Sigma-Aldrich).
Absorbance was read at 540nm.
2.10.2. Mast cell degranulation assay
RBL-2H3 rat mast cells (ATCC number CRL-2256 Lot. 2454194) were cultured in Eagle’s 
Minimal Essential Media (EMEM; ATCC) supplemented with 15% heat inactivated FBS. 
Degranulation of mast cells was measured by the release of p-hexosaminidase (Stassen et 
al. 2003). 200pl of 5x10"  ^ cells/ml were transferred into each well of a 96-well Costar® 
plate (Sigma-Aldrich) to give IxlO"  ^cells/well and incubated for 2 hours at 37°C, 5% CO2 
to allow cells to adhere. Cells were stimulated with 50pl of toxin in varying 
concentrations for 1.5h. (Heat-treated samples were heated to 65°C for lOmin prior to 
incubation with mast cells.) The plate was then centrifuged at 200g for 3 min and the 
supernatant transferred into a new 96-well plate. Remaining cells were lysed with 180pl of 
0.5% Triton X-100 (BDH biosciences, Dorset, UK) in EMEM. 2 x 20pl of lysate and 2 x 
20pi supernatant was transferred into a fresh plate. 50pl of substrate solution (1.3mg p- 
nitrophenyl-N-acetyl-p-D-glucosamine [pNAG]/ml citrate buffer; Sigma-Aldrich) was 
added to each well and incubated for 90mins at 37 °C. The reaction was stopped with 
150pl 0.2M Glycine NaOH, pH 10.7 and hydrolysis of the substrate was read at 405nm 
with an MRX plate reader. Recipes for buffers are given in Appendix I. Mast cell 
degranulation was expressed as the percentage of p-hexosaminidase released into the 
supernatant. The amount of p-hexosaminidase in the supernatant and lysate were added to 
give the total amount of p-hexosaminidase present. Mean percentage degranulation was 
plotted against toxin concentration.
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2.10.3. Cell binding by Immunoblotting
Pneumococcal cell extracts or purified Ply and derivatives were incubated with a 2% horse 
erythrocyte suspension, washed x 6 with distilled water to remove unbound toxin and lyse 
the cells. The samples were then prepared by boiling with sample buffer and were then run 
on 10% SDS-PAGE for Western blotting with anti-Ply antibody (see section 2.7.3). This 
allowed analysis of Ply’s ability to bind to erytlirocytes as previously described (Owen et 
al. 1994).
2.10.4. Cell binding by Fluorescence Microscopy
Erythi'ocyte ghosts were generated from 0.1ml human blood by repeated washing with 
distilled water. The erythrocyte ghosts were then incubated with 50pg eGFP WT Ply or 
50pg eGFP A6 Ply in 1ml 1 x PBS for 30 min at 37°C. The ghost membranes were 
pelleted, washed x 3 in PBS and were visualised by fluorescence microscopy by Mr. 
Graeme Cowan using a Zeiss Axioscop 20.
2.10.5. Binding inhibition assays
Dilutions of A6 Ply (10, 5, 2.5, 1.25 and Opg/ml) were prepared in IxPBS and transferred 
to round-bottomed 96-well plates, allocating two rows for each dilution of A6 Ply 
(50pl/well). For pre incubation of A6 Ply with erytlirocytes, 50pl of a 2% sheep 
erythrocyte suspension (prepared as described for the haemolytic assay in section 2.7.2) 
was added to each well and the plate was incubated for 30min at 37°C. Serial dilutions of 
purified WT Ply were prepared in a separate plate and transferred to the plate (50pl/well) 
containing A6 Ply and the erythrocytes and incubated for a further 30min at 37°C. For 
competitive binding analysis, A6 Ply and WT Ply were combined and then incubated with
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the erythrocyte suspension. The absorbance at 630nm of each supernatant was then read to
measure the turbidity of the sample and plotted against the amount of WT Ply added to
each sample. The A540nm was also measured to quantitate haemoglobin release and was
found to produce similar results.
2.10.6. Cross-linking of oligomers
25pi of 0.5mg/ml WT Ply and A6 Ply were incubated with 25pi erythrocyte membranes 
(prepared from a 2% erythrocyte suspension) at 37°C for 30 min. The membranes were 
then pelleted and washed x 6 in PBS to remove unbound toxin. 5pi of 25mM DSS 
(Disuccinimidyl suberate; Pierce Bioteclmology, Rockford, IL) dissolved in dimethyl 
sulfoxide (DMSO; Sigma-Aldrich) was added to the membrane bound toxin and the 
solution incubated at room temperature (RT) for 30 min in order to cross-link any toxin 
that has bound to the membranes. The reaction was quenched with 2.5pi IM glycine for 
15 min then boiled with SDS-PAGE sample buffer, run on 5% SDS-PAGE with high 
molecular weight markers (Bio-Rad, Hertfordshire, UK) and Western blotted with anti-Ply 
antibodies as described in section 2.7.3.
2.10.7. Transmission Electron Microscopy
200pl of 2% (vol/vol) horse erythi'ocyte solution was incubated with an equal volume of 
0,2mg/ml Ply or filtered pneumococcal cell extract at 37°C for 30min then centrifuged at 
maximum speed using a bench top centrifuge to pellet the membranes. The cells were 
lysed and membranes were washed 5 times with distilled water to remove unbound toxin. 
The membranes were then resuspended in 50pl dH20. 5pi of sample was placed onto 
glow discharged carbon coated grids and negatively stained with Nano Van® (Nanoprobes, 
Yaphank, NY) according to manufacturer’s instructions. Grids were viewed at x25000 
magnification using an LEO 912 Energy Filter Transmission Electron Microscope.
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2.10.8. Measurement of Ply by ELISA
A Ply ELISA developed by Cima-Cabal et al (Cima-Cabal et al. 2001) was used to 
quantify Ply expression levels from pneumococcal cell lysate with the following 
modifications; Wells were coated with lOOpl of 2.5pg/ml capture antibody, Ply 7 (de los 
Toy os et al. 1996) in coating buffer (see Appendix I). Plates were blocked with 10% foetal 
calf serum (Invitrogen) in PBS; washes were with 0.05% Tween 20 (Sigma-Aldrich) in 1 x 
PBS and dilutions were made in assay buffer (blocking buffer + 0.05% Tween 20). 
Pneumococcal cell extracts were diluted to 1:500 for the 300pg/ml total protein samples 
(or 1:2500 for the 2.35mg/ml total protein samples) and added in duplicate at lOOpl/well. 
Purified Ply, prepared as described previously (Mitchell et al. 1989), was used to provide a 
standard curve with a range from 2000pg/ml to 31.25pg/ml. lOOpl/well polyclonal a-Ply 
antibody (Mitchell et al. 1989) was then added at a 1:2000 dilution in assay buffer and 
plates were shaken for 30min at 37°C. Following 4 washes, lOOpl/well of biotinylated a- 
rabbit IgG (Amersham Biosciences) was added at 1:500 and shaken for 30min at 37°C. 
Plates were washed x 4 and incubated with a 1:2000 dilution of streptavidin HRP (KPL, 
Gaithersburg, Maryland) and developed with 3, 3', 5, 5'~tetramethylbenzidine (TMB) 
substrate (KPL) according to the manufacturers instructions.
2.11. In-vivo analysis of non-toxic Ply
All in vivo experiments were carried out in accordance with the UK Animals (Scientific 
Procedures Act) 1986. Mice had food and water ad libitum and were kept at a constant 
room temperature of 20-22°C and with a 12h light/dark cycle. All animal handling was by 
Dr, Alison R. Kerr and Dr. Gill R. Douce due to licensing restraints. However, all 
experimental design, sample processing, data acquisition and interpretation was by the 
author. Lea-Ann S. Kirkham.
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2.11.1. Inflammatory responses to i.n. instillation of Ply
Eight week-old female MFl mice (Harlan, Bichester, UK) were lightly anaesthetised with 
2% halothane/1.5% oxygen (1.5 litre/min) (Astra-Zeneca, Macclesfield, UK). Purified WT 
Ply was administered intranasally (i.n.) at Igg, 0.25pg, or O.lpg/dose and AA146 Ply at 
Ipg/dose in 50pl of sterile saline (0.09% NaCl, Baxter International Inc, Deerfield, IL) 
with a saline only control group (n=6). Mice were monitored to a 24h end-point. TNF-a, 
IL-6 and IFN-y cytokine levels were measured in the semm, BALF and lung tissue by 
ELISA using commercial matched anti-cytokine antibody pairs (BD Biosciences 
Pharmigen, San Diego, CA). Total protein levels in the BALF were measured using the 
standard Bradford’s assay described in section 2.7.1.
2.11.2. Retrieval of BALF, serum, lung and brain tissue for 
cytokine analysis
Methods used for BALF and lung retrieval and processing were similar to those described 
before (van der Poll et al. 1996). To carry out lavage o f the lungs, mice were culled by 
ceiwical dislocation and the skin and muscles above the trachea were separated. The 
trachea was clamped with forceps (Fisher Scientific, Loughborough, UK) and a 16-gauge 
angiocath was inserted into the trachea to open the airways. Lavage was carried out with 
2x1 ml volumes of PBS with a recovery volume of -1.5ml, which was transferred to a 
sterile cryotube and immersed in liquid nitrogen. Following lavage, lungs and brains were 
removed and wi'apped in aluminium foil then immediately immersed in liquid nitrogen. 
Blood was taken from the heart using a 23-gauge needle and transferred to an eppendorf to 
clot for Ih at RT or overnight at 4°C. The blood was then centrifuged at 1400g using a 
bench top centrifuge for 3 min. The supernatant (serum) was then transferred to a fresh 
tube. All samples were stored at -80°C prior to analysis.
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2.11.3. Processing of BALF, serum, lung and brain tissue for 
cytokine analysis
Whole lungs and brains were weighed then homogenised 50 times in 5ml IxPBS using 
handheld glass tissue homogeniser (Jencons, Leighton Buzzard, UK). Homogenates were 
transferred to 10ml falcon tubes and centrifuged at 1600g for 30mins at 4°C. Cell free 
supernatant was then transferred to a fresh 10ml tube and centrifuged at 5000g for 30mins 
at 4°C and then filter sterilised using 0.2pM syringe filters (Sartorious) into 5ml bijous, 
which could then be stored at -80°C. Immediately prior to analysis BALF was defrosted 
and centrifuged for 3min at maximum speed using a bench top centrifuge to remove cell 
debris.
2.11.4. Analysis of core body temperature of mice in response to 
Ply treatment
Six week-old female BALB/c mice were surgically implanted with telemetry chips as 
previously described (Kerr et al. 2002) in order to record core body temperature (Tc). 
Briefly, telemetry chips were sterilised in Cidex (Johnston & Johnston Medical Ltd, 
Skipton, UK) for 1 Omin and then washed in sterile water. Mice were lightly anaesthetised 
with 2% v/v halothane over oxygen (1.5 litre/min) and the abdomen of the animals was 
shaved. Mice were then placed on a sterile drape over a heat mat and deeply anaesthetised 
with 3-5% v/v halothane over oxygen (1.5 litre/min). An incision was made in the 
abdomen with a sterile scalpel then sterile scissors were used to open the peritoneum. The 
telemetry chip was placed in the peritoneum, the inner wound fastened by suture and the 
outer wound fastened with surgical clips (Becton Dickinson, Oxford, UK). Mice were 
monitored for two weeks to ensure complete recovery, and then they were lightly 
anaesthetised and treated intranasally (i.n.) with purified WT Ply or AA146 Ply at Ipg/dose 
in 50pl of saline with a saline only control group (n= 12-22). Immediately after treatment,
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mice were placed in cages on individual receiver boxes to allow recording of Tc. Mice
were monitored for 24h and Tc readings collected every minute. Data was collected using
Vital View® software (Mini Mitter, Oregon) and transferred to Excel for analysis, where
the data was reduced from one minute intervals to 30 minute intervals.
2.11.5. Sampling from telemetry experiments for subsequent 
cytokine analysis
Bronchoalveolar lavage (BALE), serum, brain and lung tissue samples were recovered at 
2h, 6h and 24h from 5-6 mice from the WT Ply and AA146 Ply treated groups. Samples 
were retrieved and processed as previously described in section 2.11.2 and 2.11.3 and 
stored at -80°C prior to analysis.
2.11.6. Multiplex cytokine analysis of samples from telemetry 
experiments
Commercial cytokine ELISA antibody pairs for IL-6, TNF-a and IFN-y (BD Biosciences 
Pharmigen, San Diego, CA) were used for initial analysis o f individual cytokines with the 
appropriate buffers and at the concentrations given in Appendix I. Multiplex bead 
immunoassay kits (Biosource, Nivelles, Belgium) were used in conjunction with the 
Luminex™100 system (Bio-Rad) to measmc inflammatory mediators produced in response 
to Ply treatment. Analytes can be combined from different sets to give a custom set of 
analytes for sample analysis. The technique is based on ELISA but unique antibody coated 
beads are used rather than the fixed base of 96-well plates. The Luminex system uses 
colour-coded bead sets with different fluorescent intensities which permits >100 colour 
codes. This allows the simultaneous measurement of a range of analytes in the same 
sample. The protocol was run according to manufacturers instructions. Briefly, 96-well 
plates with a Alter base were filled with 200pl wash buffer and aspirated using a vacuum
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manifold. Beads coated with antibody for all of the analytes o f interest were mixed
together and 25pi of mixture added to each well. 200pl wash solution was then added and
the beads were washed by aspiration. 50pl incubation buffer was then added to each well
and standards (comprising of all the analytes to be measured) were added in duplicate to
the first two columns of the plate. Samples were diluted two-fold in assay buffer by
adding 50pl assay buffer to sample wells then 50pl sample. The plates were protected
from light with aluminium foil and shaken at RT for 2h at 500rpm. Wells were washed
twice with wash solution and a mixture of biotinylated detection antibody for each analyte
was added at lOOpl/well and incubated at RT for Ih. The wells were washed twice and
100pi streptavidin-RPE was added at the relevant concentration for a 30min incubation.
Plates were washed x3 then lOOpl wash buffer added to each well. Plates were either
shaken for 2-3 min and read immediately with the xMap’’’^  system (Biosource) or stored at
4°C overnight and read the following day by Dr. J. Alastair Grade after a 2-3 min shake.
Precision fluidics aligns the beads into single file to pass through two lasers, one that
excites the tagged detection antibodies and another that excites the bead. This allows
reactions to be measured in real time using fluorescent intensity to identify and quantify
the reaction.
99
Chapter 2 Materials and methods
2.12. Mouse infection studies
2.12.1. Preparation of mouse passaged standard inocula
Single colonies of serotype 1 pneumococci from clinical isolates (ST227, strains 01-2696 
and 00-3645; ST306, strain 01-1956) and the Janus mutants (WT D39 and A6 D39 S. 
pneumoniae^ see section 2.9) were selected and grown up to mid-log phase in BHI as 
described in section 2.1. 1ml aliquots were stored in 20% PCS at -80°C for at least 16h 
then viable counts were assessed and 5x10^ CPU/dose injected i.p. into an MPI mouse as 
previously described (Alexander et al. 1994). At 24h the animal was sacrificed by cervical 
dislocation and blood taken by cardiac puncture and plated out onto BAB plates and 
incubated overnight at 37°C. A single colony was then selected and statically grown in 
15ml BHI at 37°C to an ODeoonm 0.6. frozen stocks of mouse passaged serotype 4 TIGR4 
S. pneumoniae (ATCC: BAA-334, ST205), virulent serotype 1 S. pneumoniae (ST615) and 
serotype 2 D39 S. pneumoniae (ST128) were also streaked out for single colonies and 
grown to mid-log phase at which point 20% PCS (Invitrogen) was then added to each 
culture and 1ml aliquots were frozen at -80°C in cryotubes. Cultures were checked for 
purity and optochin sensitivity by streaking a loopful culture onto BAB plates prior to 
freezing. The Colony-Porming Units (CPU)/ml in each culture was calculated as described 
below.
2.12.2. Viable counts from standard inocula
24h post freezing, a vial for each strain was thawed in a 37°C water bath for 2 min. 900pl 
was then transferred to an eppendorf and centrifuged at RT for 3 min at 6600g using a 
bench top centrifuge. The supernatant was discarded and the cells resuspended in 900pl 
sterile PBS (Sigma-Aldrich). 1/10 dilutions of the sample were made in a 96-well U- 
bottomed plate using sterile PBS to give dilutions ranging from 10"^  to 10'^. 3 x 20pl of
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each dilution was spotted onto BAB plates divided into 6 sectors, 2 plates per sample, and
allowed to dry. Plates were incubated anaerobically overnight in a candle jar at 37°C. The
dilution sector where there were 10-70 colonies/20pl was then counted in order to calculate
the CFU/ml for each strain.
Immediately before challenge, the standard inocula were thawed and prepared in the same 
way as described above and diluted in sterile PBS to the desired dose. Viable counts of the 
inocula were assessed prior and post challenge to check that the bacteria remained viable 
during challenge.
2.13. Challenge of mice
2.13.1. Intranasal (i.n.) challenge of mice
Eight to ten week old outbred female MFl mice, or C3 deficient mice [C3-/- (Wessels et 
al. 1995), bred in house] for challenge with the serotype 1 clinical isolates (Chapter 7), 
were lightly anaesthetised as described in section 2.11.1 and challenged with the relevant 
dose and strain of S. pneumoniae in 50pl of sterile saline. 25pl was administered to each 
nare.
2.13.2. Intraperitoneal (i.p.) challenge of mice
Eight to ten week old female MFl or BALB/c mice (Harlan) were scruffed at the neck and 
challenged i.p. by injection of the relevant dose of S. pneumoniae in lOOpl sterile PBS. 
Mice were older (16-18 weeks) when challenged post vaccination due to the length of the 
active vaccination protocol.
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2.13.3. Viable counts from blood, lung tissue and BALF
Following challenge with S. pneumoniae, mice were bled from the lateral tail vein or by 
cardiac puncture to assess bacteraemia and lungs and BALF were retrieved as described in 
section 2.11.2, however, lungs and BALF were not frozen in liquid nitrogen but were 
analysed immediately. Lungs were homogenised as described in preparation of lung tissue 
for cytokine analysis but the tissue was not centrifliged and the filtered. Whole blood and 
BALF were plated immediately. Samples were diluted in sterile PBS and plated out in the 
same way as described in section 2.12.2, with the exception of lung tissue, which was used 
neat in the first well and diluted thereafter. The CFU/ml of sample is plotted as a log value 
with a detection limit of 1.92.
2.13.4. Assessment of survival of mice post challenge with S, 
pneumoniae or Ply
Mice were monitored at frequent time intervals post treatment and were pain scored on a 
regular basis. Pain score ranged from noimal, hunched stance and/or stary coat to lethargy 
where a pain score o f ++ lethargic resulted in the humane sacrifice of the animal by 
cervical dislocation. If an animal was found dead, which was not often, the sui"vival time 
was calculated as the intermediate time between when the animal was last pain scored and 
the time it was found dead to give an estimate of when the animal reached the endpoint of 
++ lethargic.
2.14. Vaccination
2,14.1. Active Vaccination with WT Ply and AA146 Ply
Six-week-old female BALB/c mice (Harlan) were caged into group sizes of 8. Mice were 
bled from the lateral tail vein a day prior to immunisation to provide a baseline for
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antibody titres (day 0 bleed). Serum was processed as described in section 2.11.2 and
stored at -20°C. The mice were then immunised sub cutaneously with a lOOpl dose of
either 20pg WT Ply plus lOOpg Alum (Wyeth, Pearl River, NY), 20pg AA146 Ply plus
lOOpg Alum, sterile NaCl plus lOOpg Alum or NaCl only (0,9% NaCl, Baxter
International Ltd). Bleeds were taken for antibody analysis a day before each boost, of
which there were 3 at approximately 17 days apart. The animals were left for a month
before a final bleed to check antibody titres prior to challenge. The mice were then
challenged i.p. with 2x10^ CFU/lGOpl dose TIGR4 S. pneumoniae and monitored for
suiwival where the endpoint was when mice were deemed lethargic. 18h post challenge,
blood was taken from the lateral tail vein of each mouse to assess the levels of bacteraemia
in CFU/ml as described in 2.13.3.
2.14.2. Active vaccination with A6 Ply-type 4 polysaccharide 
conjugate
The protocol was the same as for active vaccination with free proteins but with the 
following modifications. Group sizes were increased to 10 to allow the groups to later be 
divided into two groups of five for i.p. challenge with either 10  ^CFU serotype 1 or TIGR4 
S. pneumoniae. A6 Ply was used instead of AA146 Ply, as this was the protein that was 
conjugated to type 4 capsule polysaccharide (CPS) by Dr. Maya Roster, Wyeth Vaccines. 
The method used for conjugation of Ply to type 4 polysaccharide was reductive amination 
where oxidised polysaccharide was combined with protein at a 2:1 ratio and incubated with 
sodium cyanoborohydride for 4-6h at 25°C then 48h at 37°C and then incubated with 
sodium borohydride solution for 24h at 4°C to cap the reaction. The conjugates were 
filtered through a lOOKda MW cut off filter and assessed for carbohydrate and protein 
content. The dose of free protein used for immunisation was 0.64pg rather than 20pg in 
section 2.14.1 as this was determined by the amount of A6 Ply conjugated to type 4 capsule
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polysaccharide (0.87mg/ml A6 Ply: 1.36mg/ml type 4 polysaccharide). The amount of
Alum was increased from lOOpg/dose in the free protein active vaccination to 200pg/dose
to match the amount of Alum in Prevnar. BALB/c mice were given a sub cutaneous 200pl
dose of either Ipg type 4 CPS plus 200pg Alum, Ipg type 4 CPS plus free 0.64pg A6 Ply
plus 200pg Alum, Ipg type 4 CPS conjugated to 0.64pg A6 Ply plus 200pg Alum, 0.64pg
A6 Ply plus 200pg Alum, 200pg Alum, PBS only, Prevnar containing 0.8pg type 4 CPS
and 200pg Alum per dose or Prevnar plus 0.64pg A6 Ply.
2.14.3. a-Ply IgG ELISA of serum following active vaccination
Serum from each day before vaccination or boosting was collected from the lateral tail vein 
and analysed for anti-Ply IgG by ELISA (de los Toyos et al. 1996) using 5pg/ml Ply to 
coat the plates overnight and HRP-labelled anti-mouse IgG as the detection antibody 
(Amersham). Five fold dilutions of serum were prepared from a starting dilution of 1/50. 
The negative control on each plate was coating buffer with no antigen and then positive 
sera was added, this gave a background level, which was subtracted from each reading. 
Absorbance was read at 450nm and titres were taken at a cut off of ODD.3.
2.15. Statistical Analysis
For a statistical test to be chosen, the data was first assessed for normal distribution using 
GraphPad® Instat (GraphPad® Software Inc., San Diego, CA), where data that is normally 
distributed (parametric) fits a parabolic curve and the curve is centred at the mean. 
Bacterial load experiments fit normal distribution (Blue 2002), allowing the mean of the 
data to be compared between two groups using an unpaired t-test for parametric data, 
which compares one variable between two groups. Bacterial loads were expressed as the
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mean ± SEM (standard error of the mean) and were statistically analysed with an unpaired
t-test.
Inflammatory mediator levels, total protein levels in samples and survival times did not fit 
normal distribution cuises and were therefore assessed with non-parametric analysis using 
a two-tailed Mann-Whitney U test (GraphPad® Software Inc.). This is a conseiwative test, 
also known as the rank sum test, which does not assume normal distribution and compares 
the median of two groups (this test cannot be used to compare more than two groups). The 
median is more robust than the mean as it is less sensitive to outliers. Two-tailed analysis, 
in comparison with one-tailed analysis, does not assume that the median of one group is 
expected to be higher than the other group prior to commencing the experiment. 
Inflammatory mediator levels were expressed as the mean ± SEM in graphs and tables but 
statistical analysis was with the median. Total protein levels in the BALF were expressed 
as the median ± MAD (Median Absolute Deviation) and survival times are shown for 
individual animals with the median survival times indicated. P<0.05 is considered 
significant and P<0.01 considered very significant (**).
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3: Purification and in vitro characterisation of pneumolysin 
mutants 
Summary
The region suri’ounding amino acid residue N143 in Ply has been implicated in playing 
a role in oligomerisation of the protein (de los Toyos et al. 1996). Initial attempts to 
understand the importance of the N143 region in Ply were made by Dr. Jennifer Search 
who previously created a double amino acid deletion (AN142N143) and a substitution 
(N143D) in Ply. However the mutants behaved in a similar manner to WT Ply (Search 
2002). In this study, eight double amino acid deletions were made surrounding the 
N142N143 site (four on either side). Of the eight double amino acid deletions 
constructed, the four upstream of N 143 resulted in expression of a non-haemolytic form 
of Ply (A5-8, Table 3.1.). Mutants were purified for further characterisation.
Methods of Ply purification were also investigated and further developed. Previously
recombinant Ply was purified using hydrophobic interaction chromatography (HIC)
(Search 2002). This technique is capable of powerful resolution of native proteins from
cell extracts, using high salt concentrations in the column media for adsorption of the
protein and low salt concentrations for desorption. The column media is phenyl ether,
which has no charge. However, HIC is not specific to Ply and should be used in
combination with other chromatography steps as the resulting protein may not be
completely pure. The major problem with purifying proteins from Gram-negative
bacteria is the high levels of contaminating cell wall LPS, which is a potent
inflammatory mediator. Inclusion of an additional purification step, anion exchange
chromatography (AEG), was introduced in attempt to remove contaminating proteins
and LPS in the HIC purified sample. AEG separates molecules based on their charge
107
Chapter 3 In vitro characterisation of Ply mutants
and is complementary to HIC. The column media involves the use of a highly positively 
charged media that retains the highly negatively charged LPS and DNA longer than Ply, 
allowing separation of Ply from contaminants by the introduction of a salt gradient from 
OM to 2M.
Cytotoxicity of the mutants to nucleated cell lines in addition to erytlirocytes was 
assessed and compared with WT Ply and the existing PdB toxoid. A mast cell assay 
was developed to investigate a sensitive method to measure residual toxicity of Ply 
mutants. Mast cells are abundant in the alveoli and nasal mucous membranes and are 
therefore in prime position to detect inhaled antigens. They form the first line of 
defence as part of the innate immune system and can proliferate at the site of 
inflammation unlike neutrophils and macrophages (Abraham et al. 1997). They are 
highly sensitive to antigens and have been shown to degranulate during the early host 
response to pneumococcal pneumonia (Kerr et ai. 2002). Two mutants, AA146 Ply and 
AA146R147 were further characterised in terms of their interaction with cells in culture, 
with assessment of binding, oligomerisation and pore formation prior to in vivo 
analysis.
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3.1. Construction of Ply mutants by site directed mutagenesis
Thirteen double amino acid deletions and two single amino acid deletions were 
constructed within the Ply protein by site-directed mutagenesis (Figure 3.1). Cell 
extracts o f  four double deletions and the two single deletions were found to have no 
detectable haemolytic activity (AV144P145, AA146R147, AM148Q149, AY150E151, 
AA146, AR147) highlighted in the green box in Figure 3.1. A list o f  all the mutations 
made in this work (and by others) is given in Table 3.1 with their haemo lytic activity in 
comparison with WT Ply.
Figure 3.1. Site of mutations made within Ply
AW134H135 = A1 
AQ136D137 = A2 
AY138G139 = A3 
AQ140V141 = A4 
AN142N143 = (Search 2002)
D385N
f AV144P145 = A5 AA146R147 = A6 
AA146 
AR147
AM148Q149 = A7 
AY150E151 = A8
W433F
AK152I153 = A9 
AT154A156 = A10 
AH157S158 = A ll 
AM159E160 = A12 
AG166S167 = A16
The location ot the amino acid mutations are highlighted in red on the Ply homology model 
based on PFO (Rossjohn et al. 1997). Structural changes in relation to these mutations have not 
been accounted for by modelling. All mutations are at the domain 1-3 interface and D385N and 
W433F are also highlighted. The mutants in the green box have no haemolytic activity.
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Table 3.1. Mutations made in Ply (and other CDCs) and 
haemolytic activity of cell lysates
Ply mutation" Reference % haemolytic activity 
compared with WT Ply
AW134H135(A1) This work 100
AQ136D137(A2) This work 100
AY138G139 (A3) This work 100
AQ140V141 (A4) This work 100
AV144P145 (A5) This work 0
AN142N143 (Search 2002) 100
N143D (Search 2002) 100
AA146R147 (A6) This work 0
AM148Q149 (A7) This work 0
AY150E151 (A8) This work 0
AK152I153 (A9) This work 37
AT154A155 (AlO) This work 77
AM158E159(A12) This work 42
AG166S167 (A16) This work 83
AA146 This work 0
AR147 This work 0
Y150A This work 57
W433F (Mitchell 1992) 1
D385N (Mitchell 1992) 100
D385NW433F This work 1
A6D385N This work 0
A6W433F This work 0
A6D385NW433F This work 0
AA191R192 PFO*’ This work 0
AA204R205 ILY^ G. Cowan 0
AA190R191 ALO" G. Cowan 0
® all mutations were constructed using the pKX233-2 vector and transformed into E. coli XL-1 blue 
supercompetent cells (ALO and ILY were cloned into pET-33b for His-tagged purification)
 ^equivalent A6 mutation made in CDCs Perfringolysin O, Intermedilysin and Anthrolysin O
bold type denotes mutants that were purified for further characterisation
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3.2. Purification of Ply and derivatives
All proteins were purified using a two-step method of hydrophobic interaction 
chiomatography (HIC) and anion exchange chi’omatography (AEC). This improved 
protein purity and yield, which was 15-20mg/L culture. In general, the mutants were 
easier to purify than WT Ply and could be concentrated to at least 3mg/ml without the 
aggregation that often occurs during WT Ply purification. The isoelectric point (pi) of 
Ply is 5.7, making it slightly negatively charged at neutral pH whereas PFO has no 
charge at PH7, with a pi of 7.1. As a result of this, PFO did not bind to the AEC 
column but the DNA and contaminating proteins did, allowing PFO to be collected in 
the wash through. The inclusion of an anion exchange step removed residual 
contaminating proteins and also reduced endotoxin levels 100 fold (section 3.4).
Figure 3.2.1. shows a representative HIC purification of WT Ply. Fractions 1-4 are the 
non-specific proteins, which are washed through the column, and the peak over 
fractions 5-8 is Ply, as shown in SDS-PAGE gels of the HIC fractions (Figure 3.2.3).
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Figure 3.2.1. HIC purification of WT Ply
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Hydrophobic Interaction Chromatography of WT Ply. The vertical numbered lines represent 
fractions that were collected in separate test tubes. The red line is the A280nm reading, which 
measures protein eontent. The green line is the A260nm reading, which measures DNA levels. 
The blue line represents eonduetivity (M) using NaCl.
Fractions 5-8 were pooled from each run and dialysed overnight at 4°C in pre-chilled 
dialysis buffer (see Appendix I) to remove NaCl. The following day, the buffer was 
replaced with fresh dialysis buffer and left for a further 4h then the HIC purified Ply 
was concentrated at 4°C using amicon centrifugation filters at 2080g (30kDa MW cut 
off). The concentrated sample was then further purified using AEC, Figure 3.2.2. Ply 
binds to the negatively charged column, allowing thorough washing and is eluted with 
O.IM NaCl, in fraction 14 (run on SDS-PAGE, Figure 3.2.3). The DNA remains tightly
112
Chapter 3 In vitro characterisation of Ply mutants
bound to the column and is only eluted when 1.5M NaCl is reached. This further 
purification step also removed significant amounts o f  LPS as shown by LPS silver 
staining o f  proteins before and after AEC (Figure 3.4.1 and Table 3.3).
Figure 3.2.2. AEC purification of WT Ply
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Anion Exchange Chromatography of WT Ply. Green vertical numbered lines represent 
fractions. Red line is A280nm protein reading, green line is the A254nm DNA reading. The 
blue line represents NaCl concentration (M). Fraction 14 was pooled from each run.
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Figure 3.2.3. Coomassie stained SDS-PAGE of WT Ply 
purification
M 1 2 3 4 5
89kDa -----► %
41kDa
#
M, kaleidoscope marker; 1-4, HIC WT Ply fractions 5-8; 5, AEC WT Ply fraction 14 (4.8pg).
When Ply is over-expressed in some strains o f  E. coli two bands are observed in SDS- 
PAGE and Western blotting. This is thought to occur when there is occasional read 
through o f  the stop codon for the p ly  gene. When supA^ E. coli strains are used the stop 
codon is always read and a single band o f expressed Ply is observed on gels (T. J. 
Mitchell, personal communication, 2003). A single band o f  Ply is observed in Western 
blots o f  Ply expressed by S. pneumoniae (See blots in Chapter 7).
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Figure 3.2.4. HIC purification of AA146 Ply
0 0 . 5
Hydrophobic Interaction Chromatography of AA146 Ply. Green vertical numbered lines 
represent fractions. Red line is A280nm protein reading; green line is the A260nm DNA 
reading. The blue line represents NaCl concentration (M).
Fractions 6-9 from HIC purification o f  AA146 Ply were pooled from each run (Figure 
3.2.4), dialysed overnight and concentrated as for WT Ply. As there was more protein 
for HIC, the AEC yield was also greater as shown in Figure 3.2.5. where fraction 14 
was collected. Protein purity is shown by SDS-PAGE, Figure 3.2.6.
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Figure 3.2.5. AEC of AA146 Ply
2 . 0 4 5 6 7 8 i 9  1 I
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Anion Exchange Chromatography of AA146 Ply. Green vertical numbered lines represent 
fractions. Red line is A280nm protein reading; green line is the A254nm DNA reading. The 
blue line represents NaCl concentration (M). Fraction 14 was pooled from each run.
Figure 3.2.6. Coomassie stained SDS-PAGE of AA146 Ply HIC and AEC fractions
1 M 2 3
89kDa
41kDa « •
1, HIC AAI46 Ply fraction 6; M, kaleidoscope marker; 2-4, HIC AA146 Ply fraction 7-9; 5, 
AEC AA146 Ply faction 14 (5.8pg).
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Following purification, the samples were assessed in a haemolytic assay (Figure 3.2.7) 
to determine their specific activity. Two fold serial dilutions o f  the purified toxin were 
incubated with a 2% erythrocyte suspension and the endpoint was taken as the well with 
50% lysis and 50% pelleted erythrocytes (as shown in the last wells o f  the WT Ply 
sample in Figure 3.2.7). The reciprocal titre o f the endpoint dilution is used to give 
Haemolytic Units (HU) per ml o f  sample (explained in section 2.7.2). Figure 3.2.7 
shows that the purified WT Ply has 8.2x10'^ HU/ml (giving a specific activity o f  8.4x10'^  
HU/mg) whereas the purified AA146 Ply mutant was not haemolytic. The aggregation 
o f  erythrocytes by AA146 Ply was observed in haemolytic assays and appeared to be 
concentration dependent. This effect is not observed with WT Ply in these assays due 
to the lysis o f  the erythrocytes however, fluorescence microscopy o f  GFP tagged WT 
Ply revealed that this aggregation is not mutant specific.
Figure 3.2.7. Haemolytic assay of purified WT Ply and AA146 
Ply
W TPly  
(0.954mg/ml)
AA146 Ply
(1.15mg/ml)
PBS
Two-fold serial dilution
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3.3. Determination of protein concentration and specific 
activity of purified protein
The concentration of purified protein was determined using an absorbance scan at 
280nm. Purified samples were to have a low A260mu (DNA concentration) and a low 
A320nm (protein aggregates). The absorbance at 280mn was then divided by the 
extinction coefficient (E) of Ply =1 .3  (Morgan et al. 1993). Protein concentrations 
were confirmed with a Bradford’s assay.
The concentration of purified protein is then divided by the HU/ml to give the specific 
activity of Ply in HU per mg of protein. The concentration and specific activities of 
purified proteins used in this study are given in Table 3.2.
Table 3.2. Concentration and specific activity of purified proteins
Protein Concentration (mg/ml) Specific Activity (HU/mg)
W TPly 0.522 6xl0f
AA146 Ply 1.31 0
A7 Ply+ 5.63 0
AS Ply+ 3.88 0
W433F 0.33 5 x l(f
A6D385N 3.71 0
A6W433F 1.26 0
A6D385NW433F 3.37 0
PFO* 0.338 2x10^
A6 PFO 0.2 0
The isoelectric point of PFO is 7.1, this means that at a neutral pH of 7, PFO has no charge. The PH of 
buffers could have been changed to 6.5 give PFO a +ve charge for cation purification. Instead, the 
column was made more hydrophobic by purifying PFO at 2M NaCl rather than IM that is used for Ply 
purification, ^purified by Wyeth.
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3.4. Measurement of LPS levels in purified proteins
As the recombinant proteins are purified from Gram-negative E. coli, the samples can 
be contaminated with LPS from the cell wall. LPS is a potent inflammatory agent and 
there are limitations of LPS levels in vaccine preparations. Because of this, LPS levels 
were assessed in purified proteins and mechanisms to remove LPS were investigated.
3.4,1. Assessment of LPS in HIC and AEC purified samples 
using silver staining
From previous work in the laboratory, LPS levels in HIC purified samples were known 
to be high (Table 3.3). Posidyne syringe filters were assessed in their ability to remove 
LPS from Ply but this was not successful (Figure 3.4.1). An additional AEC 
clu’omatography step was introduced and this resulted in considerable removal of 
contaminating LPS (Figure 3.4.1. and Table 3.3). Samples were incubated with 
Proteinase K to digest ail proteins so that only LPS (6kDa) was stained on an SDS- 
PAGE gel. The only sample that had no detectable levels of LPS was the HIC and AEC 
purified Ply (Figure 3.4.1).
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Figure 3.4.1. Silver stained SDS-PAGE gel of LPS in WT Ply samples
1 2 M 3 4  5 6  7 8 9
32kPa
18kDa
1, HIC and AEC WT Ply; 2, WT Ply cell lysate; M, kaleidoscope marker; 3, filtered WT Ply 
cell lysate; 4, posidyne filtered WT Ply cell lysate; 5-6, blank; 7-9, HIC purified fractions 6-8.
3.4.2 Quantification of LPS contamination of purified proteins 
using the LAL assay
The LAL (Limulus Amebocyte Lysate) assay was used to quantify LPS in the purified 
proteins before and after AEC. A 100 to 300-fold decrease in LPS levels was observed 
following AEC (Table 3.3). All proteins used for further investigation were HIC and 
AEC purified to ensure the lowest LPS levels possible.
Table 3.3. LPS levels in protein samples following different types of purification
Sample Reference Purification EU/mg pgLPS/pg toxin
WT Ply (Search 2002) MC “ m o o 68F
WT Ply (Search 2002) HIC 20,000 2000
AA146 Ply This work HIC 14,607 1460
WT Ply This work HIC + AEC 641 64
AA146 Ply This work HIC + AEC 125 12.5
* HIC, Hydrophobic Interaction Chromatography; AEC, Anion Exchange Chromatography; MC, Metal 
Chelate purification. Bold type denotes batch of WT Ply and AA146 Ply used for all in vivo analysis.
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3.5. Expression of mutated forms of Ply
All mutants were detected in Western blots with both rabbit polyclonal anti-Ply 
antibody (raised in our laboratory, blot not shown) and mouse monoclonal antibody 
Ply4 (kindly provided by Juan de los Toyos, Oviedo, Spain), Figure 3.5. Expression 
levels were similar, though possibly less was produced by A8 Ply (A8 Ply was also 
found to be the least soluble in expression studies by Wyeth; Dr. Deborah Dilts, 2005, 
personal communication).
Figure 3.5. Western blot of Ply double amino acid deletions 
detected by monoclonal antibody Ply 4
WT M 1 2 3 4 5 6  7 8
89kDa ----- ►
41kDa ►
WT, wild type Ply; M, Kaleidoscope marker; 1, AW134H135 Ply (Al); 2, AQ1360137 Ply 
(A2); 3, AY138G139 Ply (A3); 4, AQ140V141 Ply (A4); 5, AV144P145 Ply (A5); 6, 
AA146R147 Ply (A6); 7, AM148Q149 Ply (A7); 8, AY150E151 Ply (A8).
A6 Ply (AA146R147) and AA146 Ply were purified as described. A7 Ply and A8 Ply 
were purified by Wyeth. These mutants were further characterised and compared with 
WT Ply and the PdB mutant.
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3.6. Haemolytic activity of Ply mutants
Purified A6 (A146R147) Ply, A7, A8 and AA146 Ply were found to be non-haemolytic 
to human erythrocytes at concentrations 10,000 times greater than lytic concentrations 
o f  WT Ply (Fig. 3.6). PdB (the W433F Ply mutant) was 100 fold less haemolytic than 
WT Ply but was still lytic at Ipg/ml. AA146 Ply was concentrated to 3mg/ml and was 
still not lytic to human erythrocytes. A6, A7, A8 Ply and AA146 Ply also had no 
haemolytic activity on horse or sheep erythrocytes.
Figure 3.6. Haemolytic activity of Ply and derivatives
1 2 5 -1
(Ü 50-
AA146 Ply 
A6 Ply 
A7 Ply 
A8 Ply 
PdB Ply 
W T Ply
— I1 10 100 1000 10000 100000 
Toxin concentration (ng/ml)
The haemolytic activity of pneumolysin mutants A6, A7, AS Ply, AA146 Ply and PdB were 
compared with WT pneumolysin in a quantitative haemolytic assay. Following incubations of 
known concentrations of toxin with a human erythrocyte solution, the supernatants were 
collected and the haemoglobin content read at 540nm.
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3.7. Cytotoxicity of Ply mutants to nucleated cell lines
As the Ply mutants were not found to lyse erythrocytes they were then tested for 
cytotoxicity to nucleated cell lines. In order to investigate this, murine fibroblasts 
(Figure 3.7.1), rat mast cells (Figure 3.7.2) and human monocytes (data not shown) 
were treated with Ply and non-haemolytic derivatives and assessed for cell damage.
3.7.1, L929 murine fibroblast cytotoxicity assay
L929 murine fibroblasts were used to assess the toxicity of A6, A7, A8 Ply and AA146 
Ply to nucleated cells compared with WT Ply and PdB (W433F Ply). An MTT dye was 
used where mitochondria in live cells convert the yellow dye to a purple precipitate, 
thereby giving a high absorbance at 540nm compared with dead cells where the dye 
remains yellow. At concentrations of lOOpg/ml (1.7p,g Ply/lO"* cells), A6, A7, A8 Ply 
and AA146 Ply were not toxic to fibroblasts, whereas 725 fold less WT Ply (2.3ng 
Ply/lO"  ^cells) and 26 fold less PdB (63ng Ply/lO"  ^cells) were cytotoxic to the fibroblasts 
(Figure 3.7.1).
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Figure 3.7.1. Cytotoxicity of Ply and derivatives to L929 
murine fibroblasts
EcI
oo
0.7-1
0 .6-
0.5-
0.4-
0.3-
0.2-
0 .1-
0 .0*
W T Ply 
PdB
AA146 Ply 
A6 Ply 
A7 Ply 
A8 Ply
0.1
I10 100 — I—1000 — I10000
ng Ply/10 cells
The cytotoxicity of WT Ply and the Ply mutants to nucleated cells was assessed using L929 
murine fibroblasts. An MTT stain was used to assess viability of the cells following incubation 
with the toxins. High OD540nm indicates that the cells are alive as the mitochondria can 
convert MTT into a purple product. A low OD540nm indicated that the cells are dead and the 
MTT remains yellow.
The PdB mutant was -3 0  times less cytotoxic to fibroblasts than WT Ply. At 185ng, 
both WT Ply and PdB were completely toxic to 10"^  fibroblasts. The sensitivity o f  the 
fibroblast cytotoxicity assay (Figure 3.7.1) was similar to the haemolytic assay (Figure 
3.6), though erythrocytes were not accurately quantified, with ng levels o f  WT Ply 
detected. This assay provides a sensitive measurement o f  toxicity to nucleated cells and 
revealed that the mutants made in the A6 region o f  the protein had no residual toxicity.
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3.7.2. Release of P-hexosaminidase from RBL-2H3 mast cells 
in response to Ply treatment
Mast cells are highly sensitive and degranulate in response to antigens, releasing a range 
of molecules into the surrounding environment including p-hexosaminidase (Abraham 
et al. 1997). As mast cells are found in environments more relevant to the route of 
pneumococcal infection, such as mucosal lining and the lung, they were used in 
attempts to develop a highly sensitive assay to measure any residual activity that the 
AA146 Ply mutant may possess. 10“^ rat RBL-2H3 mast cells were incubated with serial 
dilutions of either WT Ply or AA146 Ply. Release of p-hexosaminidase was measured 
by the colourimetric conversion of pNAG substrate (see section 2.10.2). Degranulation 
of mast cells increased with increasing WT Ply concentrations but not with AA146 Ply 
treatment (Figure 3.7.2).
Heat-treated samples were also assessed to ensure the response was due to the protein 
and not LPS. The heat-treated samples did not elicit p-hexosaminidase release (data not 
shown) and also the highest concentration of AA146 Ply and therefore LPS did not 
result in degranulation. The lowest WT Ply concentration to result in degranulation of 
10  ^ mast cells was >250ng. This, although a more relevant cell line in terms of 
pneumococcal infection was not as sensitive as the fibroblast cytotoxicity assay (Figure 
3.7.1) where concentrations <10ng WT Ply were cytotoxic to 1 L929 fibroblasts. This 
is discussed at the end of the chapter.
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Figure 3.7.2. Mast cell degranulation in response to Ply or 
AA146 Ply treatment
80
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WT Ply 
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J
0.025 0.25 2.5 25 250 2500 25000
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Mast cell degranulation was assessed by measuring the release of P-hexosaminidase in response 
to treatment with either WT Ply or the non-haemolytic mutant AA146 Ply. WT Ply caused 
degranulation of RBL-2H3 mast cells in a concentration-dependent manner. This did not occur 
with AA146 Ply.
3.8. Analysis of cell binding, oligomerisation and pore forming 
ability of non-toxic Ply
As the mutants were not cytotoxic, their ability to form pores must be disrupted, though 
the stage at which this occurs i.e. host cell binding, oligomerisation or pore insertion 
was not known. The non-toxic mutants were analysed alongside WT Ply and PdB.
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3.8.1. Binding of Ply and derivatives to erythrocyte 
membranes
The mutations surrounding the A6 region are not in domain 4, the binding domain, and 
therefore the binding ability of the mutants would probably not be altered. This was 
investigated using a modified binding assay (Owen et al. 1994) and fluorescence 
microscopy of GFP-tagged WT Ply and A6 Ply. The ability of A6 Ply to protect 
erythrocytes from WT Ply lysis was also investigated.
3.8.1.1. Binding assessed by Western blotting
10j.Lg/ml of toxin was incubated with equal volumes of a 2% sheep erytlirocyte 
suspension for 30 min at 37°C. Following incubation, the membranes were washed to 
remove unbound toxin and the sample run on SDS-PAGE. Immunoblotting with 
polyclonal a-Ply antibody was then used to detect any toxin that has bound to the 
erythrocyte membrane. Lanes 2 and 10 of Figure 3.8.1 show that A6 Ply and WT Ply 
bind to erythrocyte membranes. After the first wash of the membranes, unbound toxin 
was still present in the wash (Figure 3.8.1, lanes 3 and 9), demonstrating that further 
washes of the membranes were required to remove unbound toxin (Figure 3.8.1, lanes 4, 
5, 7 and 8).
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Figure 3.8.1. Western blot of Ply and A6 Ply bound to erythrocyte membranes
1 2 3 4 5 6 7 8 9  10
89kD a ►53kD a ► _
4 1kD a ►
1, lOug/ml WT Ply control; 2, washed erythrocyte membranes incubated with A6 Ply; 3, F’ 
wash of membranes incubated with A6 Ply; 4, 2"*^ wash of membranes incubated with A6 Ply; 5, 
3'^ * wash of membranes incubated with A6 Ply; 6, kaleidoscope marker; 7, 3"^  wash of 
membranes incubated with WT Ply; 8, 2"^* wash of membranes incubated with A6 Ply; 9, 1st 
wash of membranes incubated with A6 Ply; 10, washed erythrocyte membranes incubated with 
WT Ply.
Further Ply derivatives were assessed for their binding ability. Figure 3.8.2 shows that 
the triple mutant A6D385NW433F, A6, A7 and A8 Ply bind to erythrocyte membranes. 
Although the W433F mutation is in the binding domain, binding does not seem to be 
altered. This technique is not quantitative but a FACS based method using GFP tagged 
versions o f the proteins would provide such results.
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Figure 3.8.2. Western blot of A6, A7, AS, A6D385NW433F and W433F 
Ply bound to erythrocyte membranes
M 1 2 3 4 5 6 7 8 9
50kDa
M, Precision"^  kaleidoscope marker; 1, WT Ply only; 2, A6 Ply + erythrocytes; 3, A7 + 
erythrocytes, 4, A8 + erythrocytes; 5, blank; 6, A6D385NW433F Ply + erythrocytes; 7, W433F 
Ply + erythrocytes; 8, blank; 9, WT Ply + erythrocytes. All samples were thoroughly washed to 
remove unbound protein prior to running on the gel.
3.8.I.2. Fluorescence Microscopy of cGFP tagged Ply and A6 
Ply.
The ability o f A6 Ply to bind to human erythrocyte membranes was confirmed by 
visualising GFP tagged forms o f A6 Ply and WT Ply (constructed by Mr. Graeme J. M. 
Cowan) by fluorescenee microscopy (Figure 3.8.3). Erythrocyte ghosts treated with 
eGFP alone were not visualised under fluorescence, confirming that it is Ply that binds 
to the cell membrane.
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Figure 3.8.3. Fluorescence microscopy of erythrocyte ghosts 
treated with eGFP-tagged Ply
Fluorescence microscopy of (a) eGFP-tagged WT Ply bound to erythrocyte ghosts and (b) 
eGFP-tagged A6 Ply bound to erythrocyte ghosts. Human erythrocyte ghosts were treated with 
0.05mg/ml eGFP-tagged toxin. Viewed with x 100 objective. Images courtesy of Mr. Graeme 
J. M. Cowan.
3.8.1.3. Inhibition of WT Ply lysis of erythrocytes by prior 
treatment with A6 Ply
The ability o f A6 Ply to protect erythrocytes from WT lysis was assessed by treating 
sheep erythrocytes with various concentrations of A6 Ply and WT Ply either by 
incubating both proteins together with the erythrocytes to investigate competition for 
binding (Figure 3.8.4.a) or by pre-incubating the erythrocytes with A6 Ply and then 
treating with WT Ply (Figure 3.8.4.b).
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Figure 3.8.4. Inhibition of haemolysis from WT Ply by binding of A6 
Fly
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Inhibition of sheep erythrocyte lysis from WT Ply by competitive treatment with A6 Ply (a) or 
by incubation of erythrocytes with A6 Ply prior to WT Ply treatment (b).
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Figure 3.8.4.a. shows that erythrocytes are protected from WT Ply lysis by treatment 
with A6 Ply. Both proteins were added at the same time thereby suggesting that there is 
competition for binding. 0.1 pg WT Ply was lytic to the erytlirocytes iixespective of the 
amount of A6 Ply added. However, at lower concentrations of WT Ply, A6 Ply 
prevented erythrocyte lysis in a concentration dependent mamier. 0.0125pg of WT Ply 
was lytic to erythrocytes that were not treated with A6 Ply, however, concentrations 
>0.25pg of A6 Ply protected erythrocytes from complete lysis with this concentration of 
WT Ply. Protection from lysis increased when erythi'ocytes were pre-incubated with A6 
Ply for 30min and then treated with WT Ply, Figure 3.8.4.b. Erythrocytes were 
protected from otherwise lytic concentrations of WT Ply with pre-incubation with 
>0.125pg of A6 Ply. Erythiocytes were completely protected from WT Ply lysis when 
pre-incubated with 10 times as much A6 Ply, for example, 0.5pg A6 Ply prevented 
erythrocyte lysis from O.OSpg WT Ply and 0.25pg A6 Ply protected erythrocytes from 
lysis with 0.025pg WT Ply (Figure 3.8.4.b).
3.8.2. Investigation of oligomerising and pore forming 
abilities of non-toxic Ply
As the binding step in pore formation was not altered by construction of non-toxic 
mutants, the next steps to investigate were oligomerisation and pore formation. As the 
region mutated is thought to be involved in monomer-monomer recognition, 
oligomerisation may be affected. Oligomerisation was investigated by cross linking 
membrane bound toxin with DSS (Disuccinimidyl suberate), which cross-links the 
amines on lysines and is lipophilic and membrane permeable, making it useful for 
cross-linking oligomers that are associated with the host cell membrane. Transmission
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electron microscopy was used to assess the ability of a non-toxic mutant to form pores 
in host cell membranes.
3.8.2,1. Cross-linking of toxin bound to erythrocyte 
membrane
Erythrocyte ghosts were incubated with either WT Ply or A6 Ply for 30min at 37°C and 
washed to remove unbound toxin as for the binding assays. 2mM DSS was then added 
to cross-link any membrane bound toxin prior to running on 5% SDS-PAGE, which was 
then Western blotted with anti-Ply serum (Figure 3.8.5).
Both WT Ply and A6 Ply were found to form multimeric structures when cross-linked 
with DSS (lanes 2, 6, 9, 11, 13 and 15 of Figme 3.8,5). When the proteins were 
incubated with erythrocyte membranes prior to DSS cross-linking, the higher molecular 
weight bands are more defined (lanes 2 ,6 ,  11 and 13) with the approximate size of 
trimers and tetramers (~160kDa and ~212kDa respectively). This data suggests that A6 
Ply can form multimeric structui'es in solution and may not bind to the membrane as a 
monomer.
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3.8.2.2. Investigation of pore formation using Transmission Electron 
Microscopy
Pores were readily visualised by Transmission Electron Microscopy o f negatively stained 
erythrocyte membranes treated with WT Ply (Figure 3.8.6.a) and PdB (Figure 3.8.6.b) but 
not on membranes treated with AA146 Ply (Figure 3.8.6.c). Instead, arcs and rod-like 
structures were observed on AA146 Ply treated membranes that were not present on 
untreated membranes (Fig. 3.8.6.d).
Figure 3.8.6. Transmission Electron Microscopy of erythrocyte 
membrane treated with Ply and derivatives
Electron micrograph of negatively stained horse erythrocyte membranes treated with (a) 0.2mg/ml 
WT Ply; (b) 0.2mg/ml PdB; (c) 0.2mg/ml AA146 Ply; (d) PBS. Black horizontal scale bar 
represents 200nm, magnification x 25000. White arrows highlight arc structures, the black arrows 
point to pores (>) or rod structures (► ).
135
Chapter 3 In vitro characterisation of Ply mutants
Discussion
The combination of HIC and AEC resulted in highly purified Ply with reduced levels of 
contaminating LPS. For this work and all future research in our laboratory this double 
purification method has been adopted and in the case of His-tagged proteins the AEC step 
is included after metal chelate chromatography.
The Ply mutants (A5 to A8) were recognised by niAb Ply4 (Figure 3.5). Recently, pre­
treatment with mAh Ply 4 has been shown to passively protect mice from otherwise lethal 
doses of WT Ply treatment and S. pneumoniae infection (Garcia-Suarez et al. 2004). This 
may be a result of mAh Ply4 blocking Ply’s ability to oligomerise in vivo, a property that 
has already been demonstrated in vitro (de los Toyos et al, 1996). It is important to note 
that mAh Ply4’s recognition of these mutants shows that an essential epitope has been 
retained. This epitope has previously been shov/n to be highly antigenic by epitope 
scanning and is recognised by both human convalescent sera and rabbit hyper-immune sera 
(Salo et al. 1993).
In vitro characterisation of the double amino acid deletion AA146R147 (A6 Ply) and the 
single amino acid deletion AA146 Ply revealed that they were not cytotoxic to erythi'ocytes 
or nucleated cells unlike native Ply or the PdB mutant. Erythrocytes were shown to be 
protected from WT Ply lysis by pre-incubation with A6 Ply (Figure 3,8.4.b) and this has 
been previously shown with pre-incubation of membranes with domain 4 of Ply (Baba et 
al. 2001). Such protection of cells is likely to be a result o f the saturation of the membrane 
binding sites by the non-lytic mutant thereby preventing the native toxin from binding to 
and damaging the host cell membrane.
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The ability of the mutants to activate the complement cascade was assessed using an
ELISA that measures production of C3a by C3 cleavage (data not shown). Although A6
Ply and AA146 Ply activated complement to approximately the same levels as WT Ply,
there was a lot of variation in the assay and time did not permit optimisation.
Mast cells are prominent beneath the epithelial layer of skin and mucosal linings and are 
some of the first cells to encounter and attack antigens (Abraham et al. 1997) making a 
mast cell based assay relevant to pneumococcal infection. The involvement of mast cells 
during pneumococcal colonisation or disease is not well documented. A recent study has 
shown that S. pneumoniae stimulates degranulation of RBL-2H3 mast cells without the 
release of prestored cytokines (Barbuti et al. 2006). However, in this paper the 
pneumococci are added to culture media containing penicillin, which would lyse the 
bacteria and result in the release of a range of inflammatory mediators including Ply. This 
would indeed represent the clinical situation where a patient with IPD was treated with a p- 
lactam antibiotic but does not prove that the pneumococcus stimulates mast cell 
degranulation in the absence of antibiotics. SLO, the CDC produced by S. pyogenes, has 
also been shown to cause degranulation of mast cells (Stassen et al. 2003), but this is the 
first report that purified WT Ply does this. It may be that only when Ply is released by S. 
pneumoniae, from the action of LytA or p-lactams, are mast cells degranulated in vivo. 
The AA146 Ply mutant did not cause mast cell degranulation, indicating that it is the 
haemolytic activity of Ply that is responsible for mast cell degranulation.
The mast cell assay was not as sensitive as the cytotoxicity assay using fibroblasts, which 
was able to detect cytotoxicity of WT Ply at 2ng WT P l y / 1 L 9 2 9  fibroblasts compared 
with a, minimum cytotoxic level of 250ng WT P l y / 1 R BL - 2H 3  mast cells. Different cell 
types have previously been shown to vary in their sensitivity to Ply, with human U937 
monocytes more resistant to the lytic action of Ply compared with human lung epithelial
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cell lines A549 and LI 32 (Hirst et al. 2002). Differentiated cell lines have also been 
shown to become either more or less sensitive to treatment with toxins Ply and SLO 
(Tanigawa et al. 1996; Hirst et al. 2002). Such differences in sensitivity to toxin treatment 
have been attributed to differences in the structure and dynamics of the cell membrane. In 
the work presented here we can not make such conclusions as the different cell types were 
investigated in different assays with one measuring viability of cells in response to Ply and 
the other a biochemical measure of sensitivity to Ply.
We have shown that although A6 Ply binds to erytlii'ocyte membranes (Figure 3.8.1 and 
3.8.3) and forms multimeric structures (Figure 3.8.5), it does not dismpt cell membranes 
(as shown by the haemolytic assay in Figure 3.6 and the viability assays in Figures 3.7.1 
and 3.7.2). According to the Ply structural model based on perfringolysin 0  (PFO) 
(Rossjohn et al. 1997), the CDC produced by Clostridium perfringens, the A6 Ply mutation 
is at the domain 1 and 3 interface (Figure 3.1). This region is packed in an awkward 
maimer, possibly to provide energy for the movement of domain 3 during membrane 
insertion (Tweten et al. 2001). Domain 3 of PFO has two transmembrane p-hairpins 
(TMHl and TMH2) that unfold upon oligomerisation to allow insertion of the oligomer 
into the lipid bilayer (Shepard et al. 1998). A Y181A substitution in PFO prevents 
insertion into the membrane and arrests the oligomer in a ‘prepore’ state on the membrane 
surface (Hotze et al. 2002). This mutation is immediately upstream of TMHl and is in the 
same conseiwed region as A6 in Ply. If A6 Ply behaved in the same maimer, we would 
expect to detect prepore structures on the membrane surface. Although AA146 Ply appears 
to self-associate to some extent, oligomeric rings (prepores) have not been observed. 
Instead, arcs (also evident in the WT Ply treated sample and discussed in section 1.12) and 
long chains were observed by electron microscopy of AA146 Ply treated erythrocytes 
(Figure 3.8.6.c). As arcs are formed on membranes treated with AA146 Ply (Figure 
3.8.6.C), the ‘oligomerisation preceding pore formation’ theory fits this observation, as
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AA146 Ply does not lyse cells. However, the arcs observed in WT Ply treated membranes 
appear to be inserted into the membrane (Figure 3.8.6.a). Arcs also appear to insert in a 
recent study with PFO but this is not addressed by the author (Dang et al. 2005b). The 
long chains formed by AA146 Ply treatment of erythrocytes have not been described 
before. Helical structures have been shown to form with high concentrations of Ply, both 
in solution and on membranes (Gilbert et al. 1998; Gilbert et al. 1999b), however the 
diameter of these structures is similar to the 30nm ring structures and not <10nm as 
observed by electron microscopy (Figure 3.8.6.c). A possible explanation for these long 
chains is that the self-recognition site has been altered on the AA146 Ply monomers, not so 
much that association is inhibited but enough to prevent the regulation that must occur in 
native Ply to give the uniform oligomer ring shape and size of ~50 monomers (Morgan et 
al. 1995). Figure 3.9 shows possible A6  Ply monomer interactions to give the long chains 
based on previously published dimensions of the monomer and pore (Andrew et al. 1997). 
This could be further investigated using streptavidin labelling and EM (Dang et al. 2005a) 
to investigate the orientation of domains.
Recently, specific sites on domain 3 of PFO have been identified as being involved in 
monomer-monomer interaction (Ramachandran et al. 2004). TMHl and TMH2 are linked 
together by 5 p-strands, pi to p5 . In the monomeric PFO form, pi is exposed whereas p< is 
shielded from protein interaction by p5 . When the PFO monomer binds to the cell 
membrane, a conformational change occurs that exposes P4 to allow association with the pi 
strand of another PFO monomer. The residue on pi that is proposed to recognise P4 is 
T179, immediately downstream of A177 and R178, the residues homologous to those 
deleted in A6  Ply (A146 R147). Deletion of A177 R178 in PFO and A204 R205 in ILY 
(constructed by Mr. Graeme J. M. Cowan) gives the same non-lytic phenotype as A6  Ply, 
This region is highly conseiwed throughout the CDCs (Table 3.4). By combining the 
experimental evidence with AA146 Ply and detailed analysis of PFO, deleting the residues
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within the VPARMQYE region probably modifies a self-recognition site of domain 3 on
the p 1 strand that abolishes the ability of the toxin to form oligomeric rings and insert into
the host cell membrane.
Table 3.4. Homology of A6 region in some of the sequenced CDCs
Cholesterol Dependent Cytolysin Consensus sequence to Ply
Pneumoiysin VPARMQYE
Perfringolysin 0 LPARTQYSE
Septicolysin LPARTQYSE
Streptolysin 0 LPARTQYTE
Intermedilysin VPARMQYE
Alveolysin LPARLQYAE
Anthrolysin LPARTQYTE
Cereolysin LPARTQYTE
Novylisin LPARTQYSE
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Figure 3.9. Possible interaction of AA146 Fly molecules on erythrocyte membranes
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The dimensions of the Ply monomer (a) and WT Ply pores (b) have been previously calculated 
(Andrew et al. 1997). From the electron microscopy images (Figure 3.8.6), the width of the AA146 
Ply rods are about 10-12nm and this ties in with the height of WT Ply pores, so it is possible that 
AA146 Ply multimerises in the manner shown in (c), possibly due to hydrophobic interactions of 
domain 3 with the membrane. AA146 Ply does bind to membranes, presumably via domain 4, this 
could also occur in the manner shown in (d) where domain 4 still binds to the membrane in a 
perpendicular manner and self association occurs between the hydrophobic domain 3 to give rods 
with a width of ~13nm. Or there may be a random association of hydrophobic regions of Ply 
binding to monomers already bound to cholesterol on the membrane (e).
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4: In vivo responses to i.n. treatment with non-toxic 
pneumoiysin 
Summary
A6 Ply and AA146 Ply were demonstrated to be non-toxic to erythrocytes and nucleated 
cell lines in chapter 3. If either of these Ply toxoids are to be considered for inclusion in 
the next generation of pneumococcal vaccines then they must be demonstrated to be 
non-toxic in vivo. Both outbred and inbred mice were treated intranasally (i.n.) with 
mutant Ply and the host responses were compared with mice given WT Ply. I.n. 
administration of Ply is more sensitive than other routes of administration and it also is 
a more realistic way in which a host with pneumonia may be exposed to Ply. Gross 
symptoms, inflammatory cytokine responses, core body temperature and lung integrity 
in response to Ply treatment were assessed to investigate whether the non-pore forming 
Ply caused any detrimental effects to the host.
4.1. Gross symptoms following Ply treatment
BALB/c mice treated i.n. with Ipg AA146 Ply recovered from anaesthesia quicker than 
mice receiving any dose of WT Ply from O.lpg to Ipg. In the initial hours post 
treatment the behaviour o f AA146 Ply treated mice was similar to that of the saline 
control group but WT Ply treated mice exhibited piloerection, laboured breathing and a 
hunched stance over a 6h period, recovering within 24h. When a dose of Ipg WT Ply 
was administered i.n. to five MFl mice, three reached a moribund state within 6h 
whereas i.n. administration of lOpg of A6 Ply had no adverse effects on MFl mice; 
higher doses were not investigated.
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4.2. Inflammatory responses of MFl mice to i.n. 
administration of Ply
Anaesthetised female MF 1 mice were administered i.n. with 1 pg of either WT Ply or 
AA146 Ply in 50pl of sterile saline. Less than 50% of the WT Ply treated group 
survived this treatment (2/5), therefore the dose of WT Ply was reduced to 0.25pg 
(n=6). 24h post treatment, the lungs were washed witli saline to give bronchoalveolar 
lavage fluid (BALF) and the lungs were removed and homogenised to give lung tissue. 
Both BALF and lung tissue were assessed for the presence of the inflammatory 
cytokines IL-6, TNF-a and IFN-y by ELISA.
4.2.1. Cytokines in BALF and lung tissue of M Fl mice, 24h 
post Ply treatment
IL-6 levels were measured in the limg tissue and BALF of MFl mice as a marker of Ply 
induced inflammation to the host, 24h post-treatment. IL-6 levels in the lung (and 
survival) in response to lower WT Ply doses of O.lpg and 0.25pg were investigated 
(Table 4.1). All mice survived treatment with both O.lpg and 0.25pg WT Ply. A dose 
of 0.25 pg WT Ply was then administered to a larger group size (n=6) and IL-6 levels in 
the lungs at 24h post treatment were compared with lungs from mice treated with I pg 
AA146 Ply, Figure 4.1.
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Table 4.1. Average IL-6 levels in lung 24h post i.n. treatment 
with WT Ply
WT Ply dose 
(sample size)
Average IL-6 in lung tissue 
(pg/ml)
Average IL-6 in BALF 
(pg/ml)
O.lpg (3) 132 244
0.25pg (3) 174 308
LOpg (2) 295 4278
An increase in IL-6 was observed in the lung tissue of MFl mice treated with 0.25pg 
WT Ply (P<0.05) compared with the saline control however, there were no significant 
levels o f IL-6 in the lung tissue of AA146 Ply treated mice compared with the saline 
control group (Figure 4. La). A 10-fold increase in IL-6 was found in the BALF of the 
WT Ply treated group (Figure 4. Lb) compared with AA146 Ply (P<0.01) and saline 
treatment (P<0.01). The median IL-6 level in the BALF from the WT Ply treated group 
was 272 pg/ml (range of 9 0 - 6 5 1  pg/ml) whereas the median background IL-6 level in 
saline treated mice was 33 pg/ml with no significant increase in mice treated with Ipg 
AA146 Ply (44 pg/ml). TNFa and IFNy levels in the lung tissue and BALF samples 
were also investigated, however, the levels were low in all treatment groups at 24h.
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Figure 4.1. IL-6 levels in the lungs of MFl mice 24b post i.n. treatment with 0.25pg 
WT Ply or Ipg AAI46 Ply
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Median (± MAD) IL-6 levels in lung tissue (a) and BALF (b) at 24h post treatment with either 
0.25pg WT Ply (black bar), Ipg AA146 Ply (spotted bar) or saline (striped bar). *P<0.05 when 
compared with the saline control, **P<0.01 when compared with AA146 Ply, *P<0.01 when 
compared with the saline control; n=6.
4.3. Assessment of lung integrity following i.n. Ply 
administration to MFl mice
When the lung/airway interface is damaged, host serum proteins (i.e. albumin) flow into 
the airways. MFl mice treated i.n. with 0.25pg WT Ply were found to have 10 times 
the level of total protein in their BALF, 1 mg/ml total protein, compared with MFl mice 
treated with 4 times as much AA146 Ply, 0 .1 mg/ml total protein (P<0.01, n = 6). Total 
protein levels in BALF from AA146 Ply treated mice were similar to healthy lavage 
samples. Figure 4.2.
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Figure 4.2. Total protein levels in BALF from MFl mice at 
24h post i.n. treatment with 0.25pg WT Ply or Ipg AA146 Ply
Total protein 
levels in BALF 
(rt^ml)
I  wild type Ply S  NaQ 03 AA146Ply
Significantly greater levels of protein were found in the airways of mice treated with 0.25p.g 
WT Ply (black bar) in comparison with mice treated with Igg AA146 Ply (**P <0.01, spotted 
bar) and the saline treated group (*P <0.01, striped bar). Values are expressed as the median ± 
MAD, n = 6.
4.4. Analysis of core body temperature in response to Ply 
treatment
The behaviour of mice following WT Ply treatment has been described earlier in this 
chapter and is characterised with a hunched stance and piloerection, with the animal 
feeling cold to the touch. This was thought to be evidence of a hypothermic response to 
the toxin. BALB/c mice were used for further investigation with Ply treatment as this 
allowed the core body temperature (Tc) in response to Ply to be correlated with the 
previously published observation of Tc in response to S. pneumoniae infection (Kerr et 
al. 2002). BALB/c mice can also tolerate higher doses of WT Ply compared with MFl
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mice as demonstrated in section 4.1, this allowed direct comparison between i.n. 
treatment with Ipg of WT Ply and Ipg of non-haemolytic mutant protein. Female 
BALB/c mice were implanted with telemetry chips that record the Tc of mice via radio 
waves from the chip to a transmitter box upon which an individually caged animal is 
placed. Mice were monitored for two weeks following chip implantation and then 24h 
prior to toxin treatment were placed in individual cages to record their Tc. Data was 
acquired electronically, at chosen inteiwals. Immediately after i.n. treatment with either 
Ipg WT Ply (n=22), Ipg AA146 Ply (n=22) or NaCl (n=5), the mice were placed on the 
transmitters for 24h of data acquisition (Figure 4.3). At 2h, 6h and 24h, five mice (six 
for the 24h group) from the WT Ply and AA146 Ply treatment groups were sacrificed 
and sampled for analysis of inflammatory mediators in the lung, brain, BALF and 
serum. Total protein levels were measured in the BALF of WT Ply and AA146 Ply 
treated groups at each time point.
4.4.1. Treatment of BALB/c mice with AA146 Ply does not 
result in a hypothermic response in comparison with WT Fly 
treatment
BALB/c mice treated with lp.g AA146 Ply did not exhibit the hypothermic response
observed in mice treated with Ipg  WT Ply (Figure 4.3). The Tc of all treated groups
dropped initially by approximately 1°C for the AA146 Ply and NaCl treated groups
whereas the Tc of the WT Ply treated group significantly dropped by 2°C (P<0.01).
Following this initial drop in Tc, the AA146 Ply and NaCl treated groups recovered to
their pre-treatment Tc whereas the median Tc of the WT Ply treated mice continued to
decrease to 27°C within 6h post treatment. From treatment to the 24h endpoint, the Tc
of the WT Ply treated group was statistically significantly lower than the AA146 Ply
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and NaCl treated groups. After 6h, the Tc o f  WT Ply treated mice increased to 35°C, 
however, the pre-treatment median Tc o f  37°C was not obtained within 24h.
Figure 4.3. Core body temperature of BALB/c mice in 
response to Ply treatment
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Median (± MAD) core body temperatures (Tc) of BALB/c mice over 24h following i.n. 
administration of either Ipg WT Ply, Ipg AA146 Ply (n-22 at Oh, 17 at 2h, 12 at 6h and 6 at 
24h), or NaCl (n=5). The dashed vertical line represents the time of treatment. From Ih to 23h, 
* P<0.01and at 24h P<0.05, where the Tc of the WT Ply treated group is significantly lower 
than the NaCl and AA146 Ply groups.
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4.5. Analysis of inflammatory mediator production in 
response to Ply treatment
In attempt to identify mediators involved in the hypothermic response induced by WT 
Ply or any responses to AA146 Ply treatment, the Luminex system was adopted to allow 
simultaneous measurement of multiple cytokines and chemokines in each sample at 
each time point. BALF, serum, lungs and brains were recovered at 2h, 6h and 24h post 
Ply treatment from telemetry chip implanted BALB/c mice. The samples were 
processed and analysed for the following analytes: IL -lp, IL-5, IL-6, ÏL-10, IL-12, IFN- 
y, TNF-a, GM-CSF and KC.
4.5.1. IL-6 and KC levels were significantly increased in the 
lungs of WT Ply treated BALB/c mice compared with AA146 
Ply treatment
IL-6 and KC levels were significantly higher in lung tissue from WT Ply treated mice 
compared with AA146 Ply treatment at all time points (Figure 4.4). By 24h the WT 
lung tissue had 8-fold more KC and 5-fold more IL-6 than lung tissue from the AA146 
Ply treated group. IL-6 levels in the lung tissue from WT Ply treated mice increased 
over time from 63pg/ml at 2h to 120pg/ml at 24h (Figure 4.4.a). KC levels in lung 
tissue from the WT Ply treated group increased over 24h from 159pg/ml at 2h to 
507pg/ml at 24h, with a significant increase from 2h to 6h (^^<0.01, Figure 4.4.a). 
There were no significant increases in any of the other cytokines measured in the lung 
tissue of WT Ply treated mice compared with AA146 Ply treatment.
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In the BALF, IL-6 levels were significantly higher in the WT Ply treated group at all 
time points (P<0.01) compared with the AA146 Ply treated group (Figure 4.5). The 
level of IL-6 in WT Ply BALF increased over time from a mean of 63pg/ml at 2h to 
590pg/ml by 24h post treatment. IL-6 levels were higher in the BALF than the lung 
tissue whereas KC levels were higher in the lung tissue. The levels of KC were 
significantly greater in the BALF of WT Ply treated mice at 24h compared with AA146 
Ply treatment (P<0.05). IL-5 levels were also significantly increased by 5-fold in the 
BALF of WT Ply treated mice at 24h (52 pg/ml; P<0.05) when compared with AA146 
Ply treatment (10 pg/ml), however the IL-5 levels were still low in comparison with IL- 
6 and KC levels.
Low levels of IL-10 and IL-12 were present in the lung tissue (Figure 4.4) and BALF 
(Figure 4.5) of both groups at 2h and 6h post treatment. IL-10 and IL-12 were not 
present in the lung tissue or BALF 24h post treatment. There were no significant 
differences in analyte levels in serum and brain tissue from WT Ply treated mice 
compared with AA146 Ply treated mice. However, IL-10 and IL-12 levels were high in 
the serum of both treatment groups at 2h and 6h but not at 24h (Figure 4.6.a and 4.6.c). 
These cytokines were also present at low levels in the brain tissue of both treatment 
groups at 2h and 6h (Figure 4.6.b and 4.6.d). KC was also present in the serum of both 
treatment groups at 24h (Figure 4.6.a and 4.6.c), but not in the brain tissue. KC levels 
in the lung tissue (Figure 4.4b) and BALF (Figure 4.5b) of AA146 Ply treated mice 
were below 50pg/ml at all time points. TNFa, IFNy and IL -ip  were not found at any 
time point in any of the samples.
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Figure 4.4. Analyte levels in lung tissue at 2h, 6h and 24h post Ply 
treatment
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Mean (± SEM) levels of IL-ip, IL-5, IL-6, IL-10, IL-12, GM-CSF, IFN-y, TNF-a and KC in 
the lung tissue of BALB/c mice at 2h, 6h and 24h post i.n. treatment with either l^g WT Ply (a) 
or Ipg AA146 Ply (b). *P <0.05, **P<0.01 when compared with the AA146 Ply treated group; 
^^P<0.01 when compared with 2h WT Ply KC level (asterisk colour corresponds with analyte); 
n=5/6. Statistical analysis was with the median.
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Figure 4.5. Analyte levels in BALF at 2h, 6h and 24h post Ply 
treatment
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Mean (± SEM) levels oflL-ip, IL-5, IL-6, IL-10, IL-12, GM-CSF, IFN-y, TNF-a and KC in the 
BALF of BALB/c mice at 2h, 6h and 24h post i.n. treatment with either Ipg WT Ply (a) or Ipg 
AA146 Ply (b). *P <0.05, **P<0.01 when compared with the AA146 Ply treated group (asterisk 
colour corresponds with analyte, except IL-5 where asterisk is black rather than yellow); n=5/6.
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Figure 4.6. Analyte levels in serum and brain tissue at 2h, 6h and 24h post Ply 
treatment
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Mean (± SEM) levels o f  IL -ip , IL-5, IL-6, IL-10, IL-12, GM-CSF, IFN-y, T N F-a and KC in the 
serum and brain tissue o f BALB/c mice at 2h, 6h and 24h post i.n. treatment with either Ipg  WT 
Ply (a, serum; b, brain tissue) or Ipg  AA146 Ply (c, serum; d, brain tissue); n=5/6.
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4.6. Total protein in BALF of BALB/c mice at 2h, 6h and 24h 
post Ply treatment
The total protein levels in BALF were significantly higher in the Ipg WT Ply i.n. treated 
group compared with Ipg AA146 Ply at all time points (**P<0.01, Figure 4.7). Total 
protein levels in the BALF of AA146 Ply treated mice were comparable to background 
protein levels in healthy lavage samples. Within 2h post WT Ply treatment the total 
protein in the lung airways significantly increased to levels 25-fold greater than the AA146 
Ply group. This level was maintained over 24h. The damage to lung integrity by WT Ply 
corresponds with the IL-6 and KC profile in the lung tissue and BALF, as at 2h, 6h and 
24h total protein levels, IL-6 and KC are significantly higher than the AA146 Ply treated 
group.
Figure 4.7. Total protein levels in BALF at 2h, 6h and 24h post i.n. Ply treatment
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Total protein levels in BALF at 2h, 6h and 24h post treatment with either Ipg WT Ply (blaek bars) 
or Ipg AA146 Ply (red bars). Values are expressed as the median ± MAD (n=5/6, **P<0.01 when 
compared with AA146 Ply group).
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Discussion
Treatment of inbred and outbred strains of mice with AA146 Ply does not induce the 
inflammatory effects that are associated with WT Ply treatment. Mice treated with WT Ply 
had severely damaged lungs in comparison with lungs retrieved from mice treated with 
AA146 Ply. The large amount of total protein obseiwed in the airways of WT Ply treated 
mice is a result o f Ply’s disruption of tight junctions at the capillary/airway barrier (Rubins 
et al. 1995) allowing an influx of host serum proteins to flood the lung airways. This 
vascular leakage has recently been shown to be entirely due to the cytolytic action of Ply 
and is independent of recruited leukocytes (Maus et al. 2004), though cytokines produced 
in response to Ply may intensify lung damage.
Although the nine analytes investigated were not an exhaustive list, they were chosen as 
the analytes with known or implicated roles in inflammation or hypothermia (Houldsworth 
et al. 1994; Bergeron et al. 1998; Leon et al. 1998; Ebong et al. 1999; Pillion et al. 2001; 
Baba et al. 2002; Rijneveld et al. 2002a; Rijneveld et al. 2002b; Search 2002; Borish et al. 
2003; Stricter et al. 2003; Léon 2004; Jones et al. 2005). When BALB/c mice were treated 
i.n. with WT Ply there was a localised inflammatory response within 24h following 
treatment, characterised by significant increases in IL-6 and KC levels in lung tissue and 
BALF. This response was not obseiwed in samples from mice treated with AA146 Ply. 
Localised production of IL-6 and KC in response to WT Ply and pneumococcal infection 
has previously been reported and is likely to be from alveolar macrophages and recruited 
neutrophils (Pillion et al. 2001; Rijneveld et al. 2002b; Jones et al. 2005). WT Ply treated 
mice had higher KC levels in their lung tissue compared with the BALF, which only had 
significant levels of KC at 24h. This is possibly due to the high numbers of neutrophils 
recruited into the lung tissue. KC levels may increase in the BALF following vascular 
leakage and/or neutrophil recruitment caused by WT Ply.
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KC and C5a are the main neutrophil recruiters, however, mice deficient in the C5a receptor
did not differ from WT mice in neutrophil counts in the lung during pneumococcal
pneumonia (Kerr et al. 2005b). This indicates that KC in mice, or IL-8 from human
neutrophils (Cockeran et al. 2002), is responsible for the mass influx of neutrophils into the
lungs during pneumococcal pneumonia. The timing of the increase in KC levels in the
lung following WT pneumolysin treatment mirrors with the profile of neutrophil
recruitment into the lung over 24h post i.n. infection with D39 S. pneumoniae (Figure 4.8).
By 6h post WT Ply treatment the KC level has almost reached the level observed at 24h
(Figure 4.8.a) and it is from 6h post infection that the number of neutrophils in the lung
tissue substantially increases (Figure 4.8.b). Comparing the data that shows neutrophil
recruitment during pneumococcal infection is due to Ply (Kadioglu et al. 2000) with the
KC levels in response to WT Ply (Figure 4.4.a) suggests that neutrophil recruitment is
driven by Ply’s induction of KC. It is important to note that this is not a direct comparison
as Ply negative S. pneumoniae is being compared with purified Ply and in different mouse
strains. The induction of KC by purified Ply is, however, due to the cytolytic propeify of
Ply, as treatment of mice with AA146 Ply did not induce KC production in the lung tissue.
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Figure 4.8. Comparison of lung KC levels following Ply treatment with 
neutrophil counts in lung tissue following pneumococcal pneumonia
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(a) Mean KC level in lung tissue homogenate (pg/ml) of BALB/c mice over 24h post i.n. treatment 
with Ipg of purified WT Ply (filled squares) or Ipg of purified AA146 Ply (open circles) (n=5/6), 
data plotted from results in Figure 4.4. (b) Total number of neutrophils in the lung tissue of MFl 
mice (n=5) post i.n. challenge with 10^  CFU of D39 S. pneumoniae (filled squares) or the ply 
knockout strain of D39, PLN-A (open circles), data adapted from Kadioglu et al, 2000 with an 
approximation of neutrophil counts (Kadioglu et al. 2000).
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IL-6 levels were greater in the BALF of WT treated mice compared with the lung tissue (in
contrast to KC, which was greater in the lung tissue). This is probably due to the alveolar
macrophages residing in the BALF, which instantly release IL-6 and recruit other IL-6
releasing cells, explaining the continual increase in IL-6 production. The interaction
between KC and IL-6, if any, has not been identified though both are involved in
pneumococcal pneumonia (Albiger et al. 2005) and are produced in response to WT Ply
treatment (Rijneveld et al. 2002b). IL-6 profiles in CD-I mice post pneumococcal
infection were similar in timing to this work but the levels were 10-fold greater in the lung
tissue rather than the BALF (Bergeron et al. 1998), this is the opposite of WT Ply
treatment in BALB/c mice where the IL-6 levels were greater in the BALF (Figure 4.5)
compared with lung tissue (Figure 4.4). This difference is probably due to the timing and
location of Ply release, as Ply treatment and release of Ply during infection may occur in
different locations within the host, thereby involving different cell types and inflammatory
responses and interaction with other components. For example, CbpA can stimulate IL-8
production from human alveolar epithelial cells (Murdoch et al. 2002).
IL-6 has been shown to inhibit neutrophil recruitment in the lungs by blocking the 
expression of TNF-a and other inflammatory mediators involved in this process (Mizgerd 
2002). It may be that induction of IL-6 by Ply limits neutrophil influx in the alveolar space 
thereby assisting pneumococcal growth in the lungs. This can also be taken from the 
perspective of the host in that IL-6 produetion as an anti-inflammatory cytokine may 
protect the host tissue from the damage caused by the mass influx of neutrophils. 
Hypothermia, which involves IL-6 (Leon et al. 1998), has also been shown to reduce the 
pulmonary sequestion of neutrophils to attenuate lung injury (Lim et al. 2003). The 
cytolytic activity of Ply may be important in the release of iron from erytlirocytes to 
promote pneumococcal growth in the host, this is in counterbalance with hosts production
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of IL-6 in response to Ply which has recently been shown to result in hypoferraemia to
inhibit proliferation of pathogens (Nemeth et al. 2004).
IL-5 levels were increased in the BALF of WT Ply treated mice compared with mice 
treated with AA146 Ply (Figure 4.5). IL-5 plays a key role in eosinophil-based 
inflammation as it stimulates eosinophil production and prolongs their survival by blocking 
their apoptosis (Borish et al. 2003). Interestingly increases in albumin levels in the BALF 
(as observed with WT Ply treatment, Figuie 4.7) have been shown to con-elate with an 
increase in eosinophils in the BALF (Lampinen et al. 2004), which are the main IL-5 
producing cells. In addition to eosinophils, mast cells and NK cells are known to express 
IL-5. Although the IL-5 levels are low in comparison with IL-6 and KC, it is important to 
note that low levels of cytokines can have high levels of biological activity.
TNF-a, IFN-y and IL-ip were not found in any of the samples despite previous research 
showing that in vitro treatment of cells with Ply induces IFN-y (Braun et al. 1999; Baba et 
al. 2002), IL -lp and TNF-a release (Houldsworth et al. 1994). However, the findings in 
this work correlate with other studies showing no TNF-a or IFN-y in the lungs of mice at 
6h post WT Ply treatment (Rijneveld et al. 2002b). This highlights that although tissue 
culture experiments can indicate inflammatory mediators involved in pathogenesis, host 
cytokine responses are complex and involve the interaction of an array of immune cells. In 
vivo investigation therefore provides a more realistic indication of the cytokines induced 
following Ply treatment.
Direct i.n. instillation of saline to mice did not elevate cytokine levels in the lung (Section 
4.2) compared with WT Ply. Therefore, due to home office regulations that do not permit 
repetition of such experiments, a saline group was not assessed for cytokine analysis in the 
telemetry experiment. Instead, this experiment was a direct comparison to investigate
160
Chapter 4 In vivo analysis of non-cytoiytic Ply
whether i.n. treatment of mice with AA146 Ply elicited the same inflammatory response as
WT Ply, which it clearly does not. All inflammatoiy mediators implicated in Ply’s role in
infection were not produced in mice treated with the non-cytoiytic fomi of Ply.
The initial drop in core body temperature (Tc) observed in all groups (Figure 4.3) has been 
reported to be an effect o f anaesthesia due to the high ratio of surface area to body weight, 
which makes mice particularly susceptible to hypothermia (Flecknell 1996; Leon et al. 
1998). Hypothermic responses to bacteria and endotoxins have previously been suggested 
to be beneficial to the host (Kerr et al. 2002; Lim et al. 2003; Leon 2004). BALB/c mice 
have a profound early hypothermic response to S. pneumoniae infection but are able to 
clear the infection, whereas CBA/Ca mice do not have the early hypothermic response and 
subsequently succumb to pneumococcal infection (Kerr et al. 2002). The dramatic drop 
in Tc in response to WT Ply alone has not been reported before. It is possible that the 12- 
hour hypothermia observed with pneumococcal infection (Kerr et al. 2002) may occur 
when the bacteria have established within the host and are lysing, resulting in the release of 
Ply. The immediate hypothermic response observed with purified WT Ply may be due to 
the direct intranasal administration of the toxin but this may also be a result of the mice 
being unable to maintain their Tc following treatment with the anaesthetic. Further 
experiments recording the Tc of BALB/c mice infected with the Ply negative strain of S. 
pneumoniae, PLN-A, would provide information on whether the hypothermic response 
found with D39 S. pneumoniae infection is directly due to Ply and IL-6 production.
Although the mechanisms of thermoregulation are not fully understood, cytokines are 
known to be involved in regulation/induction of hypothermia (Leon 2004). IL-6 may play 
a role in murine hypothermia following exposure to Ply and ultimately S. pneumoniae 
infection. IL-6 has been shown to act as pyrogen, inducing an increase in Tc (Gruol et al. 
1997; Leon et al. 1998), it may be that the IL-6 increase observed over 24h post Ply
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treatment counteracts the early hypothermic response to restore the Tc of the hypothermic
animals. However, IL-6 production is also known to induce hypothermia (Leon et al.
1998) and it may be that IL-6 is a contributing factor to the induction of hypothermia as
high IL-6 levels in the BALF occur within the 2-6h that hypothermia is observed.
However, the IL-6 level continues to rise in the BALF within 24h post treatment with Ply
(Figure 4.5). Treatment of IL-6 -/- mice with WT Ply would permit the investigation into
whether the hypothermic response involves IL-6.
Measurable levels of IL-10 were present in the samples in particular in the serum at 2h and 
6h post treatment. IL-10 is an anti-inflammatory cytokine that switches off the hosts 
inflammatory response by modulating TNF-a and IL-6 production. However, IL-10 was 
also found in the serum from mice treated with AA146 Ply and these mice did not have a 
hypothermic response or IL-6 production that would need to be controlled by IL-10,
Ultimately, what is important in the context of this work is that treatment of mice with 
AA146 Ply did not result in the prolonged hypothermia or inflammatory cytokines induced 
by WT Ply treatment, further supporting the safety of this toxoid for use as a vaccine 
component.
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5. Vaccination with Ply and derivatives.
Summary
Current pneumococeal vaccines are somewhat limited as they only protect against 
serotypes for which the capsule polysaccharide (CPS) is a component of the vaccine. It is 
thought that the inclusion of a common pneumococcal protein in the next generation of 
vaccines may confer protection against disease caused by all serotypes of S. pneumoniae. 
Healthy humans were recently shown to have higher anti-Ply titres in their saliva and 
serum compared with S. pneumoniae infected patients, suggesting that anti-Ply antibodies 
may protect humans from pneumococcal disease (Huo et al. 2004). Passive immunisation 
of mice with purified anti-Ply IgG from humans with non-bacteraemic pneumococcal 
pneumonia was shown to protect mice from challenge with two different pneumococcal 
serotypes (Musher et al. 2001). Ply makes a good vaccine candidate as it is produced by 
all invasive strains of S. pneumoniae (Kanclerski et al. 1987), it is relatively conserved (see 
chapter 7) and has been shown to be immunogenic in mice as a free protein (Paton et al. 
1983b; Alexander et al. 1994; Ogunniyi et al. 2001) or as a carrier protein to the 
polysaccharides in current vaccine preparations (Paton et al. 1991; Lee et al. 1994; Kuo et 
al. 1995; Michon et al. 1998; Lee et al. 2001b), conferring increased protection against 
pneumococcal disease. All previous studies either use chemically inactivated WT Ply or 
genetically produced mutants with residual haemolytic activity. The cytotoxicity of Ply 
and the PdB derivative has been demonstrated in chapters 3 and 4. This chapter compares 
the immunogenicity of non-toxic AA146 Ply with WT Ply and also investigates the 
proteetion elicited by conjugating A6 Ply to CPS from serotype 4 S. pneumoniae.
».Py
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Results 
5.1. Determining an infectious i.p. dose of 5. pneumoniae
In order to ensure that the challenge dose of S. pneumoniae to vaceinated mice would be 
lethal for the control groups, infectious doses were determined in unvaccinated mice. This 
allowed any increase in protection afforded by vaccination to be determined.
5.1.1. Determining an infectious i.p. dose of TIGR 4 & 
pneumoniae
BALB/c mice were given either 10  ^ or 10"^  CFU TIGR4 S. pneumoniae intraperitonealy 
(i.p.) in a lOOpl dose (n=4). Doses were checked immediately before and after challenge 
to ensure that the dose was correct and the pneumococci remained viable. 18h post 
infection, blood was taken from the lateral tail vein and assessed for baeteraemia. Both 
groups had similai' mean bacterial loads, 5.9x10^ CFU/ml for the 10  ^ CFU challenged 
group and 5.5x10^ CFU/ml for the 10"^  CFU challenged gi'oup (Figure 5.1.1). The survival 
times of the groups did not differ significantly, in fact, the lower dose group became 
lethargic quicker than the higher dose, but group sizes were small and it was only one 
outlier that increased the survival time of the high dose group (Figure 5.1.2.).
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Figure 5.1.1. Baeteraemia in BALB/c mice at I8I1 following i.p. infection with either 
10^  or 10^  CFU TIGR4 S, pneumoniae
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Log bacterial load in the blood of BALB/c mice 18h post i.p. infection with either 10^  CFU or 10'* 
CFU TIGR4 S. pneumoniae. Horizontal bar represents the mean; each dot represents an individual 
animal. Dashed horizontal line represents the detection limit.
Figure 5.1.2. Survival of BALB/c mice following i.p. infection with either 10^  or 10^  
CFU TIGR4 S. pneumoniae
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Survival (h) of BALB/c mice post i.p. challenge with a either 10^  CFU or 10'* CFU TIGR4 S. 
pneumoniae (n=4). Horizontal bar represents the mean; each dot represents an individual animal.
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The lower dose of 10  ^CFU TIGR4 S. pneumoniae was chosen for challenging the actively 
vaccinated mice. For a second vaccination experiment, a serotype for which capsule 
polysaccharide was not a vaccine component was required for challenge.
5.1.2. Determining an infectious i.p. dose of D39 S. pneumoniae 
(serotype 2)
D39 S. pneumoniae, the common serotype 2 laboratory strain, was initially chosen as a 
non-vaccine serotype, however this was not suitable, as the 24h viable counts in the blood 
of M Fl mice were so variable compared with a virulent serotype 1 strain ST615 (Figure 
5.1.3).
Figure 5.1.3. 24h baeteraemia in blood from MFl mice following
challenge with serotype 1 or D39 S. pneumoniae
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Log bacterial load in blood of MFl mice 24h post i.p. challenge with either 10^  CFU serotype 1 S. 
pneumoniae or 10^  CFU D39 S. pneumoniae (n=4). Horizontal bar represents the mean. Dashed 
horizontal line represents the detection limit.
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The reason for the variability of D39 S. pneumoniae was unknown. To investigate whether
this variability was due to the standard inoculum, the strain was mouse passaged by
infecting M Fl mice with 10^  CFU D39 (n=4) and taking a terminal bleed from the first
animal to succumb to infection. The blood was spread onto BAB plates supplemented
with 5% horse blood for single colonies and four single colonies were selected for
preparation of inoculum (clones 1-4). Each clone was assessed for ability to cause
infection in BALB/c mice. Even in an inbred strain of mouse, challenged with freshly
mouse-passaged clones, the bacterial loads remained highly variable, with 3 animals for 3
different clones having no detectable baeteraemia and other mice with bacterial loads of
10  ^CFU/ml and greater, Figure 5.1.4 (n-4).
All of the mice challenged with 10^  CFU serotype 1 S. pneumoniae had similar levels of 
baeteraemia at 24h post infection in comparison with mice infected with the same dose of 
D39 S. pneumoniae (Figure 5.1.3). Serotype 1 was therefore chosen as the non-vaccine 
serotype for challenge of vaccinated animals, however the minimum infectious dose was 
still to be determined.
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Figure 5.1.4. Baeteraemia in BALB/c mice at 18h post challenge with
mouse virulent clones of D39 S. pneumoniae
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Bacterial loads in blood of BALB/c mice, 18h post i.p. challenge with 10^  CFU D39 5'. pneumoniae 
(n = 4). Horizontal bar represents the mean; each dot represents an individual animal. Dashed 
horizontal line represents the detection limit. Clones 1-4 are single clones of mouse virulent D39 S. 
pneumoniae.
5.1.3. Determining the minimum infectious dose of serotype 1 S, 
pneumoniae
The minimum infectious i.p. dose of serotype 1 was determined by administering varying 
doses to BALB/c mice (n=4) and taking an 18h sample bleed for viable counts (Figure 
5.1.5) and monitoring survival times (Figure 5.1.6). Bacterial loads in the blood at 18h 
post challenge were between 10  ^ and 10  ^ CFU/ml for all groups irrespective of the 
challenge dose (Figure 5.1.5). There was little variation in survival times within each 
group and between groups administered with different doses, except the group given 10^  
CFU that survived almost 20h longer than the 10  ^CFU dose (Figure 5.1.6). From these 
experiments, a dose of 10  ^ CFU serotype 1 S. pneumoniae was chosen for challenge of 
vaccinated mice.
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Figure 5.1.5. 18h baeteraemia following infection of BALB/c 
mice with a dose range of serotype 1 S. pneumoniae
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Bacterial loads in blood of BALB/c mice 18h post i.p. infection with different doses of serotype 1 
S. pneumoniae (n=4). Horizontal bar represents the mean; each dot represents an individual 
animal. Dashed horizontal line represents the detection limit.
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Figure 5.1.6. Survival of BALB/c mice following i.p. challenge
with serotype 1 S. pneumoniae
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Survival (h) of BALB/c mice post i.p. challenge with 10 -  10 CFU serotype 1 S. pneumoniae 
(n=4). Horizontal bar represents the median survival time; each dot represents an individual 
animal.
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5.2. Active vaccination with purified Ply and derivatives
BALB/c mice were subcutaneously administered 20pg o f WT Ply or AA146 Ply plus 
lOOpg Alum, lOOpg Alum or PBS (n=8). They were boosted three times on days 10, 28 
and 44. Sample bleeds were taken before immunisation (day 0) and each boost (days 9, 
27, 43) and one month after the last boost (day 76). Anti-Ply IgG antibody levels were 
measured in each sample bleed (Figure 5.2.1.). After the first immunisation (day 9), there 
were detectable levels o f anti-Ply IgG in the groups immunised with WT Ply or A AI 46 
Ply. By day 27 after one boost, anti-Ply IgG titres in sera from groups vaccinated with 
AA146 Ply plus Alum and WT Ply plus Alum were high and plateaued after two boosts 
(day 43). There were no anti-Ply IgG antibodies found in serum from the control mice that 
were vaccinated with Alum only (Figure 5.2.1.) or PBS (data not shown).
Figure 5.2.1. Anti-Ply IgG titre in serum during active vaccination with 
Ply
II
I S
SOOOOOn
50000-
■ ■ W T  Ply
■ IA A 1 4 6  Ply 
I I Alum
day 0 day 9 day 27 day 43 day 76
Sample days
Mean anti-Ply IgG titre at OD450nm 0.3 (± SEM) in BALB/c mice before vaccination (day 0), the 
day before each boost (days 9, 27 and 43) and one month after the last boost (day 76). The 
detection limit was a titre of 50, n=8.
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The anti-Ply IgG antibodies from day 76 serum of the WT Ply plus Alum and AA146 Ply
plus Alum group were also found to neutralise Ply’s haemolytic activity (3HU/well) to a
neutralising titre o f 3200-12800 in comparison with background levels o f 800-1600 for the
Alum only group (Figure 5.2.2.).
Figure 5.2.2. Neutralising titre of day 76 serum from active vaccination 
with Ply
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Mean neutralising titre (±SEM) of day 76 serum from BALB/c mice following vaccination with 
either WT Ply plus Alum, AA146 Ply plus Alum or Alum alone (n=8). The titre is calculated as the 
reciprocal of the dilution where the antibodies no longer block the haemolytic action of 60HU/ml 
of WT Ply.
Following vaccination, mice were challenged i.p. with 10  ^ CFU TIGR4 S. pneumoniae. 
18h following challenge, the bacterial loads in the blood o f all vaccinated groups were at 
10  ^ CFU/ml (range o f 10  ^ -  10  ^ CFU/ml), with no significant difference between Ply 
vaccinated groups and control groups (Figure 5.2.3). However, mice immunised with WT 
Ply plus Alum or AA146 Ply plus Alum survived the infection significantly longer than the 
Alum control group, P<0.05 (Figure 5.2.4.) and the PBS only group. There was no
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significant difference between the protection afforded by AA146 Ply compared with WT
Ply. One mouse from the AA146 Ply plus Alum group, which had a blood bacterial load o f
2x10^ CFU/ml TIGR4 S. pneumoniae at 18h post infection, cleared the infection within 6
days and survived (Figure 5.2.4).
Figure 5.2.3. Baeteraemia at 18h in vaccinated mice following 
challenge with 10^  CFU TIGR4 S, pneumoniae
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Bacterial load in blood from vaccinated BALB/c mice at 18h post i.p. ehallenge with 10^  CFU 
TIGR4 S. pneumoniae. Horizontal bar represents the mean log bacterial load; each dot represents 
an individual animal (n=8).
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Figure 5.2.4. Survival of vaccinated mice following challenge with 10^
CFU TIGR4 S. pneumoniae
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Survival (days) of vaccinated BALB/c mice following challenge with 10^  CFU TIGR4 S. 
pneumoniae (n=8). Each dot represents an individual animal and the horizontal bar is the median 
survival time (*P<0.05 when compared with Alum alone group). There is no difference in the 
survival times between WT Ply and AA146 Ply protection; both are equally protective.
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5.3. Conjugate vaccination
A6  Ply was covalently conjugated to CPS from serotype 4 S. pneumoniae to give A6  Ply- 
type4 CPS (this was carried out at Wyeth Vaccines by Dr. Maya Koster). Tliis allowed for 
the comparison of A6  Ply with CRM ] 97 (the conjugate protein in Prevnar) in ability to act 
as a carrier protein to improve protection against infection from disease caused by a 
vaccine serotype: serotype 4 TIGR4 S. pneumoniae. The reason for using a pneumococcal 
protein as the carrier protein is that it may confer additional protection against disease 
caused by non-vaccine serotypes. BALB/c mice were vaccinated with A6 Ply-type4 CPS 
and then challenged with either TIGR4 S. pneumoniae or serotype 1 S. pneumoniae and 
assessed for baeteraemia and survival in comparison with mice vaccinated with free A6 Ply 
plus Alum, free type 4 CPS plus Alum and Alum alone. A Prevnar vaccinated group and a 
Prevnar plus A6 Ply group were also included to assess whether adding free Ply to the 
existing vaccine could confer protection against infection with a non-vaccine serotype.
5.3.1. Active vaccination with A6Ply-type4 CPS
BALB/c mice were vaccinated subcutaneousiy with 200pl of either A6 Ply-type4 CPS 
(containing Ijiig CPS and 0.64pg A6 Ply) plus 200pg Alum, Ipg type 4 CPS plus 200pg 
Alum, 0.64|Lig A6 Ply plus 200fig Alum, Prevnar (containing 0.8p,g type 4 CPS and 200pg 
Alum), Prevnar plus 0.64pg free A6 Ply, 200pg Alum, or PBS alone (n=10). All 
preparations were standardised to contain comparable amounts of CPS, protein and Alum. 
Note that the dose of protein (0.64pg) is low in comparison with the 20|Lig dose of AA146 
Ply administered in the previous vaccination experiment but this was determined by the 
dose of CPS. Also the dose of adjuvant was increased from lOOpg to 200pg, as this was 
the amount of Alum in Prevnar. Blood was taken before vaccination and before each of 
the three boosts on day 17, 33 and 52. A final bleed was taken 4 weeks after the last boost
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on day 80 and one week prior to challenge. Anti-Ply IgG levels were measured in the
serum from each bleed (Figure 5.3.1). The anti-Ply IgG titres were high and plateaued in
the groups vaccinated with either free A6 Ply or A6Ply conjugated to type 4 CPS after the
first boost on day 18 (day 33 bleed). These titres are comparable to the anti-Ply IgG titres
in BALB/c mice vaccinated with 20pg free WT Ply or AA146 Ply, however, when more
free protein was administered there was an earlier anti-Ply IgG response (Figure 5.2.1).
Figure 5.3.1. Anti-Ply IgG titres in serum post vaccination with Ply 
conjugate
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Mean anti-Ply IgG titre at OD450nm 0.3 (± SEM) in BALB/c mice before vaccination (day 0), the 
day before each boost (days 17, 33 and 52) and one month after the last boost (day 80). The 
detection limit was a titre of 50, n=10. A6 Ply + typc4PS + Alum is the conjugate vaccine.
Each group o f 10 vaccinated mice was divided to give 5 to be challenged i.p. with 10^  
TIGR4 S. pneumoniae and 5 with 10  ^ serotype 1 S. pneumoniae. Blood samples were
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taken at 18h post infection and assessed for baeteraemia (Figure 5.3.2). Mice vaccinated
with Prevnar, Prevnar plus A6  Ply and A6  Ply conjugated to type 4 CPS were completely
protected from infection with TIGR4 S. pneumoniae. Figure 5.3.2.a. Whereas mice given
free type 4 CPS plus Alum, free A6  Ply plus Alum or Alum only were bacteraemic within
18h post infection. The mean bacterial loads in blood from the A6  Ply plus Alum and type
4 CPS plus Alum vaccinated animals were lower (1.2x10^ and 1.6x10^ CFU/ml
respectively) than the Alum only control group (2.8x10^ CFU/ml); however this difference
was not statistically significant.
All mice challenged with serotype 1 S, pneumoniae were bacteraemic within 18h post 
infection (Figure 5.3.2.b) with no significant differences in bacterial loads between groups. 
Thi'ce mice in separate groups did not survive through the vaccination protocol and died of 
natural causes, this resulted in a group size of 4 for three of the groups challenged with 
serotype 1 S. pneumoniae.
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Figure 5.3.2. Baeteraemia in conjugate vaccinated animals at 18h post challenge with 
TIGR4 (a) or serotype 1 (b) S. pneumoniae
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Mean log bacterial loads (± SEM) in blood of BALB/c mice 18h post i.p. challenge with 10^  CFU 
of either (a) TIGR4 S. pneumoniae or (b) serotype 1 S. pneumoniae (n=4/5). A6  Ply + type4PS + 
Alum is the conjugate vaccine.
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Survival following infection was monitored and mice were culled when they became
lethargic. Mice were considered to have completely survived infection if they survived >7
days. The groups vaccinated with Prevnar, Prevnar plus A6  Ply and A6  Ply conjugated to
type 4 CPS survived infection with TIGR4 S. pneumoniae (Figure 5.3.3.a), There was no
significant difference in survival of mice given free type 4 CPS plus Alum or A6  Ply plus
Alum compared with the Alum only control group and all mice succumbed to infection
within 54h.
When mice were challenged with serotype 1 S. pneumoniae no groups were completely 
protected from infection, apart from one mouse in the type 4 CPS only group. This mouse 
did not have baeteraemia at 18h and may have not received the whole challenge dose; it 
was therefore not included in statistical analysis. Groups immunised with free A6  Ply 
(Prevnar plus A6  Ply group and the A6  Ply plus Alum group) survived infection 
significantly longer than the Alum only group (P<0.05), Figure 5.3.3.b.
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Figure 5.3.3. Survival of conjugate vaccinated mice following
i.p. challenge with either TIGR4 or serotype 1 S. pneumoniae.
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Survival (days) of vaccinated BALB/c mice following challenge i.p. with 10^  CFU (a) TIGR4 S. 
pneumoniae (b) serotype 1 S. pneumoniae. Each dot represents an individual animal and the 
horizontal bar is the median survival time. Mice that were alive at 7 days post challenge were 
considered to have survived infection. **P<0.01, *P<0.05 when compared with Alum alone group; 
n=4/5.
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Discussion
The reason for variation in the ability of S. pneumoniae D39 to cause invasive disease was 
not determined. Even when a single colony of mouse virulent D39 was used as the 
standard inoculum for i.p. challenge of inbred mice, there was still variation in bacterial 
loads from mice with no detectable baeteraemia to mice with 8x10^ CFU/ml (Figure 5.1.4). 
The variation was not due to the strain of mouse as both M Fl and BALB/c mice were 
assessed (Figures 5.1.3 and 5.1.4 respectively). Variation has previously been observed 
when D39 is used for challenge experiments (Ogunniyi et al. 2001; Blue 2002). The 
genome of D39 is almost complete and it has been found to possess hypervariable regions 
that are different in clones from the same strain (T. J. Mitchell, personal communication, 
2006). This variable region may be related to the variation observed in virulence and 
requires further investigation. For the pmposes of this study we decided not to use D39 as 
it was too variable. We therefore selected a serotype 1 strain for challenge experiments.
A similar immunogenic response to AA146 Ply, A6  Ply and WT Ply demonstrates that 
antibodies are still produced against these mutants. The ability o f the raised antibodies to 
block the lytic action of Ply indicates that they are fully functional and recognise an active 
region of the toxin. Mice vaccinated with AA146 Ply plus Alum or WT Ply plus Alum 
were protected from infection with TIGR4 S. pneumoniae significantly longer than animals 
that were given Alum alone (Figure 5.2.4). One mouse from the AA146 Ply plus Alum 
group, had a blood bacterial load of 2x10^ CFU/ml TIGR4 S. pneumoniae at 18h post 
infection but cleared the infection within 6  days. It may be that the anti-Ply antibodies can 
inhibit infection to allow anti-capsule opsonising antibodies to develop and clear the 
infection. To assess this, anti-type 4 CPS IgM could be measured in serum from the mouse 
that cleared the infection. Highly neutralising anti-Ply antibodies are important in 
‘mopping up’ Ply release by S. pneumoniae, thereby preventing inflammation and
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subsequent tissue invasion. Such antibodies have recently been shown to protect ciliated
ependymal cells from the toxic effects of Ply release following penicillin lysis of
pneumococci (Hirst et al. 2004b).
Having shown that AA146 Ply protects against baeteraemia, the next step is to investigate 
protection against pneumonia by challenging vaccinated mice intranasally rather than by 
the intraperitoneal route. As ultimately a vaccine that protects against pneumonia would 
add to the existing vaccines where such protection is disputable in adults and low in 
children (Black et al. 2002; Parijs et al. 2004). Prior to investigation into the variability of 
baeteraemia using D39 as the challenge strain, vaccinated MFl mice were challenged 
intranasally with D39. Mice immunised with A6  Ply plus Alum survived infection 
considerably longer than the Alum group (5.9 and 3.8 days respectively, n=10, data not 
shown), however this was not statistically significant and was probably due to the 
variability with D39 infection. This experiment should be repeated using TIGR4 for the 
challenge. Different routes of immunisation should also be investigated, e.g. mucosal 
immunisation to investigate whether the non-toxic Ply mutants confer mucosal protection 
that may protect against carriage or the transition from carriage to pneumonia.
In the conjugate vaccination, mice immunised with 30 times less free protein were only 
slightly protected from TIGR4 infection though this was not significant when compared 
with the Alum only group. The reason for this may be the lower dose of Ply administered 
in the second vaccination, however, this is unlikely as the anti-Ply IgG titres were similar 
in both groups (Figures 5.2.1 and 5.3.1) irrespective of the dose of Ply administered. What 
is more likely is that the increase in the amount of Alum in the conjugate vaccination 
experiment from lOOpg/dose to 200pg/dose, possibly resulted in Alum conferring some 
non-specific protection as the median survival time following i.p. challenge with 10  ^ CFU 
TIGR4 increased from 40.5h with lOOpg Alum (Figure 5.2.4) to 42.9h with 200pg Alum
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(Figure 5.3.3a). For this data, the increase in survival time for the Alum groups from 40.5h
to 42,9 was not significant. Larger group sizes are required to thoroughly investigate
whether increasing the dose of Alum significantly increases survival times of mice.
However, bacterial loads were significantly reduced in the A6  Ply group when compared
with the PBS alone group (P<0.05, data not shown) though not with the Alum group
following TIGR4 challenge (Figure 5.3.2a). Also following serotype 1 challenge, there
were significantly lower counts in the Alum group compared with the PBS group (P<0.05)
further supporting the evidence that the high dose of Alum provides a slight increase in
protection that may mask any subtle increases in protection afforded by Ply or CPS. The
choice o f adjuvant is important as demonstrated by the fact that a combination of MPL
(monophosphoryl lipid A) and Alum increased the immunogenicity of PdB compared with
the use of Alum alone (Ogunniyi et al. 2001).
Mice vaccinated with Prevnar, Prevnar plus A6  Ply and A6  Ply-type 4 CPS were 
completely protected from infection with TIGR4 S. pneumoniae (Figure 5.3.3.a). This 
suggests that A6  Ply is as effective a earner protein as CRM ; 97 in preventing infection from 
a vaccine serotype, though comparison with CRM ; 97 in a titration experiment is required to 
prove this. The use of Ply as a carrier protein has already been demonstrated with WT Ply 
and PdB (Paton et al. 1991; Lee et al. 2001b). Protection was not confeiTcd against TIGR 
4 S. pneumoniae when mice were vaccinated with free A6  Ply. If a larger dose of free A6  
Ply was administered in the conjugate vaccination experiment then an increase in survival 
times would be expected (e.g. 20pg as in Figure 5.2.4, which significantly increased 
survival times of BALB/c mice challenged with TIGR4 S. pneumoniae). Therefore, A6  Ply 
must be conjugated to CPS to confer complete protection against infection with a vaccine 
serotype, acting as a carrier protein like CRM 197 in Prevnar.
185
Chapter 5 Vaccination with Ply and derivatives
As free polysaccharide is the basis of 23-PPV vaccines, we hypothesised that mice
vaccinated with free type 4 CPS would be protected from TIGR4 challenge (at least
partially). However, protection against TIGR4 S. pneumoniae challenge was not conferred
when mice were vaccinated with free type 4 CPS. Immunisation with free type 4 CPS has
previously been shown to fail to elicit an antibody response in adult NIH outbred mice and
inbred BALB/c mice (Peeters et al, 1991). This may be a result of the low dose
administered or that for some reason protective antibodies are not produced in these mice.
The only groups significantly protected from serotype 1 infection were those vaccinated 
with free A6  Ply (Prevnar plus A6  Ply and A6  Ply plus Alum; Figure 5.3.3.b). As the A6  
Ply-type 4 CPS group was not significantly protected from serotype 1 infection, conjugated 
Ply may not confer additive protection against non-vaccine serotypes. This suggests that 
free protein significantly increases survival time against infection with a non-vaccine 
serotype but conjugated Ply is required for full protection against infection from vaccine 
serotypes. Perhaps the conjugation chemistry affects the nature of the Ply antigen; indeed 
the effect of reductive amination on the activity of pneumolysin is not well-defined and 
requires further investigation. It has been suggested that epitopes can be altered during 
reductive amination (Lee 2002). WT Ply conjugated to CPS was not available to 
investigate whether it loses haemolytic activity upon conjugation to CPS. If the 
haemolytic activity is destroyed by conjugation then it could be argued that there is no 
requirement for a non-toxic form of Ply, However, there is the potential of incomplete 
conjugation, resulting in free toxin. In terms of safety for clinical trials, a non-toxic form 
of Ply is preferable for vaccine design. This is the first report that Ply provides different 
levels of protection depending on whether it is administered as free protein or conjugated 
to CPS and signifies an area that requires further investigation with larger group sizes.
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As mice immunised with A6  Ply-type 4 CPS were completely protected from TIGR4 S.
pneumoniae infection but not those given free type 4 CPS, it can be assumed that the anti­
type 4 CPS antibody response is improved when A6  Ply is conjugated to type 4 CPS. Anti­
type 4 CPS antibodies will be analysed by ELISA. Previously anti-Ply and anti-CPS titres 
following immunisation with free PdB and free 19F CPS were compared with titres 
following immunisation with PdB conjugated to 19F CPS (Mitchell 1992). The levels of 
anti-Ply IgG elicited by the conjugate formulation were significantly lower than levels 
elicited by free PdB. In this present conjugate vaccination study the anti-Ply IgG titres 
were comparable irrespective of whether Ply was administered as a free protein or not 
(Figures 5.2.1 and 5.3.1).
It would be worthwhile vaccinating mice with A6  Ply-type 4 CPS plus free A6 Ply to 
investigate whether this confers protection against serotype 1 infection. It may mean that 
free Ply should be incorporated into new vaccines to give broader protection and 
conjugated Ply can be used to confer vaccine serotype protection in place of CRM197. If 
free Ply was to be used in vaccines, then A6  Ply or AA146 Ply would be safer alternatives 
to WT Ply or PdB Ply and more likely to be licensed.
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6: Chromosomal replacement of Ply in D39 S. pneumoniae with A6 Fly
Summary
Previously, Ply mutants have been used to investigate whether it is the cytolytic activity or 
complement activating ability of the toxin that contributes to pneumococcal virulence 
(Berry et al. 1995). This work indicated that with an i.p. model of infection, it was the 
cytotoxic activity of Ply that was important for virulence rather than the complement 
activating ability. However the mutants that were used, including the W433F (PdB) 
mutant, retained some haemolytic activity. As the A6  Ply mutation results in the complete 
abrogation of pore-forming activity and therefore lytic activity (as shown in chapter 3) the 
importance of pore-forming activity for pneumococcal virulence could be investigated, ply  
carrying the A6  mutation was used to replace the WT ply gene in D39 S. pneumoniae using 
Janus mutagenesis (Sung et al. 2001), which utilises the natural transformability of S. 
pneumoniae to allow the insertion of synthetic DNA into a desired site on the 
chromosomal DNA by negative selection. The resulting mutant strain, A6  D39, was then 
assessed for virulence in a mmine model of pneumococcal pneumonia. This work was 
carried out prior to the vaccination studies in chapter 5 when D39 was the common 
laboratory reference strain in which most mutations were constructed, including the 
reagents for Janus mutagenesis with ply. The A6  Ply mutation should now be made in 
another serotype such as TIGR4 to give more accurate in vivo results.
6.1. Construction of A6 Fly in D39 S, pneumoniae using Janus 
mutagenesis
Dr. Gavin K. Paterson cloned the Janus cassette, which encodes a kanamycin resistance 
marker and an rpsL+ marker, in place of the ply gene in streptomycin resistant D39 S. 
pneumoniae (also constructed by Gavin Paterson using the marker kindly supplied by Jean
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Pierre Claverys, Toulouse, France). The rpsh+ marker confers streptomycin sensitivity 
that dominates over the rpsL- allele of the host strain that gives spontaneous streptomycin 
resistance. This gives an intermediate strain, JP PCR B, which is streptomycin sensitive 
and kanamycin resistant. Successful transformation of the synthetic gene in place of the 
Janus cassette results in transformants that are streptomycin resistant and kanamycin 
sensitive. This allows for easy selection of true tranformants by plating on to streptomycin 
plates then selecting colonies for double stabbing on to streptomycin and kanamycin plates 
and choosing colonies that only grow on the streptomycin plates.
Dr. Gavin K. Paterson cloned the ply gene from D39 S. pneumoniae with flanking D39 
DNA (2.345Kb) into the 3.5 Kb TOPO-XL vector to provide the donor DNA for 
transformation into D39 gDNA. This plasmid was used to create the A6  ply mutation 
(AA146AR147) by site-directed mutagenesis. Purified plasmid DNA for the A6  ply mutant 
and WT ply was then transformed into the JP PCR B strain. The WT donor DNA was 
included to restore the WT ply gene and give a control that had been tlirough the same 
process as the A6  ply  mutant. The transformation reaction was spread on to streptomycin 
plates for single colonies. 5/100 WT ply  D39 transformants (WT15, WT2 4 , WT4 7 , WTgo, 
WTô4 ) and 4/100 A6  ply  D39 transformants (A6 g, A6 4 1 , A6 4 8 , A6 7 6 ) were streptomycin 
resistant and kanamycin sensitive. They were all optochin sensitive and pure cultures. 
Genomic DNA was prepared from cultures of each transformant and presence of the ply  
gene was checked by PCR (Figure 6.1).
6 . 1 . 2 . PCR of Janus transformants
Primers 15C and 15D (Table 2.1) anneal to the 5' and 3' end of the ply gene respectively. 
PCR with these primers only gives a positive result for gDNA that contains ply (1.4Kb). 
The original D39 strain was shown to possess the ply gene (Figure 6.1. lane 2), whereas the
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intermediate JP PCR B strain was ply negative (Figure 6.1. lane 3) as the Janus cassette is
in place of ply. 4/5 WT ply  transformants and 3/4 A6  ply  tranformants were positive for
the ply gene (Figure 6.1 : lanes 4, 6 , 7, and 12 for WT ply  and lanes 8 , 9,and 10 for A6  ply),
indicating that these strains were successfully transformed with the donor DNA. This was
confirmed by DNA sequencing.
Figure 6.1. ply PCR of genomic DNA from S. pneumoniae transformants
M 1 2 3 4 5 6 7 8 9  10 11 12
1.4kb 
 ►
M, Ikb^  marker; lane 1, no DNA; lane 2, D39 S. pneumoniae streptomycin resistant strain; lane 3, 
JP PCR B S. pneumoniae intermediate strain with Janus cassette in chromosomal position of ply, 
lanes 4-7 and 12, WT ply  transformants; lanes 8-11, A6  ply  transformants.
6.2. Expression of Ply from S. pneumoniae Janus mutants
Two successful S. pneumoniae Janus mutants for WT ply  (WTis and WT4 7 , lanes 4 and 6  
in Figure 6.1) and A6  ply  (A6 g and A6 4 8 , lanes 8  and 10 in Figure 6.1) were grown up to 
mid log phase, harvested and lysed for analysis of Ply expression (Figure 6.2) and 
haemolytic activity (Figure 6.3). There was no difference in growth rates between 
transformants. The total amount of protein in each cell lysate was determined by
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Bradford’s assay then standardised to 200pg/ml prior to analysis. Both WT D39 and A6 
D39 Janus transformants were positive for Ply expression (Figure 6.2).
Figure 6.2. Western blot of cell lysate from Janus transformants
M WT WT A6 A6 D39
15 47 8 48
50kDa ^
M, Precision kaleidoscope marker; lane 1, WT15 lysate; lane 2, WT47 lysate; lane 3, blank; lane 4, 
A6 g lysate; lane 5, A6 4 8  lysate; lane 6 , blank; lane 7, D39 S. pneumoniae lysate.
6.3. Haemolytic activity of A6 D39 5. pneumoniae
The haemolytic activity o f cell lysate from two WT D39 transformants and two A6 D39 
transformants was assessed. Ply expressed by A6 D39 was not haemolytic, whereas WT 
D39 produced haemolytic Ply (Figure 6.3.).
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Figure 6.3. Haemolytic assay of cell lysate from restored WT D39 and A6 D39 Janus 
transformants.
Two-fold
serial
dilution
WT WT A6  A6
15 47 8  48
m m
Haemolytic assay o f pneumococcal cell lysate from two WT D39 S. pneumoniae strains (W T,; and 
W T 4 7) and two strains carrying the A6  Ply mutation (A6 g and A6 4 8 ).
6.4. Virulence of A6 D39 S, pneumoniae
In order to assess the importance o f pore-forming activity in Ply for in vivo pneumococcal 
infection, MFl mice were infected i.n. with either 10  ^ CFU WT D39 S. pneumoniae 
(WT4 7) or A6 D39 S. pneumoniae (A6 4 8 ; n=20). At 24h post infection, 10 from each group 
were sacrificed for analysis o f bacterial loads in the lungs (pneumonia) and blood
(baeteraemia). Figure 6.4.1. The remaining animals were monitored for survival over a
two-week period. Figure 6.4.2. (n=10).
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6.4.1. Bacteriology at 24h post i.n. infection with A6 D39 S. 
pneumoniae
Bacterial loads were determined from BALF, lung tissue and blood samples 24h post i.n. 
infection with WT D39 or A6 D39 (Figure 6.4.1.). The bacterial load in the BALF was 
significantly higher for the A6 D39 infected group compared with the WT D39 group 
(P<0.05).
Figure 6.4.1. Bacterial load (CFU/ml) in BALF, lungs and blood at 24h post i.n. 
challenge with either WT D39 S. pneumoniae or A6 D39 S. pneumoniae.
Ü
(0
(0cQ)
(0
O)
X IWT BALF IA6D39BALF 
WT Lung Tissue 
IA6D39 Lung Tissue 
H W T  Blood
^ A 6 D 3 9  Blood
Mean log bacterial load (± SEM) in BALF, lung tissue and blood of MFl mice at 24h post i.n. 
challenge with 10^  CFU WT D39 S. pneumoniae or A6  D39 S. pneumoniae. *P<0.05 when 
bacterial loads in BALF of A6  D39 infected mice is compared with bacterial loads in BALF from 
the WT D39 group; n=10.
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6.4.2. Survival of MFl mice following intranasal infection with
A6 D39 S. pneumoniae
There was no significant difference in survival times of mice infected with A6 D39 S, 
pneumoniae compared with mice infected with WT D39 S. pneumoniae (Figure 6.4.2, 
P=0.1203 at 336h). However, the A6 D39 infected group took longer to succumb to 
infection with 50% survival (5/10 mice) at 116 hours compared with 10% survival (1/10 
mice) in the WT group (this was not quite significant, P=0.0874 at 116h).
Figure 6.4.2. Survival of M Fl mice following i.n. challenge with S. pneumoniae
100
5'E3(/)
C8S.
I
W T D39 
A6 D39
— I--------1------- 1------- 1------- 1--------196 144 192 240 288 336
Time (h)
Survival (h) of MFl mice following i.n. challenge with 10^  CFU of either WT D39 5. pneumoniae 
(black squares) or A6 D39 S. pneumoniae (red circles, n=10).
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Discussion
Cloning A6 ply into the cliromosomal DNA of D39 S. pneumoniae, shows that in situ, the 
A6 mutation still results in expression of a non-haemolytic form of Ply. However, it 
appears that for pneumonia, the pneumococcus does not require haemolytically active Ply 
to be fully virulent. This mutant may prove a usefi.il tool for investigating other functions 
of Ply during pneumococcal infection such as TLR-4 activation (Malley et al. 2003) and 
binding to epithelial cells.
As there are significantly higher numbers of A6 D39 S. pneumoniae in the BALF at 24h 
compared with WT D39 S. pneumoniae (Figure 6.4.1.), it is possible that the mutant strain 
is not cleared from the site o f infection as effectively as WT D39 S. pneumoniae. 
Improved clearance of D39 S. pneumoniae from the BALF has previously been shown to 
be a result of the host’s inflammatory response to the cytotoxicity o f WT Ply (van Rossum 
et al. 2005). When pneumococci attach to the respiratory mucosa, an array of 
inflammatory mediators are produced (Bergeron et al. 1998) in response to the numerous 
virulence factors of the pneumococcus. This results in an influx of leukocytes to the site of 
infection and WT Ply has been associated in stimulating this immune response (Kadioglu 
et al. 2000). Comparative analysis of the inflammatory responses following infection with 
WT D39 and A6 D39 S. pneumoniae may reveal mediators induced by the pore forming 
activity of Ply, this would probably include IL-6 and KC that was shown in chapter 4 to be 
produced by the murine model in response to WT Ply treatment but not the non-pore 
forming mutants.
Ply has been directly proven to facilitate bacterial invasion of epithelial cells and treatment 
with toxin alone recreates symptoms of pneumococcal infection in the lung (Feldman et al. 
1990; Feldman et al. 1991). Ply negative strains are less virulent (Beny et al. 1989b),
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however, there was no difference in bacterial loads in the lung tissue following infection
with A6 D39 compared with WT D39 and the bacterial loads were actually increased in the
BALF after A6 D39 infection (Figure 6.4.1). This indicates that there is some other
function of Ply that does not involve pore-forming activity that is important for
pneumococcal pneumonia.
It is important to address the problem in comparing host immune responses to the 
attenuated PLN-A knockout with wild type infection. Ply is obviously important for 
establishment of pneumococcal infection as the knockout strain does not grow well within 
the host but when immune responses such as cytokine induction are compared in hosts 
with WT infection and PLN-A this may just be due to the lack of bacteria and not directly 
to the omission of Ply. In light of this, point mutations that allow a known activity of Ply 
to be investigated are more favourable. Differences tend to not be noticed in growth in the 
host but subtle changes in infection are observed. Previously, Ply mutants have been used 
to investigate whether it is the cytolytic activity or complement activating ability of the 
toxin that contributes to pneumococcal virulence (Berry et al. 1995). This work indicated 
that it was the cytotoxic activity of Ply that was important for virulence in baeteraemia 
rather than the complement activating ability. However, in our intranasal model of 
infeetion, a strain of D39 with non-cytotoxic Ply is still capable of causing disease with no 
significant difference in survival times or lower bacterial loads compared with WT D39. It 
may be the route of infection, involving different cell types, that gives variable results or 
the fact that the Ply mutant used in the previous study had another function altered in 
addition to pore-forming ability. Cytolytic activity has been shown to be important during 
early bacterial growth at 3h and 6h and for acute lung injury, whereas, the complement 
activating function was important for baeteraemia at 24h post infection (Rubins et al. 
1996). It is possible that at earlier time points post challenge, A6 D39 may be less able to 
establish in the host as a result of its dysfunctional Ply, but this was not apparent by 24h.
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Growth of a Ply mutant with 0.02% haemolytic activity of WT Ply (H367R) (Alexander et
al. 1998) was found to be inliibited in the lung during the early stages of pneumococcal
pneumonia (Jounblat et al. 2003). Indicating that if earlier time points of infection were
investigated with A6 D39 there may be a difference in bacterial loads. The involvement of
Ply in pneumococcal infection is complex and it is unlikely that the function of Ply is
limited to these two activities.
Janus mutagenesis provides an elegant system for insertion of mutations into chi*omosomal 
DNA. Previous ply  mutants of S. pneumoniae in which the whole ply gene is disrupted by 
insertion-duplication mutagenesis are more intrusive and the downstream effects are not 
known. From this work, the serotype I data in chapter 7 and the fact that strains with ply 
mutations remain more virulent than ply knockout strains, it appears that there is an 
additional function of Ply other than complement activation and cytolytic activity that is 
required for full virulence.
198
Chapter 7 
Results
Naturally occurring Ply mutants in 
serotype 1 clinical isolates
199
Chapter 7 Ply diversity in serotype 1 IPD isolates
7. Naturally occurring Ply mutants in serotype 1 clinical isolates
Summary
Recently, there has been an increase in invasive pneumococcal disease (IPD) caused by 
serotype 1 S. pneumoniae tlii'oughout Europe. Serotype 1 IPD is associated with 
bacteraemia and pneumonia in Europe and North America, especially in neonates, and 
is ranked among the top five most prevalent pneumococcal serotypes in at least 10 
countries. The currently licensed paediatric pneumococcal vaccine does not afford 
protection to serotype 1.
As part of an on-going study of pneumococcal virulence genes (Jefferies, Kirkliam et al, 
manuscript in preparation), a number of clinical isolates with mutations in their ply gene 
were identified. The mutations were predominantly in the ply  gene of serotypes 1, 7 
and 8. The serotype 1 isolates had additional mutations in the ply  gene to those 
previously described for serotype 7 and 8 (Lock et al. 1996) and were chosen for further 
investigation due to their high attack rate and recent reports of an increase in serotype 1 
disease (see seetion 1.4). From the initial 252 Scottish clinical pneumococcal isolates 
(Jefferies et al. 2004) (chosen to represent all serotypes received by the Scottish 
Meningococcus and Pneumococcus Reference Laboratory, SMPRL), four were serotype 
1 and of these, two had mutations within the ply  gene. Further analysis of an additional 
28 serotype 1 isolates revealed that more than half had mutations within the ply  gene, 
which resulted in the abrogation of the haemolytic activity of the toxin. Multi Locus 
Sequence Typing (MLST; carried out at SMPRL) of the serotype 1 isolates revealed a 
correlation between mutations in the ply  gene and sequence type (Kirkham et al. 
2006b).
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7.1. Incidence of serotype 1 IPD in Scotland
The incidence rate of serotype 1 IPD in Scotland has increased from 0.67 cases/100,000 
population in 2000 to 1.25 cases/100,000 population in 2004 (Figure 7.1, calculated 
from an overall incidence of IPD in Scotland of 12/100,000 with a population of 5 
million). It is important to note that surveillance in Scotland improved in 2001 resulting 
in 90-95% of all cases in Scotland being reported to SMPRL. MLST data was available 
from 2001 onwards, allowing the incidence of each ST within serotype 1 IPD to be 
calculated. The incidence of ST306 increased from 0.04/100,000 population in 2001 to 
0.813/100,000 population in 2004 whereas the incidence of ST227 remained fairly 
unchanged with 0.196 cases/100,000 population in 2001 and 0.286 cases/100,000 
population in 2004 (Figure 7.1).
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Figure 7.1. Incidence of serotype 1 IPD in Scotland from 2000 
to 2004
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Incidence of serotype 1 caused IPD in Scotland from 2000 to 2004. MLST data for 2001 to 
2004 allows sequence type distribution within serotype 1 isolates to be recorded. Black bar 
represents ST306, white bar represents ST227 and diagonal striped bar represents all other 
sequence types. Grey bar represents total number of isolates. It is important to note that 
surveillance of IPD in Scotland improved from 2001 resulting in 90-95% of all cases being 
reported to SMPRL.
In 2003 there were 41 cases o f serotype 1 IPD in Scotland (McChlery et al. 2005), 
resulting in an incidence rate o f 0.76/100,000 population. MLST of the 2003 samples 
revealed that 23 o f these isolates were ST306, 13 were ST227 and there were 5 others: 
ST217 (1), ST1310 (2), ST 1247 (1) and ST 1239 (1). This study sampled all isolates 
from the first 9 months o f 2003, o f which there were 28 cases. Twelve o f the 28 were 
ST227 and 16 were ST306. From this group size o f 28, 25 were available for further 
study. This gave a final sample group of 29 isolates (25 from 2003 and 4 from 2000-
202
Chapter 7 Ply diversity in serotype 1 IPD isolates
2001), 16 were ST306, and 13 were ST227 (Table 7.1). ST306, allelic profile 12 8 13 5 
16 4 20, is a double locus variant of ST227, allelic profile 125 13 5 174 20, sharing 5 
of the 7 housekeeping genes assessed by MLST.
7.2. Sequencing of the Ply gene from clinical pneumococcal 
isolates
The ply  genes from the 29 serotype 1 pneumococci were sequenced by DBS genomics 
and analysed by Dr. Johanna M. C. Jefferies alongside the Ply sequence from the 
serotype 2 laboratory strain D39 (Walker et al. 1987). At the DNA level, five different 
alleles of the ply  gene were present in this collection, on translation this resulted in two 
protein alleles. DNA sequences have been deposited at NCBI under accession numbers 
DQ251177, DQ251178, DQ251179, DQ251180, DQ251181 by Dr. Johanna M. C. 
Jefferies. The two Ply protein alleles conelated with the ST of the serotype 1 
pneumococci in that all isolates of ST306 (n=16) contained mutations at six amino acid 
positions (Y150H, T172I, K224R, A265S, AV270 and AK271) when compared with the 
D39 Ply sequence (Figure 7.2.1). This protein allele is referred to as Ply306. Twelve of 
the 13 isolates of ST227 differed from the D39 sequence at only one residue, D380N. 
This protein allele is referred to as Ply227 (Figure 7.2.1) and has the same sequence as 
Ply from TIGR4 S. pneumoniae (Tettelin et al. 2001). One ST227, strain 00-3645, was 
found to have a 24 base pair insertion in the ply gene, which was a direct repeat of the 
preceding sequence and resulted in an eight amino acid insertion in the protein 
(NVRNLLKG, at residues 417-424). Structural modelling of this insert by Dr. Alan 
Riboldi-Tunnicliffe was found to result in the extension of a loop in domain 4, 
highlighted in red in Figure 7.2.2.
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Figure 7.2.1. Alignment of Ply 306 and 227 protein alleles with D39 S, pneumoniae
1 50
PlyD39 MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK
Ply227 MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK
Ply306 MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK
51 100
PlyD3 9 RSLSTNTSDI SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS
Ply227 RSLSTNTSDI SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS
Ply30 6 RSLSTNTSDI SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS
101 150
PlyD3 9 IDLPGLASSD SFLQVEDPSN SSVRGAVNDL LAKWHQDYGQ VNNVPARMQY
Ply227 IDLPGLASSD SFLQVEDPSN SSVRGAVNDL LAKWHQDYGQ VNNVPARMQY
Ply30 6 IDLPGLASSD SFLQVEDPSN SSVRGAVNDL LAKWHQDYGQ VNNVPARMQ|
151 200
PlyD3 9 EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF NSVHSGEKQI QIVNFKQIYY
Ply227 EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF NSVHSGEKQI QIVNFKQIYY
Ply306 EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF NSVHSGEKQI QIVNFKQIYY
201 250
PlyD39 TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV AYGRQVYLKL
Ply227 TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV AYGRQVYLKL
Ply306 TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV AYGRQVYLKL
251 300
PlyD39 ETTSKSDEVE AAFEALIKGV KVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA
Ply227 ETTSKSDEVE AAFEALIKGV KVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA
Ply306 ETTSKSDEVE AAFE|l IKG| gVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA
301 350
PlyD39 RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY
Ply227 RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY
Ply306 RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY
351 400
PlyD39 VETKVTAYRN GDLLLDHSGA YVAQYYITWD ELSYDHQGKE VLTPKAWDRN
Ply2 27 VETKVTAYRN GDLLLDHSGA YVAQYYITw| ELSYDHQGKE VLTPKAWDRN
Ply3 0 6 VETKVTAYRN GDLLLDHSGA YVAQYYITWD ELSYDHQGKE VLTPKAWDRN
401 450
PlyD39 GQDLTAHFTT SIPLKGNVRN LSVKIRECTG LAWEWWRTVY EKTDLPLVRK
Ply227 GQDLTAHFTT SIPLKGNVRN LSVKIRECTG LAWEWWRTVY EKTDLPLVRK
Ply30 6 GQDLTAHFTT SIPLKGNVRN LSVKIRECTG LAWEWWRTVY EKTDLPLVRK
451 470
PlyD39 RTISIWGTTL YPQVEDKVEN D
Ply227 RTISIWGTTL YPQVEDKVEN D
Ply306 RTISIWGTTL YPQVEDKVEN D
Alignments o f the amino acid sequence for ST227 and ST306 pneiimolysin compared with the 
D39 pneumolysin sequence. The mutations are highlighted in grey. ST227 pneumolysin differs 
from D39 pneumolysin by one amino acid substitution (D380N). ST306 pneumolysin differs 
from D39 pneumolysin by 4 amino acid substitutions (Y150H, T172I, K224R, A265S) and two 
amino acid deletions (V270K271).
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Figure 7.2.2. Structure of 00-3645 Ply based on PFO homology model
Structure of Ply produced by strain 00-3645 with the eight amino acid repeat highlighted in red. 
This results in the extension of a loop in domain 4.
7.3. Expression levels and haemolytic activity of Ply in 
serotype 1 clinical isolates
Western blots were run with the cell extract from each sample and all, except 00-3645,
were positive for Ply expression. Ply expressed by ST306 samples were found to run
slightly higher on 12% SDS-PAGE than ST227 Ply despite possessing two amino acid
deletions (demonstrated in Figure 7.3.1). Haemolytic assays were carried out on lysates
from the 29 serotype 1 pneumococcal isolates and D39 S. pneumoniae (Table 7.1). 55%
(16/29) o f the serotype 1 isolates produced Ply that did not lyse human erythrocytes, all
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of which were ST306. Lysates prepared from ST227 serotype 1 pneumococci and the 
positive control D39, were haemolytic. Analysis o f Ply expression levels by ELISA 
revealed that all ST306 non-haemolytic lysates contained titres comparable to, and in 
some cases higher, than lysates expressing haemolytically active Ply (Table 7.1). The 
specific activity of Ply was calculated from the haemolytic assay (Haemolytic Units; 
HU/ml) and expression levels (mg/ml) to give the specific activity in HU/mg o f toxin. 
The specific activity o f Ply produced by D39 and ST227 isolates was similar, however 
Ply expressed by ST306 strains had no specific activity (Table 7.1). Ply expression by 
strain 00-3645 was not detectable by ELISA.
M  ST227 ST306
50kDa
M, PrecisioiL kaleidoscope marker; ST227, cell lysate fr'om concentrated strain 01-2696; 
ST306, cell lysate from concentrated strain 01-1956. Blot is fr*om samples run on 12% SDS- 
PAGE using polyclonal anti-Ply serum from rabbit.
To further investigate whether the Ply306 allele produced non-haemolytic Ply or Ply 
with reduced haemolytic activity, preparations were made o f a representative ST306 
(01-1956) and ST227 (01-2696) strain to give cell extract with 8-10 fold more Ply. Cell 
extract from strain 01-1956 (ST306) contained 6.4pg/ml Ply and strain 01-2696 
(ST227) contained 5.8pg/ml Ply as detennined by ELISA, however, the ST306 Ply
Figure 7.3.1. Western blot of Ply from an ST227 and ST306 strain
;î
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remained non-haemolytic. Ply from 00-3645 was still not detected by ELISA in a 
concentrated sample, however a faint band was detected by Western blotting with anti- 
Ply antibody (Figure 7.3.2). The insoluble fraction from 00-3645 lysis was negative for 
the presence of Ply by Western blotting and ELISA. Although ELISA did not detect 
expression o f Ply by strain 00-3645, the cell extract from this strain was found to have 
residual haemolytic activity in the first well o f the haemolytic assay.
Figure 7.3.2. Western blot of Ply expression in concentrated samples
M 1 2 3 4
50kDa  ►
M, Precision^ kaleidoscope marker; 1, ST227 cell lysate (strain 01-2696), 2, ST306 cell lysate 
(01-1956); 3, same as 1; 4, 00-3645 cell lysate. All eell lysates were standardised to 2.35mg/ml 
total protein prior to analysis. Blot is from samples run on 10% SDS-PAGE using polyclonal 
anti-Ply serum fr om rabbit.
Yu Jmg cloned 00-3645 ply  into pET-33b for recombinant expression o f 00-3645 Ply. 
This was achieved, but the 00-3645 Ply was almost exclusively found in the insoluble 
cell fraction. The r00-3645Ply that was soluble possessed some haemolytic activity but 
at levels -100 times less that o f recombinant WT Ply. Expressed rOO-3645 Ply proved 
difficult to purify, despite the incorporation o f a Plis-tag.
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Chapter 7 Ply diversity in serotype 1 IPD isolates
7.4. Analysis of binding and pore forming ability of isolates 
expressing non-haemolytic Ply
Erythi'ocyte membranes were treated with cell extract from an ST306 and ST227 isolate 
and from strain 00-3645. Following washing to remove unbound toxin, samples were run 
on SDS-PAGE and Western blotted using anti-pneumolysin antibody. Ply from both 
ST306 and ST227 bound to erythrocytes (Figure 7.4.1), however, ST306 Ply did not bind 
as well. 00-3645 Ply was not observed to bind at all, though expression levels were so low 
that detection of binding would be minimal.
Figure 7.4.1. Analysis of binding of serotype 1 Ply to ei-ythrocyte membranes
1 M 2 3 4 5 6
'    _
1, lOpg/ml recombinant WT Ply; M, Precisioif kaleidoscope marker; 2, washed erytlirocyte 
membranes incubated with cell extract from ST227 strain 01-2696 (5.8pg/ml Ply); 3, washed 
erytlii'ocyte membranes incubated with cell extract from ST306 strain 01-1956 (6.4pg/ml Ply); 4, 
washed erythracyte membranes incubated with 00-3645 cell extract; 5, blank; 6, washed 
erytlirocyte membranes incubated with recombinant WT Ply.
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Analysis o f pore formation by Transmission Electron Microscopy revealed that Ply
expressed by ST306 was unable to form pores on erythrocyte membranes (Figure 7.4.2.b)
in comparison with ST227 Ply (Figure 7.4.2.a). Arcs were observed on membranes treated
with cell extract from both STs but the Ply 306 toxin did not assemble to form functional
pores in the host cell membrane. PBS treated membrane was included as a negative
control and was similar in appearance to ST306 treated membrane without the presence o f
arc structures.
1
Figure 7.4.2. TEM of erythrocyte membrane treated with serotype 1 Ply
Transmission Electron Microscopy of negatively stained erythroeyte membrane treated with 
filtered cell extract from an ST227 isolate (a) or ST306 isolate (b). Viewed at x25000 
magnification, black bar represents lOOnm. White arrow indicates a pore, filled black arrows show 
arcs that appear to be inserted into the membrane and fine black arrows indicate arcs of toxin that 
do not appear to be inserted into the membrane.
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7.5. Virulence of ST306, ST227 and strain 00-3645
MFl mice were challenged i.p. with 5x10^ CPU 00-3645 S. pneumoniae but this did not 
result in infection. In order to establish infection, complement deficient C3-/- mice were 
given the same dose but still did not succumb to infection. The mice did not display any 
clinical signs of illness following challenge. Thus 00-3645 was deemed to he avirulent in 
mice. In contrast, i.p. injection of 5x10^ CPU 01-1956 (ST306) or 01-2696 (ST227) 
resulted in bacteraemia within 24h in both MFl and C3-/- mice. I.n. inoculation of MFl 
mice with 5x10^ CFU 01-1956 or 01-2696 resulted in transient signs of infection in all 
animals. These signs ranged from a hunched stance to lethargy but all animals survived the 
challenge. At 24h post challenge 3/5 mice inoculated with either 01-2696 or 01-1956 were 
bacteraemic. There was no difference in the levels of bacteraemia caused by 01-2696 or 
01-1956.
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Discussion
Serotype 1 has remained one of the most prevalent IPD causing serotypes and has recently 
been ranlced amongst the top five IPD causing serotypes in England, Germany, Spain, 
Quebec, Chile and South Africa (Brueggemann et al. 2003b). Data collected in Scotland 
from 1999-2001 ranlced serotype 1 as the 10**’ most prevalent serotype, causing 3.5% of 
IPD (Kyaw et al. 2003). When data from 2002 was included, serotype 1 ranked 9**’ causing 
3.8% of IPD in Scotland (Denliam et al. 2005) and by 2003, serotype 1 ranked as the 4**’ 
most prevalent serotype, causing 6.7% of IPD (McChlery et al. 2005). MLST data reveals 
that this increase in serotype 1 disease in Scotland, beginning in 2002, is from the 
expansion of ST306 (Figure 7.1). This has previously occurred in Sweden where serotype 
1 caused IPD increased from 1% in 1992 to 10% in 1997 and this was shown to be solely 
due to the emergence of ST306 (Hemiques Normark et al. 2001).
ST227 and ST306 are from the same lineage and clonal group (Brueggemann et al. 2003b) 
and are almost exclusive to serotype 1 pneumococci, although an ST227 has been 
identified with 19F capsule polysaccharide (Jefferies et al. 2004). ST306 IPD is
predominant in continental Europe whereas ST227 is the most prevalent serotype 1 ST in 
England, North America and Canada (Brueggemami et al. 2003b). The reasons for this 
distribution are unclear and larger sample groups would be required for such analysis. 
Brueggemami and Spratt (Brueggemami et al. 2003b) explained the differences in ST 
distribution between England and the rest of Europe to be a result of the low carriage rate 
of serotype 1, which thereby reduces the probahility of transfer of clones between 
populations in comparison with more carriage-associated serotypes. The difference in ST 
distribution between England and Scotland is surprising, with ST306 only present in the 
Scottish samples. As isolates in the two studies are from different time periods, it may be 
that ST306 is now also found in England; however, there are no ST306 isolates from
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England in the MLST database. We are possibly witnessing the clonal expansion of
serotype 1 with the emergence of ST306 in Scotland.
All of the ST306 isolates were shown to have mutations in their ply  gene that resulted in 
the expression of non-haemolytic Ply, yet these clinical isolates were from patients with 
IPD. Despite serotype 1 pneumococci being traditionally highly virulent in mice 
(Kostyukova et al. 1995), the strains in this study were found to cause mild disease in MFl 
mice. Strain 00-3645, expressing low levels of Ply, was avirulent in both WT and immune S
compromised C3-/- mice. Intraperitoneal injection of strains 01-2696 and 01-1956, 
producing WT and non-haemolytic Ply respectively, caused terminal septicaemia. These 
strains were less virulent intranasally, causing only transient infection. There was no 
difference observed in the suiwival times or 24h bacteraemia of mice infected with either 
ST227 (strain 01-2696) or ST306 (strain 01-1956). Thus, the haemolytic activity of Ply 
does not have an effect on the virulence of these serotype 1 isolates in our model. This 
correlates with the fact that all of the serotypes analysed caused IPD in patients irrespective 
of Ply phenotype.
Ply has long been known as an important virulence factor of the pneumococcus but a 
number of studies with a ply  knockout mutant of S. pneumoniae have revealed that the 
toxin is not essential for pneumococcal induced inflammation during meningitis (Friedland 
et al. 1995; Winter et al. 1997; Wellmer et al. 2002). D39 S. pneumoniae carrying the ply 
gene was found to cause acute sepsis in mice following intravenous challenge compared 
with chi'onic bacteraemia if the ply gene was absent (Benton et al. 1995). Studies with 
defined point mutations in the ply gene showed that the haemolytic activity of Ply was 
important during sepsis (Berry et al. 1995). The haemolytic property of Ply has also been 
shown to be involved in the initial stages of pneumonia including invasion of the lung 
tissue and neutrophil recruitment, however haemolytic activity is not important in
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facilitating pneumococcal growth in the alveoli (Rubins et al. 1995; Rubins et al. 1996).
I
As serotype 1 disease is associated with pneumonia rather than meningitis in Europe and
the United States (Hausdorff et al. 2000a; Ispahani et al. 2004; Sjostrom et al. 2006) (and 
Table 7.1) it may be that haemolytically active Ply is not essential for the pathogenesis of 
certain serotype 1 sequence types, such as ST306. This may mean that there will be less 
selective pressure to conserve the nucleotide sequences that encode the haemolytic activity 
of Ply and may allow the mutations we have identified to arise. Recently, an increase in 
pneumococcal meningitis in Ghana has been attributed to serotype 1 clonal complex 
ST217 (Leimkugel et al. 2005), which the authors propose may be better equipped to cause 
meningitis. We have sequenced the ply  gene from an ST217 strain from the Ghana 
meningitis outbreak and found it carried the Ply 227 allele. This may indicate that 
haemolytically active Ply is required for pneumococci to cause meningitis but not
pneumonia. This highlights the need for closer investigation of not only serotype specific 1virulence factors but the possibility of variation within serotypes and underlines the |  
importance of MLST surveillance. s
I
As ST306 causes IPD, haemolytic activity appears to not be essential for virulence. This is 
further supported by the in vivo results in chapter 6, where mice challenged i.n. with a 
strain of D39 S. pneumoniae carrying non-haemolytic pneumolysin had similar bacterial 
loads in the lungs and blood at 24h (Figure 6.4.1) and similar survival times compared with 
mice challenged with the wild type strain (Figure 6.4.2). Indeed, the bacterial load in the 
HALF of mice challenged with D39 carrying non-haemolytic Ply was significantly greater 
than the pneumococcal counts in HALF of mice challenged with WT D39 (Figure 6.4.1).
Strains carrying Ply lacking haemolytic activity and complement binding activity have 
been demonstrated to be more virulent than strains with the ply  gene knocked out, thereby 
indicating that Ply has an additional function yet to he determined (Benton et al. 1997).
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The majority of the mutations obseiwed in Ply306 are those previously implicated in the
«■
reduction of haemolytic activity for certain serotype 7 and serotype 8 strains (Lock et ah |
-f1996). These mutations have not, until now, been associated with serotype 1 strains. 1
Further analysis of these serotype 7 and 8 strains revealed that substitution of threonine 
with isoleucine at residue 172 was responsible for reducing the haemolytic activity of the ;
pneumococcal lysates from 10  ^HU/mg Ply to 10"* HU/mg Ply and was also attributable for :
i;i
anomalously slow migration of the toxin on SDS PAGE gels. From more recent studies, 
the T172I mutation probably affects insertion of domain 3 of the toxin into the host cell 1:
membrane (Ramachandran et al. 2002; Ramachandran et ah 2004). Ply 306 also ran 
anomalously on SDS-PAGE (Figure 7.3.1) but in contrast with the serotype 7 and 8
-Ûisolates, there was no haemolytic activity observed even when the samples were
-
concentrated. The abrogation of haemolytic activity of Ply306 is probably due to the 
combination of the T172I substitution with a further mutation, Y150H, not observed in the 
serotype 7 or 8 strains. The Y150H mutation in Ply is comparable with the Y181A i;
mutation made in the related toxin perffingolysin O (PFO) (Hotze et ah 2001a). PFO
ÿrl,Y181A is unable to form pores in cell membranes thus reducing haemolytic activity to less ,7:
than 1% activity of WT PFO. Mutation of Y150 in Ply to a histidine residue would 
probably have a similar effect, indeed, substitution of this residue in Ply to alanine reduces 
the haemolytic activity to 0.2% of WT Ply (Chapter 3, Table 3.1) and deletion of this 
residue and the adjacent glutamic acid (AYl50E151 ; A8) in Ply results in a non-haemolytic 1i
form of Ply (Chapter 3).
The reduced binding ability of Ply306 and therefore inability to form pores is likely to be a Iresult of the combination of mutations in the ply  gene. Functional pores were not observed
j
on membranes treated with Ply306, however arc structures were observed on the surface of I
membrane treated with Ply306 and Ply227 (Figure 7.4.2). Arcs remain a subject of i
contention within cholesterol dependent cytolysin research (Tweten et ah 2001) and there "31r
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is debate as to whether arcs can insert into the membrane and cause membrane damage.
Here, Piy306 was not foimd to be cytolytic and thus may provide evidence that arcs are
non-functional structures formed by the toxin. Although reduced binding was observed,
there were no mutations in the binding domain (domain 4) of Ply306. This has been
shown before with mutations in domain 3 of PFO that altered the binding ability of PFO
(Heuck et al. 2000).
The eight amino acid insertion present in Ply from strain 00-3645 occurs just upstream of 
the highly conseived undecapeptide region involved In membrane binding (Jacobs et al. 
1999). A single amino acid substitution in this region reduces the haemolytic activity of 
Ply by 100 fold (Korchev et al. 1998). The residual haemolytic activity of r00-3645Ply 
indicates that it can bind to eukaryotic cells and form pores but not as effectively as the 
native toxin. This residual activity may mean that the eight amino acid repeat, which 
results in the extension of the loop involved in host cell binding, does not completely 
disrupt folding and therefore functioning of the toxin. Due to the low levels of expression, 
pore formation was not investigated with the 00-3645 strain.
The fact that Ply may be less conserved than previously assumed should not affect its use 
as the protein component of next-generation conjugate vaccines. Antibodies raised against 
WT Ply still recognised the Ply expressed by all serotype 1 pneumococci in Western blots 
and ELISA. Although mAh PLY7 (de los Toy os et al. 1996) recognised the serotype 1 Ply 
alleles, it has since been found to not detect some variants of Ply expressed by other 
serotypes (Dr. Johamia Jefferies, personal communication, 2005). This is important in 
terms of using Ply ELISAs in clinical assays. Also, the use of ply PCR as a clinical 
diagnostic tool may not be advisable in light of such variation. Some laboratories have 
already found the ply  PCR can be negative for pneumococci or positive for other species
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such as S, mitis (Neeleman et al. 2004) and have therefore changed to using lytK PCR to
distinguish pneumococci.
The Ply306 allele may be of some benefit to the pneumococci, possibly prolonging 
carriage in the nasopharynx compared with other serotype 1 STs. Indeed in Sweden, 
ST306 was found in the nasopharynx of 2 healthy siblings when ST306 was at its most 
prevalent (Sandgren et al. 2004), and was suggested to either be adapting to colonisation or 
possibly the short carriage time of this ST had heen captured. Recently, ST306 has been 
found to cause less severe IPD compared with serotype 1 ST227 (Sjostrom et ai. 2006) and 
serotype 1 ST228 (Sandgren et al. 2005). The increase in ST306 observed in Scotland and 
Sweden may be due to an increased ability to colonise the host, however there is 
insufficient MLST data of serotype 1 isolates from carriage and sequences of the ply  gene 
of the Swedish isolates were not investigated. We may be witnessing the evolution of 
serotype 1 strains to becoming less invasive and more carriage associated. This highlights 
the requirement for global MLST surveillance of both carriage and IPD associated 
pneumococci.
217
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Final Discussion
A non pore-forming form of pneumolysin was successfully constructed and shown to 
retain the immunogenicity of WT Ply without the associated toxic effects. Abrogation of 
pore fonnation also enabled the investigation of this role in pneumococcal pneumonia. 
Previous Ply mutants with reduced cytolytic activity have been used to try to understand 
this role in pathogenesis (Berry et al. 1995), however, mutants with abrogated pore- 
forming activity have not been investigated before. We have shown that the pore forming 
activity of Ply is not essential for S. pneumoniae to cause pneumonia. As the other 
identified activity, complement activation, is also not essential for IPD and mutant 
pneumococcal strains with residual cytolytic activity and abolished complement activating 
ability are still more virulent than the Ply knockout strain (Benton et al. 1997), Ply possibly 
has additional activities yet to be determined.
Our work has also shown that pore forming activity is not essential for serotype 1 S. 
pneumoniae to cause IPD as clinical isolates were found to contain Ply alleles with 
mutations that rendered Ply non-haemolytic. We have shown that Ply is not as conseived 
as once thought with 5 DNA alleles and 2 protein alleles for Ply from 29 clinical isolates of 
serotype 1 pneumococci. We also found that the non-haemolytic Ply allele was 
intrinsically associated with ST306. Similar levels of Ply expression were found in all 
isolates; however, the non-haemolytic form expressed by ST306 had reduced binding and 
therefore pore-forming activity. It is interesting to note that although the mutations 
affected binding, they were not in the binding domain of the toxin. This is in contrast to 
the non pore-forming A6 Ply and AA146 Ply mutants, which were able to bind to cells as 
well as WT Ply but did not form pores. Previous work has shown that mutations in domain 
3 of PFO have an affect on domain 4’s ability to bind to the host cell (Heuck et al. 2000) 
and this probably occurs with Ply expressed by ST306.
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By analysis of MLST data from SMPRL we have also identified the possible clonal
expansion of ST306 as being responsible for the recent increase in serotype 1 disease in
Scotland. This has also occurred in Sweden with a 10 fold increase in serotype 1 IPD over
five years that was attributable to a rise in ST306 (Hemiques Normark et al. 2001). It
would be of interest to sequence the ply  genes from the Swedish isolates. ST217 has
recently been associated with meningitis in Ghana (Leimkugel et al. 2005), sequencing of
the ST217 ply  allele revealed that it was WT ply  (the same as ST227 and that earned by
TIGR4 S. pneumoniae). It may be that haemolytically active Ply is required hy serotype 1
pneumococci to cause meningitis. This will be further investigated.
Further analysis of 252 isolates from SMPRL has found 12 different Ply protein alleles, 
with 2 protein alleles resulting in the loss of haemolytic activity (Jefferies et al, manuscript 
in preparation). This, combined with our serotype 1 data (Kirkham et al. 2006b), 
highlights the importance of surveillance of virulence genes in addition to the 
housekeeping genes monitored by MLST. The reasons for the increase in ST306 may be 
due to a favourable trait that carrying non-lytic Ply permits, such as increased tolerance of 
the host to allow carriage, yet the serotype 1 isolates were all from invasive disease. 
Another possibility is that the ST306 strain is retained in the hmgs and is unable to 
disseminate throughout the lung tissue to enter the bloodstream due to the inahility of Ply 
306 to lyse host cells. This could result in an increase in the bacterial load of ST306 in the 
lungs, as was observed with the A6D39 mutant in chapter 6, possibly providing a source of 
spread for serotype 1 pneumococci by aerosol from coughing of patients. It would be 
interesting to investigate whether ST306 is only associated with pneumonia and is unlikely 
to go on to cause bacteraemia and this would suggest that cytotoxic Ply is required for 
transmission of the bacteria from the lungs into the bloodstream as has been shown in mice 
using bioluminescent imaging (Orihuela et al. 2004). Interestingly serotype 1 is 
associated with meningitis in Africa (Leimkugel et al. 2005) and pneumonia in Europe or
220
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North America. Large scale analysis of sequence type and virulence genes of carried and
invasive isolates may help to understand this association, the role of Ply and the high attack
rates of serotype 1 pneumococci.
The variability of Ply may not be so important in terms of its use as a vaccine candidate as 
the major epitopes remain conserved and all expressed Ply was recognised hy polyclonal 
and monoclonal anti-Ply antibodies. However, thought must be taken in using ply as a 
diagnostic tool (Toikka et al. 1999; Greiner et al. 2001; Saukkoriipi et al. 2002; Cima- 
Cabal et al. 2003) as some primers used in PCR of clinical samples may not detect mutant 
forms of ply. Also, Ply was foimd to be expressed by Streptococcus mitis and this was 
detected by polyclonal anti-Ply antibody but not by the monoclonal antibody (PLY7) used 
in the Ply ELISA (our unpublished data). Recently ply sequencing in addition to MLST 
has been suggested to be used to group difficult to type or non-typeable pneumococci 
(Hanage et al. 2005); the variability of ply should be taken into consideration in these 
circumstances.
WT Ply treatment of mice was found to result in hypothermia and high levels of IL-6 and 
KC in the lungs of mice. These cytokines may play a role in the host response to Ply 
treatment, though their role was not determined in this study and they were not found 
systemically. Studies have shown that very small quantities of circulating cytokines are 
required to exert an effect on the hrain and therefore thermogenesis (Dantzer 1994). It may
g
4be that WT Ply damage of the blood brain barrier (Zysk et al. 2001) permits direct influx of 
cytokines to the brain, giving the immediate hypothermic response observed. To -f
investigate whether IL-6 and KC are involved in the hypothermic response to Ply, 
telemetry chip implanted mice could be treated with anti-IL6 or anti-KC antibodies then 
treated with WT Ply and placed on the telemetry system to monitor their Tc in comparison 
with mice treated with WT Ply only. If the hypothermic response is blocked by anti-
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cytokine antibody then it is likely that those cytokines are involved in the host response to
Ply treatment and ultimately pneumococcal infection, which could also be investigated in
the same mamier. This could be confirmed with knockout host strains such as IL-6 -/- mice
and investigating their response to Ply.
It is likely that a combination of pneumococcal proteins will be used in the next generation 
of pneumococcal vaccines and as Ply confers protection against pneumonia and 
bacteraemia (Alexander et al. 1994), it will probably be included. An additional factor to 
investigate is whether conjugated and/or free proteins will be used, as we have 
demonstrated that Ply may function differently depending upon presentation to the host.
WT Ply and A6  Ply have been demonstrated to be as effective as CRM 197 in functioning as 
a carrier protein to boost the immunogenicity of capsule polysaccharides. An advantage of 
using Ply as a carrier protein instead of CRM 197 is that it reduces the risk of carrier 
suppression that has been demonstrated with tetanus toxoid (TT) (Dagan et al. 1998).
When infants were given multiple vaccinations using TT as the carrier protein, their 
antibody levels were significantly lower than when formulations with different carrier 
proteins were administered. As CRM 197 is also in the licensed and highly successful Hib 
vaccine, there are concerns that carrier suppression may occur with CRM 197 and result in
■lireducing the efficacy of this vaccine and Prevnar. If a pneumococcal protein such as Ply, 
which we have demonstrated to be as effective as CRM 1 9 7 , is used as the carrier protein in 
the next generation of pneumococcal vaccines then this phenomenon could be avoided.
In addition to functioning as a carrier protein, immunisation with free Ply, AA146 Ply or 
A6  Ply was shown to increase suivival times following challenge with two pneumococcal 
serotypes (type 1 and 4). Such protection may inhibit pneumococcal growth to allow the 
development of anti-capsule antibodies to clear the infection. An increase in protection
against a non-vaccine serotype by mixing free A6  Ply with Prevnar revealed that the simple
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Chapter 8 Discussion
i n c l u s i o n  of A6 Ply w i t h  t h e  e x i s t i n g  v a c c i n e  c o n f e iT e d  a d d i t io n a l  p r o t e c t io n .  If f r e e  Ply
was to be included in the next generation of pneumococcal vaccines then a toxoided
version such as AA146 Ply or A6 Ply provides a safe alternative to the WT toxin. f
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Appendix I (buffers and recipes)
Unless otherwise stated, all reagents are from Sigma-Aldrich, Dorset, UK
A. Media 
Terrific broth (TB)
1 2  g bacto-tryptone 
24 g bacto-yeast extract
4 mL glycerol 
in 900 ml dHiO 
Autoclave
In a separate flask dissolve in 90 mL H2O:
2.31 g KH2PO4 monobasic
12.54 g K2HPO4 dibasic (for trihydrate 16.45 g)
Adjust volume to 100 mL with H2O
Hysoy J
1 Og Hysoy J (now discontinued in the UK)
5gNaCl
5 g yeast extract 
5.7gNa2HP04 
3.74gNaH2P04.2H20 
in IL dHzO 
autoclave
then add 20ml of filter sterilised 50% glucose
B. BioCAD buffers 
lxPB-S(dialysis buffer)
KCl - 0.2g,
KH2P04 - 0.24g,
Na2HP04 - 1.44g
3M NaCl
175.32g NaCl 
in IL millipore dH20
20% Ethauol
200ml Ethanol A. R. 
800ml millipore dH2 Û
226
' ;
Appendix I
?■
C. SDS-PAGE gel recipes
■J- ■
Stacking gel (two gels)
dPIiO 3.21ml
0.5M TrispH 6.8 1.25ml
10%SDS 0.05ml |
30% polyacrylamide 0.488ml
10% ammonium persulphate 0.025ml 
TEMED 0.005ml
10% Resolving gel (two gels)
dHzO 4.05ml
1.5MTrispH8.8 2.5ml '
10% SDS 0.1ml
30% polyacrylamide 3.3ml
10% ammonium persulphate 0.05ml
TEMED 0.005ml
(15% resolving gel; 2.35ml dHiO and 5ml polyacrylamide)
lOx Running buffer
SDS lOg
Glycine 144g
Tris base 30g
In IL dlLO
D. Western blot recipes
Transfer Buffer (4°C)
Tris Base 3.03g
Glycine 14.4g
Methanol 200ml
in IL dHiO
Tris NaCl pH7.4
Tris base 1.2g
NaCl 8.7g
in IL dHzO 
conc. HCl 800pi
Developer
(prepare just before use)
Dissolve 30mg 4-chloro-1 -napthol in 10ml methanol 
Add 30pl H2O2 (30% w/v) to 40ml Tris NaCl pH7.4 
Mix
Stop developing with water
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E. EPS Silver Staining solutions
Fixing solution
Ethanol 400ml 
Acetic acid 50ml 
dHiO 550ml
Periodic acid (0.7%)
1.4g periodic acid in 200ml fixing solution
Silver staining solution*
O.IM Sodium hydroxide 28ml 
Ammonium hydroxide 2ml 
while stirring solution, 
add 5ml of 20% silver nitrate 
(Ig silver nitrate in 5ml dHzO)
Silver stain developer 
dHiO 200ml 
Citric Acid (10mg/ml)lml 
Formaldehyde (37%) 0.1ml 
dHzO 115ml
(*note a brown precipitate will form but disappears in seconds; ensure reagent does 
not dry out and is neutralised with HCl acid as it may become explosive when dry)
F. Mast cell degranulation solutions
Mast cell lysate
0.5% Triton X-100 (BDH) 
in EMEM media (ATCC)
Substrate solution
1.3mg pNAG/ml citrate buffer, filter before use.
(pNAG = p-nitrophenyl“N-acetyl-J3~D-glucosamine)
Citrate buffer
O.IM Sodium Citrate pH 4.5 made by mixing the following solutions:
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Solution A
300ml IM NaOH
31.5g Citric Acid (Fisher Scientific)
700ml distilled water 
Solution B 
O.IM HCl
IAdd 67.8ml solution A to 32.3ml solution BStop solution (store at 4°C)
0.2M Glycine NaOH pH 10.7, made up by mixing the following solutions: 
Solution A
7.5g/l Glycine (Fisher Scientific)
5.8g/l NaCl (BDH)
IL distilled water 
Solution B 
0.2MNaOH
Add 52.8ml solution A to 47.2ml solution B
G. ELISA buffers
n.b. pH is important. Check each time before use.
Storage: 4 weeks at 4°C
Anti-Ply and Ply ELISA 
coating buffer (pH 9.6)
1.59g NazCO]
2 .9 3 gNaHC 0 3  
in IL dUiO
IFN-y ELISA
coating buffer (pH9): O.IM Na2lTP0 4  adjust to pFI9 using O.IM NaH2P0 4  
Coating Ab: 2pg/ml 
Detection Ab: 0.5pg/ml
Standard: Top standard 2000pg/ml (two fold dilutions)
IL-6  ELISA
coating buffer (pH9): O.IM Na2HP0 4  adjust to pFI9 using O.IM NaH2P 0 4  
Coating Ab: 2pg/ml 
Detection Ab:lpg/m l
Standard: Top standard lOOOpg/ml (two-fold dilutions)
TNF-a ELISA
coating buffer (pH 9): same as above 
Coating Ab: 4pg/ml 
Detection Ab: Ipg/ml
Standard: Top standard 10,000pg/ml (two-fold dilutions)
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Sequence Alignments
DNA and amino acid alignments o f mutants made by site-directed mutagenesis
Deletion Substitution
(A to G at base 791 is a silent mutation in ply to remove an internal Hind III site to 
allow subsequent cloning steps, our 
unpublished data)
Alignment of A6 Ply with D39 Ply
delta_6 
D39 PLY
201 250
ATGGCAAA TAAAGCAGTA 
ATGGCAAA TAAAGCAGTA
251 300
delta_6 AATGACTTTA TACTAGCTAT GAATTACGAT AAAAAGAAAC TCTTGACCCA
D39_PLY AATGACTTTA TACTAGCTAT GAATTACGAT AAAAAGAAAC TCTTGACCCA
301 350
delta_6 TCAGGGAGAA AGTATTGAAA ATCGTTTCAT CAAAGAGGGT AATCAGCTAC
D39_PLY TCAGGGAGAA AGTATTGAAA ATCGTTTCAT CAAAGAGGGT AATCAGCTAC
351 400
delta_6 CCGATGAGTT TGTTGTTATC GAAAGAAAGA AGCGGAGCTT GTCGACAAAT
D39_PLY CCGATGAGTT TGTTGTTATC GAAAGAAAGA AGCGGAGCTT GTCGACAAAT
401 450
delta_6 ACAAGTGATA TTTCTGTAAC AGCTACCAAC GACAGTCGCC TCTATCCTGG
D39_PLY ACAAGTGATA TTTCTGTAAC AGCTACCAAC GACAGTCGCC TCTATCCTGG
451 500
delta_6 AGCACTTCTC GTAGTGGATG AGACCTTGTT AGAGAATAAT CCCACTCTTC
D39__PLY AGCACTTCTC GTAGTGGATG AGACCTTGTT AGAGAATAAT CCCACTCTTC
501 550
delta_6 TTGCGGTTGA TCGTGCTCCG ATGACTTATA GTATTGATTT GCCTGGTTTG
D39_PLY TTGCGGTTGA TCGTGCTCCG ATGACTTATA GTATTGATTT GCCTGGTTTG
551 600
delta__6 GCAAGTAGCG ATAGCTTTCT CCAAGTGGAA GACCCCAGCA ATTCAAGTGT
D39 PLY GCAAGTAGCG ATAGCTTTCT CCAAGTGGAA GACCCCAGCA ATTCAAGTGT
601 650
delta_6 TCGCGGAGCG GTAAACGATT TGTTGGCTAA GTGGCATCAA GATTATGGTC
D39_PLY TCGCGGAGCG GTAAACGATT TGTTGGCTAA GTGGCATCAA GATTATGGTC
651     700
delta_6 AGGTCAATAA TGTCCCA[f. . ...Ia TGCAGT ATGAAAAAAT AACGGCTCAC
D39 PLY AGGTCAATAA TGTCCCAGCT AGAATGCAGT ATGAAAAAAT AACGGCTCAC
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701 750
delta_6 AGCATGGAAC AACTCAAGGT CAAGTTTGGT TCTGACTTTG AAAAGACAGG
D39_PLY AGCATGGAAC AACTCAAGGT CAAGTTTGGT TCTGACTTTG AAAAGACAGG
751 800
delta_6 GAATTCTCTT GATATTGATT TTAACTCTGT CCATTCAGGT GAAAAGCAGA
039 PLY GAATTCTCTT GATATTGATT TTAACTCTGT CCATTCAGGT GAAAAGCAGA
801 850
delta_6 TTCAGATTGT TAATTTTAAG CAGATTTATT ATACAGTCAG CGTAGACGCT 
D39_PLY TTCAGATTGT TAATTTTAAG CAGATTTATT ATACAGTCAG CGTAGACGCT
851 900
delta_6 GTTAAAAATC CAGGAGATGT GTTTCAAGAT ACTGTAACGG TAGAGGATTT 
D39_PLY GTTAAAAATC CAGGAGATGT GTTTCAAGAT ACTGTAACGG TAGAGGATTT
901 950
delta_6 AAAACAGAGA GGAATTTCTG CAGAGCGTCC TTTGGTCTAT ATTTCGAGTG 
D 3 9 _ P L Y  AAAACAGAGA GGAATTTCTG CAGAGCGTCC TTTGGTCTAT ATTTCGAGTG
951 1000
delta_6 TTGCTTATGG GCGCCAAGTC TATCTCAAGT TGGAAACCAC GAGTAAGAGT 
D39_PLY TTGCTTATGG GCGCCAAGTC TATCTCAAGT TGGAAACCAC GAGTAAGAGT
1001 1050
delta_6 GATGAAGTAG AGGCTGCTTT TGAGGCTTTG ATAAAAGGAG TCAAGGTAGC 
D39_PLY GATGAAGTAG AGGCTGCTTT TGAAGCTTTG ATAAAAGGAG TCAAGGTAGC
1051 1100
delta_6 TCCTCAGACA GAGTGGAAGC AGATTTTGGA CAATACAGAA GTGAAGGCGG 
D39_PLY TCCTCAGACA GAGTGGAAGC AGATTTTGGA CAATACAGAA GTGAAGGCGG
1101 1150
delta_6 TTATTTTAGG GGGCGACCCA AGTTCGGGTG CCCGAGTTGT AACAGGCAAG 
D39_PLY TTATTTTAGG GGGCGACCCA AGTTCGGGTG CCCGAGTTGT AACAGGCAAG
1151 1200
delta_6 GTGGATATGG TAGAGGACTT GATTCAAGAA GGCAGTCGCT TTACAGCAGA 
D39_PLY GTGGATATGG TAGAGGACTT GATTCAAGAA GGCAGTCGCT TTACAGCAGA
1201 1250
delta_6 TCATCCAGGC TTGCCGATTT CCTATACAAC TTCTTTTTTA CGTGACAATG 
D39_PLY TCATCCAGGC TTGCCGATTT CCTATACAAC TTCTTTTTTA CGTGACAATG
1251 1300
delta_6 TAGTTGCGAC CTTTCAAAAC AGTACAGACT ATGTTGAGAC TAAGGTTACA 
D3 9_PLY TAGTTGCGAC CTTTCAAAAC AGTACAGACT ATGTTGAGAC TAAGGTTACA
1301 1350
delta_6 GCTTACAGAA ACGGAGATTT ACTGCTGGAT CATAGTGGTG CCTATGTTGC 
D3 9_PLY GCTTACAGAA ACGGAGATTT ACTGCTGGAT CATAGTGGTG CCTATGTTGC
1351 1400
delta_6 CCAATATTAT ATTACTTGGG ATGAATTATC CTATGATCAT CAAGGTAAGG 
D39_PLY CCAATATTAT ATTACTTGGG ATGAATTATC CTATGATCAT CAAGGTAAGG
1401 1450
delta_6 AAGTCTTGAC TCCTAAGGCT TGGGACAGAA ATGGGCAGGA TTTGACGGCT 
D39_PLY AAGTCTTGAC TCCTAAGGCT TGGGACAGAA ATGGGCAGGA TTTGACGGCT
1451 1500
delta_6 CACTTTACCA CTAGTATTCC TTTAAAAGGG AATGTTCGTA ATCTCTCTGT 
D39 PLY CACTTTACCA CTAGTATTCC TTTAAAAGGG AATGTTCGTA ATCTCTCTGT
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1501 1550
delta_6 CAAAATTAGA GAGTGTACCG GGCTTGCCTG GGAATGGTGG CGTACGGTTT 
D39 PLY CAAAATTAGA GAGTGTACCG GGCTTGCCTG GGAATGGTGG CGTACGGTTT
1551 1600
delta_6 ATGAAAAAAC CGATTTGCCA CTAGTGCGTA AGCGGACGAT TTCTATTTGG 
D39 PLY ATGAAAAAAC CGATTTGCCA CTAGTGCGTA AGCGGACGAT TTCTATTTGG
1601 1650
delta_6 GGAACAACTC TCTATCCTCA GGTAGAGGAT AAGGTAGAAA ATGACTAGGA
D39_PLY GGAACAACTC TCTATCCTCA GGTAGAGGAT AAGGTAGAAA ATGACTAGGA
1651
delta_6 GAGGAGAATG CTTGCGACAA AAAGA
D39 PLY GAGGAGAATG CTTGCGACAA AAAGA
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Alignment of AA146 Ply with D39 Ply
Sequence Alignments
201
delta_A14 6 
D39 PLY DNA
delta_Al4 6 
039 PLY DNA
delta_Al4 6 
D39 PLY DNA
delta_Al4 6 
D39 PLY DNA
delta__Al4 6 
D39 PLY DNA
250
ATG
ATG
251 300
GCAAATAAAG CAGTAAATGA CTTTATACTA GCTATGAATT ACGATAAAAA 
GCAAATAAAG CAGTAAATGA CTTTATACTA GCTATGAATT ACGATAAAAA
301 350
GAAACTCTTG ACCCATCAGG GAGAAAGTAT TGAAAATCGT TTCATCAAAG 
GAAACTCTTG ACCCATCAGG GAGAAAGTAT TGAAAATCGT TTCATCAAAG
351 400
AGGGTAATCA GCTACCCGAT GAGTTTGTTG TTATCGAAAG AAAGAAGCGG 
AGGGTAATCA GCTACCCGAT GAGTTTGTTG TTATCGAAAG AAAGAAGCGG
401 450
AGCTTGTCGA CAAATACAAG TGATATTTCT GTAACAGCTA CCAACGACAG 
AGCTTGTCGA CAAATACAAG TGATATTTCT GTAACAGCTA CCAACGACAG
451 500
delta_A14 6 TCGCCTCTAT CCTGGAGCAC TTCTCGTAGT GGATGAGACC TTGTTAGAGA
D39_PLY_DNA TCGCCTCTAT CCTGGAGCAC TTCTCGTAGT GGATGAGACC TTGTTAGAGA
501 550
delta_Al4 6 ATAATCCCAC TCTTCTTGCG GTTGATCGTG CTCCGATGAC TTATAGTATT
D39 PLY DNA ATAATCCCAC TCTTCTTGCG GTTGATCGTG CTCCGATGAC TTATAGTATT
delta_Al4 6 
039 PLY DNA
delta_Al4 6 
D39 PLY DNA
delta_Al4 6 
D39 PLY DNA
delta_Al4 6 
D39 PLY DNA
delta_Al46 
D39 PLY DNA
delta_Al4 6 
D39 PLY DNA
delta_Al4 6 
D39 PLY DNA
551 600
GATTTGCCTG GTTTGGCAAG TAGCGATAGC TTTCTCCAAG TGGAAGACCC 
GATTTGCCTG GTTTGGCAAG TAGCGATAGC TTTCTCCAAG TGGAAGACCC
601 650
CAGCAATTCA AGTGTTCGCG GAGCGGTAAA CGATTTGTTG GCTAAGTGGC 
CAGCAATTCA AGTGTTCGCG GAGCGGTAAA CGATTTGTTG GCTAAGTGGC
651 700
ATCAAGATTA TGGTCAGGTC AATAATGTCC CAUJ^AGAAT GCAGTATGAA 
ATCAAGATTA TGGTCAGGTC AATAATGTCC CAGCTAGAAT GCAGTATGAA
701 750
AAAATAACGG CTCACAGCAT GGAACAACTC AAGGTCAAGT TTGGTTCTGA 
AAAATAACGG CTCACAGCAT GGAACAACTC AAGGTCAAGT TTGGTTCTGA
751 800
CTTTGAAAAG ACAGGGAATT CTCTTGATAT TGATTTTAAC TCTGTCCATT 
CTTTGAAAAG ACAGGGAATT CTCTTGATAT TGATTTTAAC TCTGTCCATT
801 850 
CAGGTGAAAA GCAGATTCAG ATTGTTAATT TTAAGCAGAT TTATTATACA 
CAGGTGAAAA GCAGATTCAG ATTGTTAATT TTAAGCAGAT TTATTATACA
851 900
GTCAGCGTAG ACGCTGTTAA AAATCCAGGA GATGTGTTTC AAGATACTGT 
GTCAGCGTAG ACGCTGTTAA AAATCCAGGA GATGTGTTTC AAGATACTGT
901 950
delta_Al4 6 AACGGTAGAG GATTTAAAAC AGAGAGGAAT TTCTGCAGAG CGTCCTTTGG 
D39 PLY DNA AACGGTAGAG GATTTAAAAC AGAGAGGAAT TTCTGCAGAG CGTCCTTTGG
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951 1000
delta_Al4 6 TCTATATTTC GAGTGTTGCT TATGGGCGCC AAGTCTATCT CAAGTTGGAA
D39__PLY_DNA TCTATATTTC GAGTGTTGCT TATGGGCGCC AAGTCTATCT CAAGTTGGAA
1001 1050
delta_Al4 6 ACCACGAGTA AGAGTGATGA AGTAGAGGCT GCTTTTGAGG CTTTGATAAA
D 3 9 _ P L Y _ D N A  ACCACGAGTA AGAGTGATGA AGTAGAGGCT GCTTTTGAAG CTTTGATAAA
1051 1100
delta__Al4 6 AGGAGTCAAG GTAGCTCCTC AGACAGAGTG GAAGCAGATT TTGGACAATA
D39__PLY_DNA AGGAGTCAAG GTAGCTCCTC AGACAGAGTG GAAGCAGATT TTGGACAATA
1101 1150
delta_Al4 6 CAGAAGTGAA GGCGGTTATT TTAGGGGGCG ACCCAAGTTC GGGTGCCCGA
D39__PLY_DNA CAGAAGTGAA GGCGGTTATT TTAGGGGGCG ACCCAAGTTC GGGTGCCCGA
1151 1200
delta_Al4 6 GTTGTAACAG GCAAGGTGGA TATGGTAGAG GACTTGATTC AAGAAGGCAG
D39__PLY_DNA GTTGTAACAG GCAAGGTGGA TATGGTAGAG GACTTGATTC AAGAAGGCAG
1201 1250
delta_Al4 6 TCGCTTTACA GCAGATCATC CAGGCTTGCC GATTTCCTAT ACAACTTCTT
D39 PLY DNA TCGCTTTACA GCAGATCATC CAGGCTTGCC GATTTCCTAT ACAACTTCTT
delta__Al4 6 
D3 9 PLY DNA
delta_Al4 6 
D39 PLY DNA
delta_Al4 6 
039 PLY DNA
1251 1300
TTTTACGTGA CAATGTAGTT GCGACCTTTC AAAACAGTAC AGACTATGTT 
TTTTACGTGA CAATGTAGTT GCGACCTTTC AAAACAGTAC AGACTATGTT
1301 1350
GAGACTAAGG TTACAGCTTA CAGAAACGGA GATTTACTGC TGGATCATAG 
GAGACTAAGG TTACAGCTTA CAGAAACGGA GATTTACTGC TGGATCATAG
1351 1400
TGGTGCCTAT GTTGCCCAAT ATTATATTAC TTGGGATGAA TTATCCTATG 
TGGTGCCTAT GTTGCCCAAT ATTATATTAC TTGGGATGAA TTATCCTATG
1401 1450
delta_Al4 6 ATCATCAAGG TAAGGAAGTC TTGACTCCTA AGGCTTGGGA CAGAAATGGG
D39_PLY_DNA ATCATCAAGG TAAGGAAGTC TTGACTCCTA AGGCTTGGGA CAGAAATGGG
1451 1500
delta_Al4 6 CAGGATTTGA CGGCTCACTT TACCACTAGT ATTCCTTTAA AAGGGAATGT
D39_PLY_DNA CAGGATTTGA CGGCTCACTT TACCACTAGT ATTCCTTTAA AAGGGAATGT
1501 1550
delta_Al4 6 TCGTAATCTC TCTGTCAAAA TTAGAGAGTG TACCGGGCTT GCCTGGGAAT
D 3 9 _ P L Y _ D N A  TCGTAATCTC TCTGTCAAAA TTAGAGAGTG TACCGGGCTT GCCTGGGAAT
1551 1600
delta_Al4 6 GGTGGCGTAC GGTTTATGAA AAAACCGATT TGCCACTAGT GCGTAAGCGG
D39_PLY_DNA GGTGGCGTAC GGTTTATGAA AAAACCGATT TGCCACTAGT GCGTAAGCGG
1601 1550
delta_Al4 6 ACGATTTCTA TTTGGGGAAC AACTCTCTAT CCTCAGGTAG AGGATAAGGT
0 3 9  PLY DNA ACGATTTCTA TTTGGGGAAC AACTCTCTAT CCTCAGGTAG AGGATAAGGT
1651
delta_Al4 6 AGAAAATGAC TAGGAGAGGA GAATGCTTGC GACAAAAAGA 
0 3 9  PLY DNA AGAAAATGAC TAGGAGAGGA GAATGCTTGC GACAAAAAGA
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Amino acid sequence alignment of sequenced A6 W433F Ply
with D39 Ply
1 50
D39_Ply MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK
d6_W4 33F MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK
51 100
D39_Ply RSLSTNTSDI SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS
d6_W4 33F RSLSTNTSDI SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS
101 150
D39_Ply IDLPGLASSD SFLQVEDPSN SSVRGAVNDL LAKWHQDYGQ VNNVPA_RMQY
d6_W4 33F IDLPGLASSD SFLQVEDPSN SSVRGAVNDL LAKWHQDYGQ VNNVP[._.jMQY
151 200
D39_Ply EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF NSVHSGEKQI QIVNFKQIYY
d6_W4 33F EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF NSVHSGEKQI QIVNFKQIYY
201 250
D39__Ply TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV AYGRQVYLKL
d6_W4 33F TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV AYGRQVYLKL
251 300
D 3 9 _ P l y  ETTSKSDEVE AAFEALIKGV KVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA
d6_W4 33F ETTSKSDEVE AAFEALIKGV KVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA
301 350
D39_Ply RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY
d6_W4 33F RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY
3 5 1  4 0 0
D39_Ply VETKVTAYRN GDLLLDHSGA YVAQYYITWD ELSYDHQGKE VLTPKAWDRN
d6_W4 33F VETKVTAYRN GDLLLDHSGA YVAQYYITWD ELSYDHQGKE VLTPKAWDRN
401 450
D39_Ply GQDLTAHFTT SIPLKGNVRN LSVKIRECTG LAWEWWRTVY EKTDLPLVRK
d6_W4 33F GQDLTAHFTT SIPLKGNVRN LSVKIRECTG LAFEWWRTVY EKTDLPLVRK
451 471
D39_Ply RTISIWGTTL YPQVEDKVEN D
d6 W4 33F RTISIWGTTL YPQVEDKVEN D
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Amino acid sequence alignment of sequenced A6D385NW433F
Fly with D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
d6_D385N_W433F 
D39 Ply
1 50
MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK 
MANKAVNDFI LAMNYDKKKL LTHQGESIEN RFIKEGNQLP DEFVVIERKK
51 100
RSLSTNTSDI SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS 
RSLSTNTSDI SVTATNDSRL YPGALLVVDE TLLENNPTLL AVDRAPMTYS
101 150
IDLPGLASSD SFLQVEDPSN SSVRGAVNDL LAKWHQDYGQ VNNVP[TfMQY 
IDLPGLASSD SFLQVEDPSN SSVRGAVNDL LAKWHQDYGQ VNNVPARMQY
151 200
EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF NSVHSGEKQI QIVNFKQIYY 
EKITAHSMEQ LKVKFGSDFE KTGNSLDIDF NSVHSGEKQI QIVNFKQIYY
201 250
TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV AYGRQVYLKL 
TVSVDAVKNP GDVFQDTVTV EDLKQRGISA ERPLVYISSV AYGRQVYLKL
251 300
ETTSKSDEVE AAFEALIKGV KVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA 
ETTSKSDEVE AAFEALIKGV KVAPQTEWKQ ILDNTEVKAV ILGGDPSSGA
301 350
RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY 
RVVTGKVDMV EDLIQEGSRF TADHPGLPIS YTTSFLRDNV VATFQNSTDY
351 400
VETKVTAYRN GDLLLDHSGA YVAQYYITWD ELSYNHQGKE VLTPKAWDRN 
VETKVTAYRN GDLLLDHSGA YVAQYYITWD ELSYDHQGKE VLTPKAWDRN
401 450
GQDLTAHFTT SIPLKGNVRN LSVKIRECTG LAFEWWRTVY EKTDLPLVRK 
GQDLTAHFTT SIPLKGNVRN LSVKIRECTG LAWEWWRTVY EKTDLPLVRK
451  471
RTISIWGTTL YPQVEDKVEN D 
RTISIWGTTL YPQVEDKVEN D
-Î
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Alignment of DNA sequence of Janus A6 D39 ply S. pneumoniae with D39 ply
201 250
d6D39_janus ....... ATG GCAAATAAAG CAGTAAATGA CTTTATACTA GCTATGAATT
WT_PLY ....... ATG GCAAATAAAG CAGTAAATGA CTTTATACTA GCTATGAATT
251 300
d6D39_janus ACGATAAAAA GAAACTCTTG ACCCATCAGG GAGAAAGTAT TGAAAATCGT 
WT_PLY ACGATAAAAA GAAACTCTTG ACCCATCAGG GAGAAAGTAT TGAAAATCGT
301 350
d6D39_janus TTCATCAAAG AGGGTAATCA GCTACCCGAT GAGTTTGTTG TTATCGAAAG 
WT_PLY TTCATCAAAG AGGGTAATCA GCTACCCGAT GAGTTTGTTG TTATCGAAAG
351 400
d6D39_janus AAAGAAGCGG AGCTTGTCGA CAAATACAAG TGATATTTCT GTAACAGCTA 
WT_PLY AAAGAAGCGG AGCTTGTCGA CAAATACAAG TGATATTTCT GTAACAGCTA
401 450
d6D39_janus CCAACGACAG TCGCCTCTAT CCTGGAGCAC TTCTCGTAGT GGATGAGACC 
WT_PLY CCAACGACAG TCGCCTCTAT CCTGGAGCAC TTCTCGTAGT GGATGAGACC
451 500
d6D39_janus TTGTTAGAGA ATAATCCCAC TCTTCTTGCG GTTGATCGTG CTCCGATGAC 
WT_PLY TTGTTAGAGA ATAATCCCAC TCTTCTTGCG GTTGATCGTG CTCCGATGAC
501 550
d6D39_janus TTATAGTATT GATTTGCCTG GTTTGGCAAG TAGCGATAGC TTTCTCCAAG 
WT_PLY TTATAGTATT GATTTGCCTG GTTTGGCAAG TAGCGATAGC TTTCTCCAAG
551 600
d6D39_janus TGGAAGACCC CAGCAATTCA AGTGTTCGCG GAGCGGTAAA CGATTTGTTG 
WT_PLY TGGAAGACCC CAGCAATTCA AGTGTTCGCG GAGCGGTAAA CGATTTGTTG
601 650
d6D39_janus GCTAAGTGGC ATCAAGATTA TGGTCAGGTC AATAATGTCC CA[.-. ^ fljAT 
WT_PLY GCTAAGTGGC ATCAAGATTA TGGTCAGGTC AATAATGTCC CAGCTAGAAT
651 700
d6D39_janus GCAGTATGAA AAAATAACGG CTCACAGCAT GGAACAACTC AAGGTCAAGT 
WT_PLY GCAGTATGAA AAAATAACGG CTCACAGCAT GGAACAACTC AAGGTCAAGT
701 750
d6D39_janus TTGGTTCTGA CTTTGAAAAG ACAGGGAATT CTCTTGATAT TGATTTTAAC 
WT_PLY TTGGTTCTGA CTTTGAAAAG ACAGGGAATT CTCTTGATAT TGATTTTAAC
75 1  80 0
d6D3 9_janus TCTGTCCATT CAGGTGAAAA GCAGATTCAG ATTGTTAATT TTAAGCAGAT 
WT_PLY TCTGTCCATT CAGGTGAAAA GCAGATTCAG ATTGTTAATT TTAAGCAGAT
801 850
d6D3 9_janus TTATTATACA GTCAGCGTAG ACGCTGTTAA AAATCCAGGA GATGTGTTTC 
WT_PLY TTATTATACA GTCAGCGTAG ACGCTGTTAA AAATCCAGGA GATGTGTTTC
851 900
d6D39_janus AAGATACTGT AACGGTAGAG GATTTAAAAC AGAGAGGAAT TTCTGCAGAG 
WT_PLY AAGATACTGT AACGGTAGAG GATTTAAAAC AGAGAGGAAT TTCTGCAGAG
901 950
d6D39__janus CGTCCTTTGG TCTATATTTC GAGTGTTGCT TATGGGCGCC AAGTCTATCT 
WT_PLY CGTCCTTTGG TCTATATTTC GAGTGTTGCT TATGGGCGCC AAGTCTATCT
951 1000
d6D39_janus CAAGTTGGAA ACCACGAGTA AGAGTGATGA AGTAGAGGCT GCTTTTGAAG
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WT PLY CAAGTTGGAA ACCACGAGTA AGAGTGATGA AGTAGAGGCT GCTTTTGAAG
d6D39_janus 
WT PLY
d6D39_janus 
WT PLY
d6D3 9__i anus 
WT PLY
d6D39_janus 
WT PLY
d6D3 9_j anus 
WT PLY
d6D39_j anus 
WT PLY
d6D3 9_j anus 
, WT PLY
d6D3 9_j anus 
WT PLY
1001 1050
CTTTGATAAA AGGAGTCAAG GTAGCTCCTC AGACAGAGTG GAAGCAGATT 
CTTTGATAAA AGGAGTCAAG GTAGCTCCTC AGACAGAGTG GAAGCAGATT
1051 1100
TTGGACAATA CAGAAGTGAA GGCGGTTATT TTAGGGGGCG ACCCAAGTTC 
TTGGACAATA CAGAAGTGAA GGCGGTTATT TTAGGGGGCG ACCCAAGTTC
1101 1150
GGGTGCCCGA GTTGTAACAG GCAAGGTGGA TATGGTAGAG GACTTGATTC 
GGGTGCCCGA GTTGTAACAG GCAAGGTGGA TATGGTAGAG GACTTGATTC
1151 1200
AAGAAGGCAG TCGCTTTACA GCAGATCATC CAGGCTTGCC GATTTCCTAT 
AAGAAGGCAG TCGCTTTACA GCAGATCATC CAGGCTTGCC GATTTCCTAT
1201 1250
ACAACTTCTT TTTTACGTGA CAATGTAGTT GCGACCTTTC AAAACAGTAC 
ACAACTTCTT TTTTACGTGA CAATGTAGTT GCGACCTTTC AAAACAGTAC
1251 1300
AGACTATGTT GAGACTAAGG TTACAGCTTA CAGAAACGGA GATTTACTGC 
AGACTATGTT GAGACTAAGG TTACAGCTTA CAGAAACGGA GATTTACTGC
1301 1350
TGGATCATAG TGGTGCCTAT GTTGCCCAAT ATTATATTAC TTGGGATGAA 
TGGATCATAG TGGTGCCTAT GTTGCCCAAT ATTATATTAC TTGGGATGAA
1351
TTATCCTATG
TTATCCTATG
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Alignment of DNA sequence of Janus WT ply S, pneumoniae with D39 ply
201 250
janus_WT_Ply ........ATG GCAAATAAAG CAGTAAATGA CTTTATACTA GCTATGAATT
D3 9 ply DNA ........ATG GCAAATAAAG CAGTAAATGA CTTTATACTA GCTATGAATT
j anus_WT_Ply 
D39_ply_DNA
j anus_WT_Ply 
D3 9_ply_DNA
j anus_WT_Ply 
D39 ply DNA
j anus_WT_Ply 
D39 ply DNA
j anus___WT_Ply 
D 3 9 _ p ly _ D N A
j anus_WT_Ply 
D3 9_ply_DNA
janus_WT__Ply 
D3 9 ply_DNA
251 300
ACGATAAAAA GAAACTCTTG ACCCATCAGG GAGAAAGTAT TGAAAATCGT 
ACGATAAAAA GAAACTCTTG ACCCATCAGG GAGAAAGTAT TGAAAATCGT
301 350
TTCATCAAAG AGGGTAATCA GCTACCCGAT GAGTTTGTTG TTATCGAAAG 
TTCATCAAAG AGGGTAATCA GCTACCCGAT GAGTTTGTTG TTATCGAAAG
351 400
AAAGAAGCGG AGCTTGTCGA CAAATACAAG TGATATTTCT GTAACAGCTA 
AAAGAAGCGG AGCTTGTCGA CAAATACAAG TGATATTTCT GTAACAGCTA
401 450
CCAACGACAG TCGCCTCTAT CCTGGAGCAC TTCTCGTAGT GGATGAGACC 
CCAACGACAG TCGCCTCTAT CCTGGAGCAC TTCTCGTAGT GGATGAGACC
451 500
TTGTTAGAGA ATAATCCCAC TCTTCTTGCG GTTGATCGTG CTCCGATGAC 
TTGTTAGAGA ATAATCCCAC TCTTCTTGCG GTTGATCGTG CTCCGATGAC
501 550
TTATAGTATT GATTTGCCTG GTTTGGCAAG TAGCGATAGC TTTCTCCAAG 
TTATAGTATT GATTTGCCTG GTTTGGCAAG TAGCGATAGC TTTCTCCAAG
551 600
TGGAAGACCC CAGCAATTCA AGTGTTCGCG GAGCGGTAAA CGATTTGTTG 
TGGAAGACCC CAGCAATTCA AGTGTTCGCG GAGCGGTAAA CGATTTGTTG
janus_WT__Ply 
D39 ply DNA
601 650
GCTAAGTGGC ATCAAGATTA TGGTCAGGTC AATAATGTCC CAGCTAGAAT 
GCTAAGTGGC ATCAAGATTA TGGTCAGGTC AATAATGTCC CAGCTAGAAT
janus_WT_Ply 
D39 ply DNA
j anus_WT__Ply 
D3 9_ply_DNA
janus_WT_Ply 
D3 9 ply DNA
651 700
GCAGTATGAA AAAATAACGG CTCACAGCAT GGAACAACTC AAGGTCAAGT 
GCAGTATGAA AAAATAACGG CTCACAGCAT GGAACAACTC AAGGTCAAGT
701 750
TTGGTTCTGA CTTTGAAAAG ACAGGGAATT CTCTTGATAT TGATTTTAAC 
TTGGTTCTGA CTTTGAAAAG ACAGGGAATT CTCTTGATAT TGATTTTAAC
751 800
TCTGTCCATT CAGGTGAAAA GCAGATTCAG ATTGTTAATT TTAAGCAGAT 
TCTGTCCATT CAGGTGAAAA GCAGATTCAG ATTGTTAATT TTAAGCAGAT
j anus_WT_Ply 
D39 ply DNA
801 850
TTATTATACA GTCAGCGTAG ACGCTGTTAA AAATCCAGGA GATGTGTTTC 
TTATTATACA GTCAGCGTAG ACGCTGTTAA AAATCCAGGA GATGTGTTTC
j anus_WT__Ply 
0 3 9  ply DNA
j anus__WT__Ply 
0 3 9  ply DNA
j anus_WT_Ply 
0 3 9  ply DNA
851 900
AAGATACTGT AACGGTAGAG GATTTAAAAC AGAGAGGAAT TTCTGCAGAG 
AAGATACTGT AACGGTAGAG GATTTAAAAC AGAGAGGAAT TTCTGCAGAG
901 950
CGTCCTTTGG TCTATATTTC GAGTGTTGCT TATGGGCGCC AAGTCTATCT 
CGTCCTTTGG TCTATATTTC GAGTGTTGCT TATGGGCGCC AAGTCTATCT
951 1000
CAAGTTGGAA ACCACGAGTA AGAGTGATGA AGTAGAGGCT GCTTTTGAAG 
CAAGTTGGAA ACCACGAGTA AGAGTGATGA AGTAGAGGCT GCTTTTGAAG
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j anus_WT_Ply 
D39 ply DNA
Sequence Alignments
1001 1050
CTTTGATAAA AGGAGTCAAG GTAGCTCCTC AGACAGAGTG GAAGCAGATT 
CTTTGATAAA AGGAGTCAAG GTAGCTCCTC AGACAGAGTG GAAGCAGATT
j anus_WT__Ply 
D39 ply DNA
1051 1100
TTGGACAATA CAGAAGTGAA GGCGGTTATT TTAGGGGGCG ACCCAAGTTC 
TTGGACAATA CAGAAGTGAA GGCGGTTATT TTAGGGGGCG ACCCAAGTTC
j anus_WT_Ply 
D39 ply DNA
1101 1150
GGGTGCCCGA GTTGTAACAG GCAAGGTGGA TATGGTAGAG GACTTGATTC 
GGGTGCCCGA GTTGTAACAG GCAAGGTGGA TATGGTAGAG GACTTGATTC
j anus_WT__Ply 
D39 ply DNA
1151 1200
AAGAAGGCAG TCGCTTTACA GCAGATCATC CAGGCTTGCC GATTTCCTAT 
AAGAAGGCAG TCGCTTTACA GCAGATCATC CAGGCTTGCC GATTTCCTAT
j anus__WT__Ply 
D3 9 ply DNA
1201 1250
ACAACTTCTT TTTTACGTGA CAATGTAGTT GCGACCTTTC AAAACAGTAC 
ACAACTTCTT TTTTACGTGA CAATGTAGTT GCGACCTTTC AAAACAGTAC
j anus_WT_Ply 
D39 ply DNA
1251 1300
AGACTATGTT GAGACTAAGG TTACAGCTTA CAGAAACGGA GATTTACTGC 
AGACTATGTT GAGACTAAGG TTACAGCTTA CAGAAACGGA GATTTACTGC
j anus_WT_Ply 
D39 ply DNA
1301 1350
TGGATCATAG TGGTGCCTAT GTTGCCCAAT ATTATATTAC TTGGGATGAA 
TGGATCATAG TGGTGCCTAT GTTGCCCAAT ATTATATTAC TTGGGATGAA
j anus_WT_Ply 
D39 ply DNA
1351
TTATCCTATG
TTATCCTATG
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